0001557376 2025-11-01 2026-06-30 0001557376 2025-04-30 0001557376 2026-10-12 0001557376 2026-06-30 0001557376 2025-10-31 0001557376 us-gaap:SeriesCPreferredStockMember 2026-06-30 0001557376 us-gaap:SeriesCPreferredStockMember 2025-10-31 0001557376 2024-11-01 2025-10-31 0001557376 2023-11-01 2024-10-31 0001557376 us-gaap:CommonStockMember 2023-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001557376 us-gaap:RetainedEarningsMember 2023-10-31 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2023-10-31 0001557376 us-gaap:NoncontrollingInterestMember 2023-10-31 0001557376 2023-10-31 0001557376 us-gaap:CommonStockMember 2024-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001557376 us-gaap:RetainedEarningsMember 2024-10-31 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2024-10-31 0001557376 us-gaap:NoncontrollingInterestMember 2024-10-31 0001557376 2024-10-31 0001557376 us-gaap:CommonStockMember 2025-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0001557376 us-gaap:RetainedEarningsMember 2025-10-31 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2025-10-31 0001557376 us-gaap:NoncontrollingInterestMember 2025-10-31 0001557376 us-gaap:CommonStockMember 2023-11-01 2024-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2023-11-01 2024-10-31 0001557376 us-gaap:RetainedEarningsMember 2023-11-01 2024-10-31 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2023-11-01 2024-10-31 0001557376 us-gaap:NoncontrollingInterestMember 2023-11-01 2024-10-31 0001557376 us-gaap:CommonStockMember 2024-11-01 2025-10-31 0001557376 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-10-31 0001557376 us-gaap:RetainedEarningsMember 2024-11-01 2025-10-31 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2024-11-01 2025-10-31 0001557376 us-gaap:NoncontrollingInterestMember 2024-11-01 2025-10-31 0001557376 us-gaap:CommonStockMember 2025-11-01 2026-06-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-06-30 0001557376 us-gaap:RetainedEarningsMember 2025-11-01 2026-06-30 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2025-11-01 2026-06-30 0001557376 us-gaap:NoncontrollingInterestMember 2025-11-01 2026-06-30 0001557376 us-gaap:CommonStockMember 2026-06-30 0001557376 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001557376 us-gaap:RetainedEarningsMember 2026-06-30 0001557376 ZEOX:TotalStockholdersDeficitAttributableToZeoMember 2026-06-30 0001557376 us-gaap:NoncontrollingInterestMember 2026-06-30 0001557376 ZEOX:LargeDistributorMember 2025-11-01 2026-06-30 0001557376 ZEOX:LargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-06-30 0001557376 ZEOX:AnotherLargeDistributorMember 2025-11-01 2026-06-30 0001557376 ZEOX:AnotherLargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-06-30 0001557376 ZEOX:LargeMedicalPacticeGroupMember 2024-11-01 2025-10-31 0001557376 ZEOX:LargeMedicalPacticeGroupMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001557376 ZEOX:LargeDistributorMember 2024-11-01 2025-10-31 0001557376 ZEOX:LargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001557376 ZEOX:AnotherLargeDistributorMember 2024-11-01 2025-10-31 0001557376 ZEOX:AnotherLargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001557376 ZEOX:LargeDistributorMember 2023-11-01 2024-10-31 0001557376 ZEOX:LargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001557376 ZEOX:AnotherLargeDistributorMember 2023-11-01 2024-10-31 0001557376 ZEOX:AnotherLargeDistributorMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-11-01 2024-10-31 0001557376 ZEOX:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-06-30 0001557376 ZEOX:OneSupplierMember 2026-06-30 0001557376 ZEOX:OneSupplierMember 2025-11-01 2026-06-30 0001557376 ZEOX:TwoSupplierMember 2026-06-30 0001557376 ZEOX:TwoSupplierMember 2025-11-01 2026-06-30 0001557376 ZEOX:OneSupplierMember 2025-10-31 0001557376 ZEOX:OneSupplierMember 2024-11-01 2025-10-31 0001557376 ZEOX:TwoSupplierMember 2025-10-31 0001557376 ZEOX:TwoSupplierMember 2024-11-01 2025-10-31 0001557376 ZEOX:OneSupplierMember 2024-10-31 0001557376 ZEOX:CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember 2025-11-01 2026-06-30 0001557376 ZEOX:CommonSharesIssuableUponTheExerciseOfUnissuedRestrictedStockMember 2025-11-01 2026-06-30 0001557376 ZEOX:CommonSharesIssuableUponTheExerciseOfOunvestedSharesOfRestrictedStockMember 2025-11-01 2026-06-30 0001557376 us-gaap:ConvertibleDebtSecuritiesMember 2025-11-01 2026-06-30 0001557376 ZEOX:CommonSharesIssuableUponTheFuturePaymentsMember 2025-11-01 2026-06-30 0001557376 ZEOX:CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember 2024-11-01 2025-10-31 0001557376 ZEOX:CommonSharesIssuableUponTheExerciseOfUnissuedRestrictedStockMember 2024-11-01 2025-10-31 0001557376 ZEOX:CommonSharesIssuableUponTheExerciseOfOunvestedSharesOfRestrictedStockMember 2024-11-01 2025-10-31 0001557376 us-gaap:ConvertibleDebtSecuritiesMember 2024-11-01 2025-10-31 0001557376 ZEOX:CommonSharesIssuableUponTheFuturePaymentsMember 2024-11-01 2025-10-31 0001557376 ZEOX:FinanceLeaseEquipmentMember 2026-06-30 0001557376 ZEOX:FinanceLeaseEquipmentMember 2025-10-31 0001557376 ZEOX:ManufacturingEquipmentMember 2026-06-30 0001557376 ZEOX:ManufacturingEquipmentMember 2025-10-31 0001557376 ZEOX:SalesRepresentativeAgreementMember 2025-11-01 2026-06-30 0001557376 ZEOX:SalesRepresentativeAgreementMember 2024-11-01 2025-10-31 0001557376 ZEOX:SalesRepresentativeAgreementMember 2023-11-01 2024-10-31 0001557376 ZEOX:LeaseAgreementMember 2025-04-30 0001557376 ZEOX:LeaseAgreementMember 2025-04-02 2025-04-30 0001557376 ZEOX:LeaseAgreementMember 2025-06-30 0001557376 ZEOX:LeaseAgreementMember 2025-06-02 2025-06-30 0001557376 ZEOX:IanBothwellMember ZEOX:SerephonMember 2026-05-01 2026-05-12 0001557376 ZEOX:DrGeorgeShapiroMember ZEOX:SerephonMember 2026-05-01 2026-05-12 0001557376 ZEOX:GreytVenturesLLCMember ZEOX:SerephonMember 2026-05-01 2026-05-12 0001557376 ZEOX:SerephonMember 2026-05-01 2026-05-12 0001557376 ZEOX:SerephonMember 2025-11-01 2026-06-30 0001557376 ZEOX:SerephonMember 2026-06-30 0001557376 ZEOX:ConvertiblePromissoryNotesMember 2025-11-01 2026-06-30 0001557376 ZEOX:ConvertiblePromissoryNotesMember 2026-06-30 0001557376 us-gaap:WarrantMember ZEOX:FourInvestorsMember 2025-11-01 2026-06-30 0001557376 us-gaap:WarrantMember ZEOX:FourInvestorsMember 2026-06-30 0001557376 ZEOX:HolderMember 2025-10-10 0001557376 ZEOX:HolderMember 2025-10-02 2025-10-10 0001557376 ZEOX:ConvertiblePromissoryNotesMember 2024-11-01 2025-10-31 0001557376 ZEOX:ConvertiblePromissoryNotesMember 2025-10-31 0001557376 ZEOX:ConvertiblePromissoryNotesMember 2023-11-01 2024-10-31 0001557376 2022-11-01 2023-10-31 0001557376 ZEOX:SeriesCNonConvertiblePreferredStockMember 2022-08-17 0001557376 us-gaap:InvestorMember 2024-07-01 2024-07-08 0001557376 us-gaap:InvestorMember 2025-11-01 2026-06-30 0001557376 ZEOX:FifteenInvestorsMember 2025-11-01 2026-06-30 0001557376 ZEOX:EightInvestorsMember 2025-11-01 2026-06-30 0001557376 ZEOX:N22021PlanMember 2021-09-01 2021-09-30 0001557376 ZEOX:N22021PlanMember 2023-06-01 2023-06-06 0001557376 ZEOX:N22021PlanMember 2026-06-01 2026-06-10 0001557376 ZEOX:N22021PlanMember 2026-06-30 0001557376 ZEOX:N22021PlanMember 2025-10-31 0001557376 2024-01-01 2024-01-31 0001557376 ZEOX:SalescoMember ZEOX:SalesDistributionAgreementMember 2024-04-01 0001557376 ZEOX:SalescoMember ZEOX:SalesDistributionAgreementMember 2024-03-30 2024-04-01 0001557376 ZEOX:SalescoMember ZEOX:SalesDistributionAgreementMember 2024-11-01 2025-10-31 0001557376 ZEOX:SalescoMember ZEOX:SalesDistributionAgreementMember 2023-11-01 2024-10-31 0001557376 ZEOX:TwentyIndividualsMember srt:MinimumMember 2024-08-31 0001557376 ZEOX:TwentyIndividualsMember srt:MaximumMember 2024-08-31 0001557376 ZEOX:TwentyIndividualsMember 2024-04-02 2024-08-31 0001557376 ZEOX:TwentyIndividualsMember 2025-11-01 2026-06-30 0001557376 ZEOX:TwentyIndividualsMember 2024-11-01 2025-10-31 0001557376 ZEOX:TwentyIndividualsMember 2023-11-01 2024-10-31 0001557376 ZEOX:RestrictedStockAwardsMember 2025-02-02 0001557376 ZEOX:RestrictedStockAwardsMember 2024-11-01 2025-10-31 0001557376 ZEOX:ConsultantMember ZEOX:ConsultingAgreementMember 2025-05-01 2025-05-08 0001557376 ZEOX:SecondConsultantMember ZEOX:ConsultingAgreementMember 2025-05-01 2025-05-23 0001557376 ZEOX:BioLuminaLLCMember 2025-06-01 2025-06-25 0001557376 ZEOX:ConsultantMember ZEOX:ConsultingAgreementMember 2025-11-30 2025-12-01 0001557376 ZEOX:ConsultantMember ZEOX:ConsultingAgreementMember 2025-12-01 0001557376 ZEOX:ConsultantMember ZEOX:ConsultingAgreementMember 2025-11-01 2026-06-30 0001557376 ZEOX:EmployeeMember ZEOX:N2021IncentiveStockPlanMember 2025-12-02 2025-12-23 0001557376 ZEOX:EmployeeMember ZEOX:N2021IncentiveStockPlanMember 2025-12-23 0001557376 ZEOX:EmployeeMember ZEOX:N2021IncentiveStockPlanMember 2025-11-01 2026-06-30 0001557376 ZEOX:IanBothwellMember srt:ChiefExecutiveOfficerMember ZEOX:N2021PlanMember 2026-01-01 2026-01-14 0001557376 ZEOX:DrGeorgeShapiroMember ZEOX:ChiefMedicalOfficerMember ZEOX:N2021PlanMember 2026-01-01 2026-01-14 0001557376 ZEOX:GreytVenturesLLCMember ZEOX:N2021PlanMember 2026-01-01 2026-01-14 0001557376 ZEOX:N2021PlanMember 2026-01-01 2026-01-14 0001557376 ZEOX:N2021PlanMember 2026-01-14 0001557376 ZEOX:N2021PlanMember 2025-11-01 2026-06-30 0001557376 ZEOX:DrKisidayMember ZEOX:N2021PlanMember ZEOX:EmploymentAgreementMember 2026-01-01 2026-01-23 0001557376 ZEOX:DrKisidayMember ZEOX:N2021PlanMember ZEOX:EmploymentAgreementMember 2026-01-23 0001557376 ZEOX:ConsultantMember 2025-11-01 2026-06-30 0001557376 ZEOX:ConsultantMember srt:MinimumMember 2026-06-30 0001557376 ZEOX:ConsultantMember srt:MaximumMember 2026-06-30 0001557376 ZEOX:ConsultantMember 2024-11-01 2025-06-30 0001557376 ZEOX:ConsultantMember 2023-11-01 2024-06-30 0001557376 ZEOX:ConsultantMember 2025-11-01 2026-04-30 0001557376 ZEOX:ConsultantMember 2024-11-01 2025-04-30 0001557376 ZEOX:ConsultantMember 2023-11-01 2024-04-30 0001557376 ZEOX:UnvestedStockGrantsMember 2025-11-01 2026-06-30 0001557376 ZEOX:UnvestedStockGrantsMember 2024-11-01 2025-10-31 0001557376 ZEOX:UnvestedStockGrantsMember 2023-11-01 2024-10-31 0001557376 ZEOX:UnvestedSharesMember 2026-06-30 0001557376 ZEOX:UnvestedSharesMember 2024-11-01 2025-10-31 0001557376 us-gaap:StockOptionMember 2023-10-31 0001557376 us-gaap:StockOptionMember 2022-11-01 2023-10-31 0001557376 us-gaap:StockOptionMember 2023-11-01 2024-10-31 0001557376 us-gaap:StockOptionMember 2024-10-31 0001557376 us-gaap:StockOptionMember 2024-11-01 2025-10-31 0001557376 us-gaap:StockOptionMember 2025-10-31 0001557376 us-gaap:StockOptionMember 2025-11-01 2026-06-30 0001557376 us-gaap:StockOptionMember 2026-06-30 0001557376 srt:DirectorMember 2023-11-01 2024-10-31 0001557376 srt:DirectorMember 2024-10-31 0001557376 ZEOX:DrLeiderMember 2024-11-01 2025-10-31 0001557376 ZEOX:DrHowardGolubMember 2024-11-01 2025-10-31 0001557376 ZEOX:EmployeeMember 2024-11-01 2025-10-31 0001557376 srt:DirectorMember 2024-11-01 2025-10-31 0001557376 srt:DirectorMember 2025-10-31 0001557376 ZEOX:Dr.EvertsMember 2024-11-01 2025-10-31 0001557376 ZEOX:Dr.EvertsMember 2025-10-31 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember 2025-05-08 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember 2025-05-01 2025-05-08 0001557376 ZEOX:EmployeesMember 2025-11-01 2026-06-30 0001557376 ZEOX:EmployeesMember 2024-11-01 2025-10-31 0001557376 ZEOX:OptionsVestingMember 2025-11-01 2026-06-30 0001557376 ZEOX:OptionsVestingMember 2024-11-01 2025-10-31 0001557376 ZEOX:OptionsVestingMember 2023-11-01 2024-10-31 0001557376 ZEOX:OptionsOutstandingMember 2025-11-01 2026-06-30 0001557376 us-gaap:WarrantMember 2024-07-01 2024-07-08 0001557376 us-gaap:WarrantMember 2024-07-01 2024-07-11 0001557376 ZEOX:TwoConsultantsMember 2024-07-01 2024-07-11 0001557376 us-gaap:WarrantMember 2024-08-01 2024-08-31 0001557376 ZEOX:ThirdPartyMember 2024-08-01 2024-08-31 0001557376 ZEOX:ConsultantsMember ZEOX:ConsultingAgreementMember 2025-05-01 2025-05-08 0001557376 ZEOX:N4tranchesMember ZEOX:ConsultingAgreementMember 2025-11-01 2026-06-30 0001557376 ZEOX:N4tranchesMember ZEOX:ConsultingAgreementMember 2026-06-30 0001557376 2025-05-01 2025-05-08 0001557376 2025-05-08 0001557376 us-gaap:WarrantMember 2025-11-01 2026-06-30 0001557376 us-gaap:WarrantMember 2024-11-01 2025-10-31 0001557376 us-gaap:WarrantMember 2023-11-01 2024-10-31 0001557376 us-gaap:WarrantMember 2026-06-30 0001557376 us-gaap:WarrantMember 2025-10-31 0001557376 us-gaap:WarrantMember 2024-10-31 0001557376 srt:MinimumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2024-10-31 0001557376 srt:MaximumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2024-10-31 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2023-11-01 2024-10-31 0001557376 srt:MinimumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2023-11-01 2024-10-31 0001557376 srt:MaximumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2023-11-01 2024-10-31 0001557376 srt:MinimumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2025-10-31 0001557376 srt:MaximumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2025-10-31 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2024-11-01 2025-10-31 0001557376 srt:MinimumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2024-11-01 2025-10-31 0001557376 srt:MaximumMember ZEOX:EmployeesOfficersAndDirectorsMember us-gaap:StockOptionMember 2024-11-01 2025-10-31 0001557376 srt:MinimumMember ZEOX:IanBothwellMember us-gaap:StockOptionMember 2026-06-30 0001557376 srt:MaximumMember ZEOX:IanBothwellMember us-gaap:StockOptionMember 2026-06-30 0001557376 ZEOX:Dr.EvertsMember us-gaap:StockOptionMember 2025-11-01 2026-06-30 0001557376 srt:MinimumMember ZEOX:IanBothwellMember us-gaap:StockOptionMember 2025-11-01 2026-06-30 0001557376 srt:MaximumMember ZEOX:IanBothwellMember us-gaap:StockOptionMember 2025-11-01 2026-06-30 0001557376 us-gaap:WarrantMember 2023-10-31 0001557376 us-gaap:WarrantMember 2022-11-01 2023-10-31 0001557376 ZEOX:GreytVenturesLLCMember us-gaap:StockOptionMember 2025-05-08 0001557376 ZEOX:GreytVenturesLLCMember us-gaap:StockOptionMember 2025-05-01 2025-05-08 0001557376 ZEOX:IanBothwellMember 2026-06-02 2026-06-10 0001557376 ZEOX:Dr.GeorgeShapiroMember 2026-06-02 2026-06-10 0001557376 ZEOX:GreytVenturesLLCMember 2026-06-02 2026-06-10 0001557376 ZEOX:N2021IncentiveStockPlanMember 2026-06-01 2026-06-10 0001557376 ZEOX:MonteCarloSimulationMember 2025-11-01 2026-06-30 0001557376 ZEOX:MonteCarloMember srt:MaximumMember ZEOX:N2021IncentiveStockPlanMember 2025-11-01 2026-06-30 0001557376 ZEOX:MonteCarloMember srt:MinimumMember ZEOX:N2021IncentiveStockPlanMember 2025-11-01 2026-06-30 0001557376 ZEOX:MonteCarloMember 2025-10-31 0001557376 ZEOX:MonteCarloMember 2025-11-01 2026-06-30 0001557376 ZEOX:MonteCarloMember 2026-06-30 0001557376 ZEOX:DrKisidayMember ZEOX:N2021IncentiveStockPlanMember ZEOX:EmploymentAgreementMember 2026-01-01 2026-01-23 0001557376 ZEOX:SupplyAgreementMember 2026-06-30 0001557376 ZEOX:SupplyAgreementMember 2025-10-31 0001557376 2024-11-01 2024-11-13 0001557376 ZEOX:ConsultantsMember ZEOX:SettlementAgreementMember 2025-08-01 2025-08-05 0001557376 ZEOX:HowardGolubMember 2025-11-01 2025-11-14 0001557376 ZEOX:ManagementServicesOrganizationMember 2025-11-01 2026-06-30 0001557376 ZEOX:ManagementServicesOrganizationMember 2024-11-01 2025-10-31 0001557376 ZEOX:ManagementServicesOrganizationMember 2023-11-01 2024-10-31 0001557376 ZEOX:DrGeorgeShapiroMember ZEOX:ManagementServicesOrganizationMember 2025-11-01 2026-06-30 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember 2025-11-01 2026-06-30 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember 2024-11-01 2025-10-31 0001557376 ZEOX:EmployeesOfficersAndDirectorsMember 2023-11-01 2024-10-31 0001557376 ZEOX:RelatedPartiesMember 2025-11-01 2026-06-30 0001557376 ZEOX:RelatedPartiesMember 2024-11-01 2025-10-31 0001557376 ZEOX:RelatedPartiesMember 2023-11-01 2024-10-31 0001557376 2025-06-01 2025-06-26 0001557376 ZEOX:BioLuminaLLCMember ZEOX:ZeoSharesMember 2025-06-01 2025-06-25 0001557376 2024-11-01 2025-06-30 0001557376 ZEOX:ConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2026-09-30 0001557376 ZEOX:ConvertiblePromissoryNotesMember us-gaap:SubsequentEventMember 2026-09-01 2026-09-30 0001557376 ZEOX:IanTBothwellMember 2026-06-30 0001557376 ZEOX:IanTBothwellMember1Member 2026-06-30 0001557376 ZEOX:IanTBothwellMember2Member 2026-06-30 0001557376 ZEOX:IanTBothwellMember3Member 2026-06-30 0001557376 ZEOX:IanTBothwellMember4Member 2026-06-30 0001557376 ZEOX:IanTBothwellMember5Member 2026-06-30 0001557376 ZEOX:DrGeorgeShapiroMember 2026-06-30 0001557376 ZEOX:DrGeorgeShapiro1Member 2026-06-30 0001557376 ZEOX:DrGeorgeShapiro2Member 2026-06-30 0001557376 ZEOX:DrGeorgeShapiro3Member 2026-06-30 0001557376 ZEOX:DrGeorgeShapiro4Member 2026-06-30 iso4217:USD shares iso4217:USD shares pure ZEOX:Integer false 2026 FY 0001557376 10-KT false true 2025-11-01 2026-06-30 --06-30 000-55008 ZEO SCIENTIFIX, INC NV 47-4180540 3321 College Avenue Suite 246 Davie FL 33314 888 963-7881 No No Yes Yes Non-accelerated Filer true false false false false 7129000 7837441 None 572 Weinberg & Company P.A. Los Angeles, CA 2265000 221000 245000 35000 179000 279000 796000 423000 3485000 958000 595000 569000 18000 4098000 1527000 2075000 1980000 30000 33000 2000 7000 248000 243000 22000 19000 818000 598000 227000 3420000 2873000 59000 77000 3479000 2950000 0.001 0.001 100 100 100 100 100 100 0.001 0.001 2500000000 2500000000 7837441 7837441 6747441 6747441 8000 7000 73383000 66304000 -72808000 -67734000 583000 -1423000 36000 619000 -1423000 4098000 1527000 70000 88000 199000 5868000 5199000 4620000 1128000 931000 844000 4740000 4268000 3776000 4697000 4091000 3445000 10165000 9654000 9095000 -5425000 -5386000 -5319000 -390000 27000 98000 92000 3000 2000 136000 45000 27000 101000 751000 -5038000 -5521000 -4705000 36000 -5074000 -5521000 -4705000 -0.68 -0.68 -0.86 -0.86 -0.74 -0.74 7493536 7493536 6409953 6409953 6336392 6336392 7283483 7000 56260000 -57508000 -1241000 -1241000 250000 500000 500000 500000 5803 -1164742 -1000 1000 -237602 -80000 -80000 -80000 20000 20000 20000 20000 187875 450000 450000 450000 953000 953000 953000 2450000 2450000 2450000 -4705000 -4705000 -4705000 6344817 6000 60554000 -62213000 -1653000 -1653000 75000 300000 300000 300000 136000 136000 136000 171347 1000 513000 514000 514000 30000 58000 58000 58000 21277 50000 50000 50000 105000 233000 233000 233000 1523000 1523000 1523000 2937000 2937000 2937000 -5521000 -5521000 -5521000 6747441 7000 66304000 -67734000 -1423000 -1423000 537500 2150000 2150000 2150000 552500 1000 1118000 1119000 1119000 3596000 3596000 3596000 215000 215000 215000 -5074000 -5074000 36000 -5038000 7837441 8000 73383000 -72808000 583000 36000 619000 -5038000 -5521000 -4705000 52000 73000 74000 5000 39000 23000 -390000 3000 2000 136000 45000 221000 4930000 4693000 3853000 227000 -0 -0 9000 210000 -159000 185000 -3000 -9000 -100000 25000 -27000 422000 191000 -78000 158000 200000 -851000 -18000 7000 220000 -286000 387000 -383000 -718000 -1450000 78000 23000 45000 376000 298000 -23000 -45000 21000 45000 24000 80000 50000 2150000 300000 500000 2129000 305000 396000 2044000 -436000 -1099000 221000 657000 1756000 2265000 221000 657000 20000 68000 50000 14000 140000 58000 514000 100000 16000 21000 20000 <p id="xdx_807_eus-gaap--NatureOfOperations_zLVphlL1XSBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – <span id="xdx_823_zvPz6KkN1WNb">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Zeo ScientifiX, Inc. (“ZEO” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). Effective February 20, 2024, we further amended our Articles of Incorporation to assume our current name, Zeo ScientifiX, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. In connection with the state of Florida’s new “stem cell therapy” law, effective July 1, 2025 (“SB 1768”), Tennessee’s enacted HB 2246/SB 2586, Public Chapter 1016 became effective July 1, 2026 and Georgia’s enacted HB 1275, Act 453, effective July 1, 2026, the Company has implemented clinical research and commercial sales strategies that are compliant with the newly enacted state stem cell laws. The Company has a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly matrix. The Company’s principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. ZEO also manufactures Patient Pure X™ (“PPX™”), a proprietary autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood. ZEO’s products are all manufactured in FDA-registered, cGMP-compliant laboratory facilities. Our portfolio of products (“RAAM Products”) and related services are principally used in the health care industry administered through doctors and clinics (“Providers”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the Company’s efforts to now supply products that are compliant with the newly enacted state stem cell laws, the Company has recently developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective November 28, 2023, we implemented a <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20251101__20260630_zqNAzo3uqOL1" title="Reverse stock split">one-for-200</span> reverse stock split (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on the Company’s balance sheet attributable to the Company’s common stock was reduced proportionately based on the Reverse Split ratio of one-for-200 and the additional paid-in capital account was credited with the amount by which the stated capital was reduced. All share and per share amounts referenced herein give effect to the Reverse Split as of the earliest period presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> one-for-200 <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zZwC4A0bhok3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 – <span id="xdx_822_z5vng7j4KGm">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Change in Fiscal Year</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective September 10, 2026, the Company changed its fiscal year end from October 31 to June 30. As a result of this change, the Company is presenting audited consolidated financial statements for the eight-month transition period from November 1, 2025 through June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated balance sheets are presented as of June 30, 2026 and October 31, 2025. The consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows are presented for the eight-month transition period ended June 30, 2026 and for the fiscal years ended October 31, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain unaudited financial information for the eight-month period ended June 30, 2025 is presented for comparative purposes (see Note 20). The unaudited comparative information has been prepared on the same basis as the Company’s audited consolidated financial statements and, in the opinion of management, includes all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s results of operations for such period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the change in fiscal year end, the Company’s results for the eight-month transition period ended June 30, 2026 are not directly comparable to the results for the fiscal years ended October 31, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqqai8fG8Bh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_863_zsFjBF616vq1">Basis of Presentation</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company is considered the primary beneficiary of a VIE when it has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. All significant intercompany accounts and transactions of consolidated VIEs have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zzprdBMAFqa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_ziiERFuzSUrb">Concentrations of Risk</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_c20251031_pp0p" title="FDIC limits per institutions">250,000</span> per institution. At June 30, 2026, the Company had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_c20251031_pp0p" title="Cash balances">930,000</span> of cash balances in one financial institution in excess of FDIC insurance coverage limits and $499,000 of cash balances in another financial institution in excess of FDIC insurance coverage limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Customer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the eight months ended June 30, 2026, the Company sold products and services totaling approximately $<span id="xdx_909_eus-gaap--Revenues_c20251101__20260630__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p" title="Revenues">638,000</span> (<span id="xdx_90C_ecustom--ConcentrationPercentage_c20251101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pd" title="Concentration percentage">10.9%</span>) to a large distributor and medical practice group and approximately $<span id="xdx_904_eus-gaap--Revenues_c20251101__20260630__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p" title="Revenues">598,000</span> (<span id="xdx_903_ecustom--ConcentrationPercentage_c20251101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pd" title="Concentration percentage">10.2%</span>) to another large distributor and medical practice group.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2025, the Company sold products and services totaling approximately $<span id="xdx_909_eus-gaap--Revenues_c20241101__20251031__srt--MajorCustomersAxis__custom--LargeMedicalPacticeGroupMember_pp0p" title="Revenues">741,000</span> (<span id="xdx_906_ecustom--ConcentrationPercentage_c20241101__20251031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeMedicalPacticeGroupMember_zYfq2bXYhSTf" title="Concentration percentage">14.3%</span>) to a large medical practice group, approximately $<span id="xdx_90F_eus-gaap--Revenues_c20241101__20251031__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p" title="Revenues">597,000</span> (<span id="xdx_902_ecustom--ConcentrationPercentage_c20241101__20251031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_zHscPbzCyi21" title="Concentration percentage">11.5%</span>) to a large distributor and medical practice group and approximately $<span id="xdx_902_eus-gaap--Revenues_c20241101__20251031__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p" title="Revenues">568,000</span> (<span id="xdx_900_ecustom--ConcentrationPercentage_c20241101__20251031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_zgCKfsHdhwJa" title="Concentration percentage">10.9%</span>) to another large distributor and medical practice group.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2024, the Company sold products and services totaling approximately $<span id="xdx_900_eus-gaap--Revenues_c20231101__20241031__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p" title="Revenues">661,000</span> (<span id="xdx_902_ecustom--ConcentrationPercentage_c20231101__20241031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_zh1dHbyjPKs" title="Concentration percentage">14.3%</span>) to a large distributor and medical practice group and approximately $<span id="xdx_903_eus-gaap--Revenues_c20231101__20241031__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p" title="Revenues">556,000</span> (<span id="xdx_908_ecustom--ConcentrationPercentage_c20231101__20241031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_zGnHQARrDXTi" title="Concentration percentage">12.0%</span>) to another large distributor and medical practice group.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2026, the Company had accounts receivable from one customer which comprised <span id="xdx_90B_ecustom--ConcentrationPercentage_c20251101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_pd" title="Concentration percentage">94%</span> of its gross accounts receivable. As of October 31, 2025, the Company had accounts receivable from one customer which comprised 100% of its gross accounts receivable. There were no other customers that accounted for more than 10% of accounts receivable at June 30, 2026 or October 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Supplier</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has contracts with more than one supplier of the tissue raw material used in manufacturing of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the eight months ended June 30, 2026, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $<span id="xdx_906_eus-gaap--InventoryRawMaterials_c20260630__srt--MajorCustomersAxis__custom--OneSupplierMember_pp0p" title="Raw material">104,000</span> (<span id="xdx_909_ecustom--ConcentrationPercentage_c20251101__20260630__srt--MajorCustomersAxis__custom--OneSupplierMember_pd" title="Concentration percentage">61%</span> of total raw material purchases) and $<span id="xdx_908_eus-gaap--InventoryRawMaterials_c20260630__srt--MajorCustomersAxis__custom--TwoSupplierMember_pp0p" title="Raw material">66,000</span> (<span id="xdx_900_ecustom--ConcentrationPercentage_c20251101__20260630__srt--MajorCustomersAxis__custom--TwoSupplierMember_pd" title="Concentration percentage">39%</span> of total raw material purchases).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended October 31, 2025, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $<span id="xdx_90B_eus-gaap--InventoryRawMaterials_c20251031__srt--MajorCustomersAxis__custom--OneSupplierMember_pp0p" title="Raw material">120,000</span> (<span id="xdx_90E_ecustom--ConcentrationPercentage_c20241101__20251031__srt--MajorCustomersAxis__custom--OneSupplierMember_zOXxdtuEEpPa" title="Concentration percentage">72%</span> of total raw material purchases) and $<span id="xdx_909_eus-gaap--InventoryRawMaterials_iI_pp0d_c20251031__srt--MajorCustomersAxis__custom--TwoSupplierMember_zHOkT3WfnWt" title="Raw material">45,000</span> (<span id="xdx_905_ecustom--ConcentrationPercentage_c20241101__20251031__srt--MajorCustomersAxis__custom--TwoSupplierMember_zkYxROuuBMqb" title="Concentration percentage">28%</span> of total raw material purchases). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended October 31, 2024, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $<span id="xdx_908_eus-gaap--InventoryRawMaterials_iI_pp0d_c20241031__srt--MajorCustomersAxis__custom--OneSupplierMember_zfotTbrIWXzj" title="Raw material">135,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zQ0cpksSe3xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_869_zTuhVgtac1il">Use of Estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing share-based compensation liability and equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zTFW87bnWOyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z7cfo9I6LcDc">Cash Equivalents</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zVRYvpP68nAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_860_zp6N6K1wZu06">Accounts Receivable</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Most of the Company’s sales do not provide for installment payments and amounts are typically due upon invoicing. However, for those customers that are granted payment terms, the policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company are exhausted, the determination for charging off uncollectible receivables is made. Management determined that no allowance for bad debts was necessary at June 30, 2026 and October 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_z2qvgTWpOBib" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_864_zyU1Q05RKvf9">Inventory</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides a reserve for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At June 30, 2026 and October 31, 2025, the Company determined that no reserves were required in connection with our inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zkwKv3IoKM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86B_zwBxfgSSLpEg">Property and Equipment</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 15 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_ecustom--LeaseholdImprovementsPolicyTextBlock_zXc4XT7ePYK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86B_zcYyZYXSuUt2">Leasehold Improvements</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Leasehold improvements in excess of $1,000 that are made in connection with leases having a term of more than 12 months are capitalized by the Company and amortized over the shorter of the useful life of the asset or the remaining lease periods and renewals that are deemed to be reasonably certain at the date the leasehold improvements are purchased. Costs associated with leasehold improvements that do not exceed $1,000 are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zRgJXcdZYEpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86A_zC2NzxHqcRgi">Revenue Recognition</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASC”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zafX89Mg5Uk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"></span> <span style="text-decoration: underline">Net Income (Loss) Per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2026, the Company had <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">8,207,357</span> common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfUnissuedRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">290,000</span> unissued restricted stock (<span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOunvestedSharesOfRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">178,333</span> unvested), $<span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">250,000</span> of convertible debt securities (convertible into a maximum of 41,667 shares) and $<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheFuturePaymentsMember_zudSofA1PhXb" title="Antidilutive securities excluded from computation of earnings per share">50,000</span> of future obligations in connection with the purchase of the BioLumina assets that may be settled through the issuance of common stock (convertible into a maximum of 20,000 shares) that were not included in the computation of diluted loss per share because their inclusion is anti-dilutive for the eight months ended June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At October 31, 2025, the Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">4,265,444</span> common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfUnissuedRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">212,500</span> unissued restricted stock (<span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOunvestedSharesOfRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">178,333</span> unvested), $<span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">250,000</span> of convertible debt securities (convertible into a maximum of 41,667 shares) and $<span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheFuturePaymentsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">100,000</span> of future obligations in connection with the purchase of the BioLumina assets that may be settled through the issuance of common stock (convertible into a maximum of 40,000 shares) that were not included in the computation of diluted loss per share because their inclusion is anti-dilutive for the year ended October 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At October 31, 2024, the Company had 3,522,527 common shares issuable upon the exercise of options and warrants (vested and unvested), 185,000 unvested and unissued restricted stock and $725,000 of convertible debt securities (convertible into a maximum of 120,834 shares) that were not included in the computation of diluted loss per share because their inclusion is anti-dilutive for the nine months ended October 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAlXxe1By7Ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><i><span id="xdx_86D_z8X0L9GaYHfj">Stock-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock-based payments are recognized in the financial statements based on their fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based awards granted to employees, nonemployee directors, and consultants in accordance with ASC 718, “<i>Compensation—Stock Compensation</i>.” Stock-based awards are measured at fair value, and compensation expense is recognized over the applicable requisite service period. The Company accounts for forfeitures as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Awards</i>. The fair value of restricted stock awards is measured based on the closing market price of the Company’s common stock on the grant date. Compensation expense is recognized over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Service-Based Stock Options</i>. The fair value of stock options subject solely to service-based vesting conditions is measured on the grant date using the Black-Scholes option-pricing model. Compensation expense is recognized on a straight-line basis over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options with Market or Performance Conditions</i>. The fair value and derived service period of stock options containing a market condition are estimated on the grant date using a Monte Carlo simulation model. For awards that vest upon the first to occur of a market condition or a performance condition, compensation expense is recognized over the derived service period. If the performance condition becomes probable of achievement and its associated implicit service period is shorter than the derived service period, any unrecognized compensation expense is recognized prospectively over the revised requisite service period. If either condition is achieved before the end of the requisite service period, any unrecognized compensation expense is recognized immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Liability-Classified Stock Options</i>. Stock options indexed to a factor in addition to the Company’s share price that is not a market, performance, or service condition are classified as liabilities. Liability-classified awards are measured at fair value on the grant date and remeasured at the end of each reporting period until settlement. During the requisite service period, compensation expense is recognized based on changes in the fair value of the award, adjusted for the portion of the requisite service rendered through each reporting period. If the award vests before completion of the requisite service period, any unrecognized compensation expense based on the then-current fair value is recognized immediately. After vesting or completion of the requisite service period, subsequent changes in fair value are recognized in compensation expense until settlement.</p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0li5P9yFa5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86E_zEa2WWgf2Dni">Research and Development Costs</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $<span id="xdx_90E_ecustom--OperatingAndFinanceLeaseObligation_c20251101__20260630_pp0p" title="Operating and finance lease obligation">65,000</span>, $<span id="xdx_903_ecustom--OperatingAndFinanceLeaseObligation_c20241101__20251031_pp0p" title="Operating and finance lease obligation">100,000</span> and $<span id="xdx_905_ecustom--OperatingAndFinanceLeaseObligation_c20231101__20241031_pp0p" title="Operating and finance lease obligation">164,000</span> for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWWRQ04jvsNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"></span><span style="text-decoration: underline"><span id="xdx_86A_zRdyFm8ItJL7">Income Taxes</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files a consolidated tax return that includes all of its subsidiaries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znSAFIJMAQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_860_zTJbYuwDkYE9">Fair Value of Financial Instruments</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Level one</i> — Quoted market prices in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Level two</i> — Inputs other than level one inputs that are either directly or indirectly observable such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Level three</i> — Unobservable inputs that are supported by little or no market activity and developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of convertible notes approximate their fair values because interest rates on these obligations are based on prevailing market interest rates. The estimated fair value of the share-based compensation liability is determined using Level 3 inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_ecustom--OperatingLeaseObligationsPolicyTextBlock_zAgBUulbyfQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_869_zByfofDXmxSb">Operating Lease Obligations</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating and financing leases upon commencement of the lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $15,000 in determining whether any future operating leases will be capitalized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zlZSihzgkxwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_zyWYqai7zR88">Subsequent Events</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events that occurred after June 30, 2026 through the financial statement issuance date for subsequent event disclosure or recording.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHcm7asP03Qa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_860_zQwpVMzdT9Kg">Recently Issued Accounting Pronouncements</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on its financial statement disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed all accounting pronouncements recently issued by the FASB and the SEC. The authoritative pronouncements that we have already adopted did not have a material effect on our financial condition, results of operations, cash flows or reporting thereof, and except as otherwise noted above, we do not believe that any of the authoritative pronouncements that we have not yet adopted will have a material effect upon our financial condition, results of operations, cash flows or reporting thereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zqqai8fG8Bh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_863_zsFjBF616vq1">Basis of Presentation</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company is considered the primary beneficiary of a VIE when it has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. All significant intercompany accounts and transactions of consolidated VIEs have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zzprdBMAFqa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_ziiERFuzSUrb">Concentrations of Risk</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_c20251031_pp0p" title="FDIC limits per institutions">250,000</span> per institution. At June 30, 2026, the Company had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_c20251031_pp0p" title="Cash balances">930,000</span> of cash balances in one financial institution in excess of FDIC insurance coverage limits and $499,000 of cash balances in another financial institution in excess of FDIC insurance coverage limits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Customer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the eight months ended June 30, 2026, the Company sold products and services totaling approximately $<span id="xdx_909_eus-gaap--Revenues_c20251101__20260630__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p" title="Revenues">638,000</span> (<span id="xdx_90C_ecustom--ConcentrationPercentage_c20251101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_pd" title="Concentration percentage">10.9%</span>) to a large distributor and medical practice group and approximately $<span id="xdx_904_eus-gaap--Revenues_c20251101__20260630__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p" title="Revenues">598,000</span> (<span id="xdx_903_ecustom--ConcentrationPercentage_c20251101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pd" title="Concentration percentage">10.2%</span>) to another large distributor and medical practice group.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2025, the Company sold products and services totaling approximately $<span id="xdx_909_eus-gaap--Revenues_c20241101__20251031__srt--MajorCustomersAxis__custom--LargeMedicalPacticeGroupMember_pp0p" title="Revenues">741,000</span> (<span id="xdx_906_ecustom--ConcentrationPercentage_c20241101__20251031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeMedicalPacticeGroupMember_zYfq2bXYhSTf" title="Concentration percentage">14.3%</span>) to a large medical practice group, approximately $<span id="xdx_90F_eus-gaap--Revenues_c20241101__20251031__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p" title="Revenues">597,000</span> (<span id="xdx_902_ecustom--ConcentrationPercentage_c20241101__20251031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_zHscPbzCyi21" title="Concentration percentage">11.5%</span>) to a large distributor and medical practice group and approximately $<span id="xdx_902_eus-gaap--Revenues_c20241101__20251031__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p" title="Revenues">568,000</span> (<span id="xdx_900_ecustom--ConcentrationPercentage_c20241101__20251031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_zgCKfsHdhwJa" title="Concentration percentage">10.9%</span>) to another large distributor and medical practice group.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2024, the Company sold products and services totaling approximately $<span id="xdx_900_eus-gaap--Revenues_c20231101__20241031__srt--MajorCustomersAxis__custom--LargeDistributorMember_pp0p" title="Revenues">661,000</span> (<span id="xdx_902_ecustom--ConcentrationPercentage_c20231101__20241031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargeDistributorMember_zh1dHbyjPKs" title="Concentration percentage">14.3%</span>) to a large distributor and medical practice group and approximately $<span id="xdx_903_eus-gaap--Revenues_c20231101__20241031__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_pp0p" title="Revenues">556,000</span> (<span id="xdx_908_ecustom--ConcentrationPercentage_c20231101__20241031__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AnotherLargeDistributorMember_zGnHQARrDXTi" title="Concentration percentage">12.0%</span>) to another large distributor and medical practice group.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2026, the Company had accounts receivable from one customer which comprised <span id="xdx_90B_ecustom--ConcentrationPercentage_c20251101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_pd" title="Concentration percentage">94%</span> of its gross accounts receivable. As of October 31, 2025, the Company had accounts receivable from one customer which comprised 100% of its gross accounts receivable. There were no other customers that accounted for more than 10% of accounts receivable at June 30, 2026 or October 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Major Supplier</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has contracts with more than one supplier of the tissue raw material used in manufacturing of its products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the eight months ended June 30, 2026, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $<span id="xdx_906_eus-gaap--InventoryRawMaterials_c20260630__srt--MajorCustomersAxis__custom--OneSupplierMember_pp0p" title="Raw material">104,000</span> (<span id="xdx_909_ecustom--ConcentrationPercentage_c20251101__20260630__srt--MajorCustomersAxis__custom--OneSupplierMember_pd" title="Concentration percentage">61%</span> of total raw material purchases) and $<span id="xdx_908_eus-gaap--InventoryRawMaterials_c20260630__srt--MajorCustomersAxis__custom--TwoSupplierMember_pp0p" title="Raw material">66,000</span> (<span id="xdx_900_ecustom--ConcentrationPercentage_c20251101__20260630__srt--MajorCustomersAxis__custom--TwoSupplierMember_pd" title="Concentration percentage">39%</span> of total raw material purchases).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended October 31, 2025, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $<span id="xdx_90B_eus-gaap--InventoryRawMaterials_c20251031__srt--MajorCustomersAxis__custom--OneSupplierMember_pp0p" title="Raw material">120,000</span> (<span id="xdx_90E_ecustom--ConcentrationPercentage_c20241101__20251031__srt--MajorCustomersAxis__custom--OneSupplierMember_zOXxdtuEEpPa" title="Concentration percentage">72%</span> of total raw material purchases) and $<span id="xdx_909_eus-gaap--InventoryRawMaterials_iI_pp0d_c20251031__srt--MajorCustomersAxis__custom--TwoSupplierMember_zHOkT3WfnWt" title="Raw material">45,000</span> (<span id="xdx_905_ecustom--ConcentrationPercentage_c20241101__20251031__srt--MajorCustomersAxis__custom--TwoSupplierMember_zkYxROuuBMqb" title="Concentration percentage">28%</span> of total raw material purchases). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended October 31, 2024, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $<span id="xdx_908_eus-gaap--InventoryRawMaterials_iI_pp0d_c20241031__srt--MajorCustomersAxis__custom--OneSupplierMember_zfotTbrIWXzj" title="Raw material">135,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 250000 930000 638000 0.109 598000 0.102 741000 0.143 597000 0.115 568000 0.109 661000 0.143 556000 0.120 0.94 104000 0.61 66000 0.39 120000 0.72 45000 0.28 135000 <p id="xdx_84F_eus-gaap--UseOfEstimates_zQ0cpksSe3xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_869_zTuhVgtac1il">Use of Estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing share-based compensation liability and equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zTFW87bnWOyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z7cfo9I6LcDc">Cash Equivalents</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zVRYvpP68nAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_860_zp6N6K1wZu06">Accounts Receivable</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Most of the Company’s sales do not provide for installment payments and amounts are typically due upon invoicing. However, for those customers that are granted payment terms, the policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company are exhausted, the determination for charging off uncollectible receivables is made. Management determined that no allowance for bad debts was necessary at June 30, 2026 and October 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_z2qvgTWpOBib" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_864_zyU1Q05RKvf9">Inventory</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides a reserve for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At June 30, 2026 and October 31, 2025, the Company determined that no reserves were required in connection with our inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zkwKv3IoKM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86B_zwBxfgSSLpEg">Property and Equipment</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 to 15 years. Upon sale or retirement, the cost and related accumulated depreciation and amortization are eliminated from their respective accounts, and the resulting gain or loss is included in results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84C_ecustom--LeaseholdImprovementsPolicyTextBlock_zXc4XT7ePYK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86B_zcYyZYXSuUt2">Leasehold Improvements</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Leasehold improvements in excess of $1,000 that are made in connection with leases having a term of more than 12 months are capitalized by the Company and amortized over the shorter of the useful life of the asset or the remaining lease periods and renewals that are deemed to be reasonably certain at the date the leasehold improvements are purchased. Costs associated with leasehold improvements that do not exceed $1,000 are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zRgJXcdZYEpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86A_zC2NzxHqcRgi">Revenue Recognition</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the guidance of the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASC”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zafX89Mg5Uk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"></span> <span style="text-decoration: underline">Net Income (Loss) Per Common Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2026, the Company had <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">8,207,357</span> common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfUnissuedRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">290,000</span> unissued restricted stock (<span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOunvestedSharesOfRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">178,333</span> unvested), $<span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">250,000</span> of convertible debt securities (convertible into a maximum of 41,667 shares) and $<span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheFuturePaymentsMember_zudSofA1PhXb" title="Antidilutive securities excluded from computation of earnings per share">50,000</span> of future obligations in connection with the purchase of the BioLumina assets that may be settled through the issuance of common stock (convertible into a maximum of 20,000 shares) that were not included in the computation of diluted loss per share because their inclusion is anti-dilutive for the eight months ended June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At October 31, 2025, the Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOptionsAndWarrantsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">4,265,444</span> common shares issuable upon the exercise of options and warrants (vested and unvested), <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfUnissuedRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">212,500</span> unissued restricted stock (<span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheExerciseOfOunvestedSharesOfRestrictedStockMember_pd" title="Antidilutive securities excluded from computation of earnings per share">178,333</span> unvested), $<span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pd" title="Antidilutive securities excluded from computation of earnings per share">250,000</span> of convertible debt securities (convertible into a maximum of 41,667 shares) and $<span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20251031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonSharesIssuableUponTheFuturePaymentsMember_pd" title="Antidilutive securities excluded from computation of earnings per share">100,000</span> of future obligations in connection with the purchase of the BioLumina assets that may be settled through the issuance of common stock (convertible into a maximum of 40,000 shares) that were not included in the computation of diluted loss per share because their inclusion is anti-dilutive for the year ended October 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At October 31, 2024, the Company had 3,522,527 common shares issuable upon the exercise of options and warrants (vested and unvested), 185,000 unvested and unissued restricted stock and $725,000 of convertible debt securities (convertible into a maximum of 120,834 shares) that were not included in the computation of diluted loss per share because their inclusion is anti-dilutive for the nine months ended October 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 8207357 290000 178333 250000 50000 4265444 212500 178333 250000 100000 <p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zAlXxe1By7Ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><i><span id="xdx_86D_z8X0L9GaYHfj">Stock-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock-based payments are recognized in the financial statements based on their fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based awards granted to employees, nonemployee directors, and consultants in accordance with ASC 718, “<i>Compensation—Stock Compensation</i>.” Stock-based awards are measured at fair value, and compensation expense is recognized over the applicable requisite service period. The Company accounts for forfeitures as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Awards</i>. The fair value of restricted stock awards is measured based on the closing market price of the Company’s common stock on the grant date. Compensation expense is recognized over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Service-Based Stock Options</i>. The fair value of stock options subject solely to service-based vesting conditions is measured on the grant date using the Black-Scholes option-pricing model. Compensation expense is recognized on a straight-line basis over the vesting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options with Market or Performance Conditions</i>. The fair value and derived service period of stock options containing a market condition are estimated on the grant date using a Monte Carlo simulation model. For awards that vest upon the first to occur of a market condition or a performance condition, compensation expense is recognized over the derived service period. If the performance condition becomes probable of achievement and its associated implicit service period is shorter than the derived service period, any unrecognized compensation expense is recognized prospectively over the revised requisite service period. If either condition is achieved before the end of the requisite service period, any unrecognized compensation expense is recognized immediately.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Liability-Classified Stock Options</i>. Stock options indexed to a factor in addition to the Company’s share price that is not a market, performance, or service condition are classified as liabilities. Liability-classified awards are measured at fair value on the grant date and remeasured at the end of each reporting period until settlement. During the requisite service period, compensation expense is recognized based on changes in the fair value of the award, adjusted for the portion of the requisite service rendered through each reporting period. If the award vests before completion of the requisite service period, any unrecognized compensation expense based on the then-current fair value is recognized immediately. After vesting or completion of the requisite service period, subsequent changes in fair value are recognized in compensation expense until settlement.</p> <p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_z0li5P9yFa5g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86E_zEa2WWgf2Dni">Research and Development Costs</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $<span id="xdx_90E_ecustom--OperatingAndFinanceLeaseObligation_c20251101__20260630_pp0p" title="Operating and finance lease obligation">65,000</span>, $<span id="xdx_903_ecustom--OperatingAndFinanceLeaseObligation_c20241101__20251031_pp0p" title="Operating and finance lease obligation">100,000</span> and $<span id="xdx_905_ecustom--OperatingAndFinanceLeaseObligation_c20231101__20241031_pp0p" title="Operating and finance lease obligation">164,000</span> for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, respectively. The research and development costs primarily relate to the filing and approval of IND applications and the performance of clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 65000 100000 164000 <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zWWRQ04jvsNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"></span><span style="text-decoration: underline"><span id="xdx_86A_zRdyFm8ItJL7">Income Taxes</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files a consolidated tax return that includes all of its subsidiaries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znSAFIJMAQBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_860_zTJbYuwDkYE9">Fair Value of Financial Instruments</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Level one</i> — Quoted market prices in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Level two</i> — Inputs other than level one inputs that are either directly or indirectly observable such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><i>Level three</i> — Unobservable inputs that are supported by little or no market activity and developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, accounts payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of convertible notes approximate their fair values because interest rates on these obligations are based on prevailing market interest rates. The estimated fair value of the share-based compensation liability is determined using Level 3 inputs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_ecustom--OperatingLeaseObligationsPolicyTextBlock_zAgBUulbyfQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_869_zByfofDXmxSb">Operating Lease Obligations</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating and financing leases upon commencement of the lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $15,000 in determining whether any future operating leases will be capitalized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zlZSihzgkxwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_zyWYqai7zR88">Subsequent Events</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events that occurred after June 30, 2026 through the financial statement issuance date for subsequent event disclosure or recording.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHcm7asP03Qa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_860_zQwpVMzdT9Kg">Recently Issued Accounting Pronouncements</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. The Company is currently evaluating the provisions of this guidance and assessing the potential impact on its financial statement disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed all accounting pronouncements recently issued by the FASB and the SEC. The authoritative pronouncements that we have already adopted did not have a material effect on our financial condition, results of operations, cash flows or reporting thereof, and except as otherwise noted above, we do not believe that any of the authoritative pronouncements that we have not yet adopted will have a material effect upon our financial condition, results of operations, cash flows or reporting thereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_802_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zHxwOkreVauh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 – <span id="xdx_82F_zreDvYCQ3mU2">GOING CONCERN</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company incurred a net loss of $<span id="xdx_900_eus-gaap--NetIncomeLoss_iN_pp0d_di_c20251101__20260630_zykA2Isu1pke" title="Net loss">5,074,000</span> for the eight months ended June 30, 2026 and used $<span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0d_di_c20251101__20260630_z9ahxIg0MvH8" title="Cash from operating activities">383,000</span> of cash from operating activities during that period. In addition, the Company had an accumulated deficit at June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in an evolving regulatory environment governing regenerative biologics and human cells, tissues and cellular and tissue-based products (“HCT/Ps”). Certain products regulated by the United States Food and Drug Administration (“FDA”) as biological products under Section 351 of the Public Health Service Act require an approved biologics license application (“BLA”) before being marketed. In addition, certain states, including Florida, Tennessee and Georgia, have enacted legislation permitting the use of certain regenerative therapies under specified conditions, subject to applicable federal and state requirements. The Company believes its current operations are consistent with applicable regulatory requirements; however, it has not sought formal determinations from regulatory authorities regarding the classification or compliance status of its products and related activities. Accordingly, there can be no assurance that the FDA or other regulatory authorities will not adopt a different interpretation or challenge the Company’s compliance in the future, which could affect its ability to manufacture, distribute or sell certain products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management’s plans to address the Company’s operating and liquidity requirements include increasing revenues from existing operations, expanding domestic and international sales, developing additional products and commercial opportunities, and continuing its clinical research and development programs. The Company also expects to remain dependent on additional working capital through debt or equity financing to support its operations, product development and clinical studies. Its ability to obtain such financing may be affected by prevailing market conditions, the liquidity and market value of its common stock, available authorized shares and its limited assets available to secure borrowings. There can be no assurance that sufficient financing will be available on acceptable terms, or that the Company’s operating and commercialization strategies will achieve the anticipated results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s ability to continue its operations is dependent upon successfully implementing its business and financing strategies, generating sufficient revenues to meet its operating obligations, and maintaining the ability to manufacture and commercialize its products in accordance with applicable regulatory requirements. If these objectives are not achieved, the Company may be required to reduce or defer expenditures, modify its operating plans, seek additional financing or pursue other strategic alternatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the foregoing conditions and uncertainties, management has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for the twelve months following the issuance of these consolidated financial statements. The accompanying consolidated financial statements do not include any adjustments to the carrying amounts or classification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> -5074000 -383000 <p id="xdx_80C_eus-gaap--InventoryDisclosureTextBlock_zb5hyXL3qsLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 – <span id="xdx_82F_z3sWgTyFv995">INVENTORIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zNPfPMuIBseb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8BC_z8IWBLkVFoK9">Schedule of inventories</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260630_z0kTgWE0CHdk" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_495_20251031_zVRWukvTdOBh" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pp0d_maINzEvT_zbUyM5Gtu1t2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Raw materials and supplies</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">208,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">208,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0d_maINzEvT_zK1CWAjsOadh" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">588,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">215,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iTI_pp0d_mtINzEvT_zkb3UwY7mxv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Total inventories</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">796,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">423,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zNPfPMuIBseb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8BC_z8IWBLkVFoK9">Schedule of inventories</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_493_20260630_z0kTgWE0CHdk" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_495_20251031_zVRWukvTdOBh" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterialsAndSuppliesNetOfReserves_iI_pp0d_maINzEvT_zbUyM5Gtu1t2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Raw materials and supplies</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">208,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">208,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pp0d_maINzEvT_zK1CWAjsOadh" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">588,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">215,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iTI_pp0d_mtINzEvT_zkb3UwY7mxv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Total inventories</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">796,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">423,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 208000 208000 588000 215000 796000 423000 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zgKT2fHCsUj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 – <span id="xdx_820_zCg02qBfETBg">PROPERTY AND EQUIPMENT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaHOR6zx0Jy8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B6_zEVrmNDhUhHj">Schedule of property and equipment</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Finance lease equipment</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FinanceLeaseEquipmentMember_zBpnQe5CgXe3" title="Property and equipment, gross">156,000</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20251031__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FinanceLeaseEquipmentMember_zSewyrDvQLl5" title="Property and equipment, gross">156,000</span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Manufacturing equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zZBOGYJdceB8" title="Property and equipment, gross">856,000</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20251031__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zoorTiJFQUj6" title="Property and equipment, gross">778,000</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20260630_zZIjj5oYAima" title="Property and equipment, gross">1,012,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20251031_zUfjNIFYJ7g8" title="Property and equipment, gross">934,000</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_c20260630_zztdkVZcKmhh" title="Less: accumulated depreciation">(417,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_c20251031_z7NQAkejqY1d" title="Less: accumulated depreciation">(365,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total property and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_c20260630_zlRH7fYfVTxh" title="Total property and equipment, net">595,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_c20251031_zBSKggjbhSG" title="Total property and equipment, net">569,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense totaled $<span id="xdx_908_eus-gaap--Depreciation_pp0d_c20251101__20260630_zy0f7W7foCe6" title="Depreciation expense">52,000</span>, $<span id="xdx_90B_eus-gaap--Depreciation_c20241101__20251031_pp0p" title="Depreciation expense">73,000</span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20231101__20241031_pp0p" title="Depreciation expense">74,000</span> for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--PropertyPlantAndEquipmentTextBlock_zaHOR6zx0Jy8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B6_zEVrmNDhUhHj">Schedule of property and equipment</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Finance lease equipment</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FinanceLeaseEquipmentMember_zBpnQe5CgXe3" title="Property and equipment, gross">156,000</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20251031__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FinanceLeaseEquipmentMember_zSewyrDvQLl5" title="Property and equipment, gross">156,000</span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Manufacturing equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zZBOGYJdceB8" title="Property and equipment, gross">856,000</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20251031__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ManufacturingEquipmentMember_zoorTiJFQUj6" title="Property and equipment, gross">778,000</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20260630_zZIjj5oYAima" title="Property and equipment, gross">1,012,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0d_c20251031_zUfjNIFYJ7g8" title="Property and equipment, gross">934,000</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_c20260630_zztdkVZcKmhh" title="Less: accumulated depreciation">(417,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0d_di_c20251031_z7NQAkejqY1d" title="Less: accumulated depreciation">(365,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total property and equipment, net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_c20260630_zlRH7fYfVTxh" title="Total property and equipment, net">595,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0d_c20251031_zBSKggjbhSG" title="Total property and equipment, net">569,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 156000 156000 856000 778000 1012000 934000 417000 365000 595000 569000 52000 73000 74000 <p id="xdx_804_ecustom--EquityInNonmarketableSecuritiesOfAffiliatedEntity_zbtdOBJoVCm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 – <span id="xdx_82C_z8OYNUFO7pwa">EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--SchedulrOfEquityInNonMarketableSecuritiesAffiliatedEntityTableTextBlock_zWyyThqjqc3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B3_zhNx38pdtZK6">Schedule of equity in non marketable securities</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_496_20260630_z8bLokI2MdO" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49A_20251031_zw5UOxrIIkCi" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_ecustom--EquityInNonmarketableSecurities_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Equity in non-marketable securities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities_iI_pp0p" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Reserve on carrying value of investment in non-marketable securities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(145,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--MarketableSecuritiesNoncurrent_iI_pp0d_zNqGugD8hWoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity in non-marketable securities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 31, 2025, the Company had invested $<span id="xdx_90F_ecustom--EquityInNonmarketableSecurities_c20251031_pp0p" title="Equity in non-marketable securities">145,000</span> in the non-marketable equity securities of Exotropin (“Exotropin”), a privately-held skin-care formulator in an effort to accelerate the Company’s development of expertise with respect to the skincare industry and the potential supply of the Company’s products in future formulations. As of October 31, 2025, the Company had recorded total reserves against the carrying value of its investment in Exotropin of $145,000, based on the limited financial history of Exotropin to date and the lack of any information to ascertain the fair value of Exotropin.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2026 (“Execution Date”) the Company, Greyt Ventures, LLC (“Greyt”), a principal shareholder of the Company and Skycrest Holdings, LLC, a former principal shareholder of the Company (“Skycrest” and, together with the Company and Greyt, each a “Seller” and collectively “Sellers”), AML Group Holdings, LLC, a Florida limited liability company (“AML”) BRM Holdings LLC a Delaware limited liability company (“BRM”), B4U2 LLC a Delaware limited liability company (“B4U2”), and GFourz Holdings LLC an Illinois limited liability company (“Gfourz” and, together with AML, BRM, and B4U2 each a “Purchaser” and collectively “Purchasers”), and Exotropin (Exotropin together with Purchasers and Sellers, each a “Party” and collectively the “Parties”) entered into a purchase and sales agreement (“Agreement”) whereby each Seller agreed to sell to Purchasers, and Purchasers agreed to purchase from each Seller, all of such Seller’s Membership Units in Exotropin, including, without limitation, the corresponding rights, powers, benefits, and privileges relating thereto or arising therefrom, and the obligations thereunder, pursuant to <span id="xdx_90A_ecustom--AggregateCashConsiderationDescription_c20251101__20260630_zS12SY4N6Ztj" title="Aggregate cash consideration description">Exotropin’s Limited Liability Company Agreement (as amended to date, the “LLC Agreement”) relating to the Membership Units (collectively, the “Membership Interests”), for the aggregate cash consideration of $2,788,000 (the “Purchase Price”). The Parties agreed to allocate the Purchase Price as follows: $376,000 to the Company in respect of the Company’s Membership Interests; $1,206,000 to Greyt in respect of Greyt’s Membership Interests; and $1,206,000 to Skycrest in respect of Skycrest’s Membership Interests (the foregoing amounts allocated to each of the Sellers, an “Allocated Purchase Price”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The closing of the purchase and sale of the Membership Interests, including payment of the Allocated Purchase Price took place on April 7, 2026 (“Closing”). At the Closing, (i) each Seller delivered to the Purchasers an Assignment of its Membership Interests (ii) Purchasers paid the Allocated Purchase Price to each Seller by wire transfer, (iii) Exotropin delivered to the Company a dismissal notice dismissing its pending lawsuit against the Company with prejudice and with each party agreeing to bear its own fees and costs (see Note 15) and (iv) the Company returned all remaining inventory of Exotropin held by Seller as of the date of the Agreement. In addition, under the terms of the Agreement, effective as of the Closing, and without any further action of the Company or Exotropin, the Sales Representative Agreement (“Sales Agreement”) between the Company and Exotropin was terminated and was of no further force or effect and the Company and none of the provisions of the Sales Agreement survive termination of the Sales Agreement. The Agreement also provided for other terms regarding non solicitation and each party provided mutual general releases. During the eight months ended June 30, 2026, the Company recorded a gain of $<span id="xdx_902_ecustom--GainFromSaleOfExotropinInterests_c20251101__20260630_pp0p" title="Gain from sale of Exotropin interests">390,000</span> from the sale of its Exotropin interests comprised of the proceeds of $<span id="xdx_90D_ecustom--ProceedsFromSaleOfInterestsInExotropin_c20251101__20260630_pp0p" title="Proceeds from sale of interests in Exotropin">376,000</span> received from the sale of its interests in Exotropin and the reduction of previously recorded liabilities of $<span id="xdx_907_ecustom--ReductionOfPreviouslyRecordedLiabilities_c20251101__20260630_pp0p" title="Reduction of previously recorded liabilities">14,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, $<span id="xdx_909_ecustom--PaymentsForCommission_pp0d_c20251101__20260630__us-gaap--TypeOfArrangementAxis__custom--SalesRepresentativeAgreementMember_zENwKQWuTNq7" title="Commissions">0</span>, $<span id="xdx_90D_ecustom--PaymentsForCommission_pp0d_c20241101__20251031__us-gaap--TypeOfArrangementAxis__custom--SalesRepresentativeAgreementMember_z1ySIyv1nOS6" title="Commissions">61,000</span> and $<span id="xdx_906_ecustom--PaymentsForCommission_pp0d_c20231101__20241031__us-gaap--TypeOfArrangementAxis__custom--SalesRepresentativeAgreementMember_zYVg8XyVOv6j" title="Commissions">87,000</span> of commissions, respectively, were paid to the Company in connection with the Sales Agreement. The commissions earned under the Sales Agreement are reflected in other income in the consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--SchedulrOfEquityInNonMarketableSecuritiesAffiliatedEntityTableTextBlock_zWyyThqjqc3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B3_zhNx38pdtZK6">Schedule of equity in non marketable securities</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_496_20260630_z8bLokI2MdO" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49A_20251031_zw5UOxrIIkCi" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_ecustom--EquityInNonmarketableSecurities_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Equity in non-marketable securities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ReserveOnCarryingValueOfInvestmentInNonmarketableSecurities_iI_pp0p" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Reserve on carrying value of investment in non-marketable securities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(145,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--MarketableSecuritiesNoncurrent_iI_pp0d_zNqGugD8hWoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity in non-marketable securities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 145000 -145000 145000 Exotropin’s Limited Liability Company Agreement (as amended to date, the “LLC Agreement”) relating to the Membership Units (collectively, the “Membership Interests”), for the aggregate cash consideration of $2,788,000 (the “Purchase Price”). The Parties agreed to allocate the Purchase Price as follows: $376,000 to the Company in respect of the Company’s Membership Interests; $1,206,000 to Greyt in respect of Greyt’s Membership Interests; and $1,206,000 to Skycrest in respect of Skycrest’s Membership Interests (the foregoing amounts allocated to each of the Sellers, an “Allocated Purchase Price”). 390000 376000 14000 0 61000 87000 <p id="xdx_80F_ecustom--FinanceLeaseObligationsTextBlock_zIkADAMKkdTf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 – <span id="xdx_828_z0UTYKAvULs5">FINANCE LEASE OBLIGATIONS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During April 2025, the Company entered into a lease agreement for certain lab equipment in the amount of $<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentOther_c20250430__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_pp0p" title="Payment to acquire">125,000</span> (“Lease Agreement”). The Lease Agreement was accounted for as a finance lease obligation. Under the terms of the lease agreement, the Company is required to make 60 equal monthly payments of $<span id="xdx_90E_eus-gaap--OperatingLeasePayments_c20250402__20250430__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_pp0p" title="Monthly payments">1,600</span> plus applicable sales taxes. Under the lease agreement, the Company has the option to acquire all of the leased equipment for a nominal amount upon termination of the lease. The annual interest rate charged in connection with the lease is <span id="xdx_904_eus-gaap--LesseeFinanceLeaseDiscountRate_c20250430__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_pd" title="Annual interest rate">2.7%</span>. Lease payments and depreciation of the leased equipment began during June 2025, the date that the lease equipment was installed and became operational. The leased equipment is included in Property and equipment and is being depreciated over its estimated useful lives of <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250430__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zmUrUR6kV2Xi" title="Estimated useful lives of leased equipment">15</span> years beginning from the date it became operational.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During June 2025, the Company entered into a lease agreement for certain lab equipment in the amount of $<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentOther_c20250630__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_pp0p" title="Payment to acquire">15,000</span> (“Lease Agreement”). The Lease Agreement was accounted for as a finance lease obligation. Under the terms of the lease agreement, the Company is required to make 36 equal monthly payments of $<span id="xdx_90A_eus-gaap--OperatingLeasePayments_c20250602__20250630__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_pp0p" title="Monthly payments">500</span> plus applicable sales taxes. Under the lease agreement, the Company has the option to acquire all of the leased equipment for a nominal amount upon termination of the lease. The annual interest rate charged in connection with the lease is <span id="xdx_90A_eus-gaap--LesseeFinanceLeaseDiscountRate_c20250630__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_pd" title="Annual interest rate">8.0%</span>. Lease payments and depreciation of the leased equipment began during June 2025, the date that the lease equipment was installed and became operational. The leased equipment is included in Property and Equipment and is being depreciated over its estimated useful life of <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zcIveDqU3GH" title="Estimated useful lives of leased equipment">3 </span>years beginning from the date it became operational.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2026 and October 31, 2025, finance lease obligations were $<span id="xdx_90C_ecustom--FinanceLeaseObligations_iI_pp0d_c20260630_zX2xyT3z48pj" title="Finance lease obligations">89,000</span> and $<span id="xdx_902_ecustom--FinanceLeaseObligations_iI_pp0d_c20251031_zD7WrAkhdZ6c" title="Finance lease obligations">110,000</span>, respectively, of which $<span id="xdx_906_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pp0d_c20260630_zMscChjVGhe" title="Finance lease obligations current">30,000</span> and $<span id="xdx_902_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pp0d_c20251031_zZNlCKvwZAi" title="Finance lease obligations current">33,000</span> were current, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining term of the Company’s finance leases as of June 30, 2026 was <span id="xdx_902_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_pp0d_dtM_c20260630_znTCeZA11Mwg" title="Weighted average remaining term of finance leases">36.2</span> months. The minimum lease payments pursuant to the finance lease are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zgBc48hsI6bi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCE LEASE OBLIGATIONS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left; width: 88%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="display: none"><span id="xdx_8B7_zCmQukFUAg36">Schedule of minimum lease payment to finance lease</span></span></p> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td id="xdx_49B_20260630_zBiewl0VZfK3" style="text-align: right; width: 9%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><b>For The Year Ended June 30,</b></td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> <p style="margin-top: 0; margin-bottom: 0">Minimum<br/> Lease Payments</p></td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_maFLLPDzh6u_zVw0jxde525g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2027</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">33,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_maFLLPDzh6u_zvuUMi3LuZSd" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2028</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pp0d_maFLLPDzh6u_zqgh5FicGeIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2029</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pp0d_maFLLPDzh6u_zI0o2hybFY74" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2030</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pp0d_maFLLPDzh6u_zNN8ertz2ppc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2031</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0d_maFLLPDzh6u_zhKC50c6nlwh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pp0d_mtFLLPDzh6u_zKhvakXuEsH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.375in; text-align: left">Total undiscounted finance lease payments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">94,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0d_di_z3Cn5ZyUlA0l" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.375in; padding-bottom: 1pt; text-align: left">Less: imputed interest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(5,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiability_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.375in; padding-bottom: 1pt; text-align: left">Present value of finance lease liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">89,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, the Company leased its administrative and research facility on a month-to-month basis. Rent expense was $<span id="xdx_902_ecustom--RentExpense_c20251101__20260630_zLPXPkQvXuij" title="Rent expense">13,000</span>, $<span id="xdx_901_ecustom--RentExpense_c20241101__20251031_zfBguOJsRDxl" title="Rent expense">20,000</span> and $<span id="xdx_900_ecustom--RentExpense_c20231101__20241031_zmFlRBbB0vik" title="Rent expense">20,000</span> during the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, respectively (see Note 21).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 125000 1600 0.027 P15Y 15000 500 0.080 P3Y 89000 110000 30000 33000 P36M6D <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zgBc48hsI6bi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCE LEASE OBLIGATIONS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left; width: 88%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="display: none"><span id="xdx_8B7_zCmQukFUAg36">Schedule of minimum lease payment to finance lease</span></span></p> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td id="xdx_49B_20260630_zBiewl0VZfK3" style="text-align: right; width: 9%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left"><b>For The Year Ended June 30,</b></td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> <p style="margin-top: 0; margin-bottom: 0">Minimum<br/> Lease Payments</p></td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0d_maFLLPDzh6u_zVw0jxde525g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2027</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">33,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pp0d_maFLLPDzh6u_zvuUMi3LuZSd" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2028</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">25,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pp0d_maFLLPDzh6u_zqgh5FicGeIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2029</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pp0d_maFLLPDzh6u_zI0o2hybFY74" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2030</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pp0d_maFLLPDzh6u_zNN8ertz2ppc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; text-align: left">2031</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0d_maFLLPDzh6u_zhKC50c6nlwh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pp0d_mtFLLPDzh6u_zKhvakXuEsH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.375in; text-align: left">Total undiscounted finance lease payments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">94,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0d_di_z3Cn5ZyUlA0l" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.375in; padding-bottom: 1pt; text-align: left">Less: imputed interest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(5,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiability_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.25in; padding-left: 0.375in; padding-bottom: 1pt; text-align: left">Present value of finance lease liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">89,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 33000 25000 20000 16000 94000 5000 89000 13000 20000 20000 <p id="xdx_807_ecustom--VariableInterestEntityWithRelatedPartyTextBlock_zD9E7rxn0Nb9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 – <span id="xdx_82A_zaUyByVPKPtg">VARIABLE INTEREST ENTITY WITH RELATED PARTY</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><b>Investment in Serephon</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2026, Greyt Ventures LLC (“Greyt”), a principal shareholder of the Company, Dr. George Shapiro, the Company’s Chief Medical Officer, Mr. Ian Bothwell, the Company’s Chief Executive Officer, and the Company formed Serephon LLC (“Serephon”), a Delaware limited liability company. Serephon intends to act as a management services organization providing non-clinical administrative, operational, advisory, technology, marketing, management, equipment, procurement, and other lawful support services to physician-owned medical practices and other lawful healthcare-adjacent businesses, while not engaging in the practice of medicine. The Board of Directors determined that the Company had no intention of engaging in the clinical services being offered by Serephon other than described below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Serephon business, the Company agreed to supply biologic products to Serephon and/or Serephon’s participating clinics, in exchange for an initial fifty percent (50%) Class A limited liability company membership interest (48 units) in Serephon, with the remaining Class A limited liability company membership interests owned equally by Greyt (16 units), Dr. Shapiro (16 Units) and Mr. Bothwell (16 Units).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Serephon’s governing agreements, in connection with future issuances of equity interests, the Company may be subject to disproportionate dilution until its ownership interest is equal to the ownership interest of each of the other members.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective May 12, 2026, Serephon approved annual compensation of $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0d_c20260501__20260512__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember__srt--CounterpartyNameAxis__custom--IanBothwellMember_zwAtrMXZQAJ" title="Annual compensation"><span id="xdx_905_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0d_c20260501__20260512__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember__srt--CounterpartyNameAxis__custom--DrGeorgeShapiroMember_zWOkY6Yy767d" title="Annual compensation"><span id="xdx_903_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260501__20260512__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember__srt--CounterpartyNameAxis__custom--GreytVenturesLLCMember_pp0p" title="Annual compensation">150,000</span></span></span> for each of Ian T. Bothwell, Dr. George Shapiro and Greyt Ventures LLC for services provided to Serephon. Upon Serephon achieving cumulative revenues in excess of $2.5 million, the annual compensation payable to each party will increase to $<span id="xdx_906_ecustom--CumulativeRevenues_c20260501__20260512__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember_pp0p" title="Cumulative revenues">250,000</span>. Such compensation will accrue until Serephon has sufficient cash flow to make payments, as determined by the Manager. Any accrued and unpaid compensation remains an obligation of Serephon. As of June 30, 2026, aggregate compensation of $53,000 related to these agreements was accrued for services provided during the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated its interest in Serephon and its relationships with the other members in accordance with ASC 810, <i>Consolidation</i>, including the related-party provisions thereof. Based upon the structure and purpose of Serephon, the Company’s significant economic interest in Serephon, the relationships among the members, and the Company’s involvement in the activities that most significantly affect Serephon’s economic performance, the Company determined that Serephon is a variable interest entity and that the Company is its primary beneficiary. Accordingly, the Company consolidates Serephon in its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interests in Serephon not owned by the Company are presented as noncontrolling interests in the Company’s consolidated financial statements. Net income or loss attributable to the noncontrolling interests is separately presented in the consolidated statements of operations. All significant intercompany balances and transactions between the Company and Serephon are eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Serephon’s operations are subject to state-specific laws governing clinic ownership, licensure and the practice of medicine. If applicable regulations require that licensure or structural changes are needed, Serephon may seek clinic licensure, modify its ownership or operating arrangements, or operate as an MSO supporting a physician-owned clinical entity, any of which could impact revenues, increase costs or delay operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended June 30, 2026, Serephon recognized revenues of $<span id="xdx_909_ecustom--RecognizedRevenues_pp0d_c20251101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember_z1RxCBr0pori" title="Recognized revenues">431,000</span> and had a net profit of $<span id="xdx_90B_eus-gaap--ProfitLoss_pp0d_c20251101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember_zfurruvt8nZd" title="Net profit">72,000</span>, included in the accompanying consolidated statements of operations. As of June 30, 2026, Serephon had total assets of $<span id="xdx_90E_eus-gaap--Assets_iI_pp0d_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember_zxnCYnCAxbS5" title="Total assets">134,000</span> and total liabilities of $<span id="xdx_90A_eus-gaap--Liabilities_iI_pp0d_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SerephonMember_zytXEvwiYyo5" title="Total liabilities">62,000</span>. The Company has not provided financial support to Serephon that it was not contractually required to provide and has no contractual obligation to provide additional financial support to Serephon.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 150000 150000 150000 250000 431000 72000 134000 62000 <p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z7zPP6vBYpe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 – <span id="xdx_82B_z3bXYFFkj0Wj">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zAsdCmHZ9lF5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BA_znG6QpPkqsf6">Schedule of account payable and accrued expenses</span></span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20260630_zKyfiKwSw8Of" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_499_20251031_zmSFypx5Jtza" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0d_maAPAALzpov_zTwW5hn9l7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued payroll related liabilities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LabEquipmentAndSuppliesPayables_iI_pp0d_maAPAALzpov_zKoipc3uUw62" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lab equipment and supplies payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">41,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">120,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ClinicalTrialPayables_iI_pp0d_maAPAALzpov_zztHPLZ6jCcb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Clinical trial and research payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">638,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">634,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--LegalFeesPayables_iI_pp0d_maAPAALzpov_zRdeu3L0nqFe" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Legal fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">282,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">244,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0d_maAPAALzpov_zxwBDhXA3j74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other professional fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">95,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">121,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InterestPayableCurrent_iI_pp0d_maAPAALzpov_zrdlO3aUkHG5" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0d_maAPAALzpov_zgLzjLsOvKE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Royalty payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedCommissionsPayable_iI_pp0d_maAPAALzpov_zX54H4QYlnb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued commissions payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">117,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">37,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ConstructionPayables_iI_pp0d_maAPAALzpov_zXQrsOL3Ziyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Construction payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedSerephonCompensation_iI_pp0d_maAPAALzpov_z8azhz4E3Wmj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued Serephon compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">53,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pp0d_maAPAALzpov_zsl1RbrQeTE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other payables and accrued expenses</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">108,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">47,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pp0d_mtAPAALzpov_zKIQpjuGu8lk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total Accounts Payable and Accrued Expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,075,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,980,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zAsdCmHZ9lF5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BA_znG6QpPkqsf6">Schedule of account payable and accrued expenses</span></span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20260630_zKyfiKwSw8Of" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_499_20251031_zmSFypx5Jtza" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0d_maAPAALzpov_zTwW5hn9l7tf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Accrued payroll related liabilities</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">667,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LabEquipmentAndSuppliesPayables_iI_pp0d_maAPAALzpov_zKoipc3uUw62" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lab equipment and supplies payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">41,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">120,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ClinicalTrialPayables_iI_pp0d_maAPAALzpov_zztHPLZ6jCcb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Clinical trial and research payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">638,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">634,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--LegalFeesPayables_iI_pp0d_maAPAALzpov_zRdeu3L0nqFe" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Legal fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">282,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">244,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0d_maAPAALzpov_zxwBDhXA3j74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other professional fees payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">95,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">121,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InterestPayableCurrent_iI_pp0d_maAPAALzpov_zrdlO3aUkHG5" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0d_maAPAALzpov_zgLzjLsOvKE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Royalty payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AccruedCommissionsPayable_iI_pp0d_maAPAALzpov_zX54H4QYlnb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued commissions payable</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">117,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">37,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--ConstructionPayables_iI_pp0d_maAPAALzpov_zXQrsOL3Ziyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Construction payables</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedSerephonCompensation_iI_pp0d_maAPAALzpov_z8azhz4E3Wmj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accrued Serephon compensation</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">53,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_iI_pp0d_maAPAALzpov_zsl1RbrQeTE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other payables and accrued expenses</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">108,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">47,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pp0d_mtAPAALzpov_zKIQpjuGu8lk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total Accounts Payable and Accrued Expenses</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">2,075,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,980,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 667000 667000 41000 120000 638000 634000 282000 244000 95000 121000 15000 1000 50000 100000 117000 37000 9000 9000 53000 108000 47000 2075000 1980000 <p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zmNGQo9XKzI" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 – <span id="xdx_828_zAurvUWkJYAk">NOTES PAYABLE</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDebtTableTextBlock_zCldXbwYQVA9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B0_zWgRQXscpHd2">Schedule of notes payable</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49D_20260630_zlwyZYbOg9A6" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_490_20251031_zLJUNf91Xd1j" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebt_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Convertible Promissory Notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0d_di_zsCooepJqkig" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Unamortized discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(2,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtCurrent_iI_pp0d_z8HSZq7Ok5f1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total Notes Payable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">248,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">243,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Promissory Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Convertible Promissory Note is due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20251101__20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zg40ktYQ8sY4" title="Due date">September 30, 2026</span>. Interest on the Convertible Promissory Note is <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_c20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pd" title="Interest rate">8.0%</span> payable annually and together with the principal amount on the maturity date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Convertible Promissory Note may be prepaid by the Company, in whole, but not in part, at any time prior to the Maturity Date, subject to payment of a premium of 10%, provided that the Company gives the holder fifteen (15) business days notice prior to prepayment, during which period, the investor may elect to convert the Note and accrued but unpaid interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Note) for twenty (20) consecutive trading days ending on the date the Company gives the holder of the Convertible Promissory Note notice of prepayment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Holder of the Convertible Promissory Note will have the right, at any time during the period commencing on April 1, 2024 and ending on the earliest to occur of the Maturity Date, the date of a Prepayment or the date of an automatic conversion, to convert the Convertible Promissory Note in whole, but not in part, and accrued interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Convertible Promissory Note) for twenty consecutive (<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_c20251101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourInvestorsMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2wWGdU7SHag" title="Trading days">20</span>) trading days ending on the date the investor gives the Company a notice of conversion, subject to a minimum conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourInvestorsMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z2cYpHQMoAHf" title="Conversion price">6.00</span> per Share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Convertible Promissory Note and accrued but unpaid interest thereon will automatically convert into Shares in the event that prior to the Maturity Date, the Company consummates a “Qualified Financing” or a “Qualified Sale” (as defined in the Convertible Promissory Note) at a conversion price equal to 80% of the offering price of Shares sold in the Qualified Financing or 80% of the purchase price per Share to be received by stockholders following consummation of a Qualified Sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: #001D35; background-color: white">As of November 1, 2024, the balance of the Convertible notes was $725,000. On October 3, 2025, the Company offered each Holder of the </span>Notes <span style="color: #001D35; background-color: white">the opportunity to convert their </span>Note on October 10, 2025 <span style="color: #001D35; background-color: white">(including accrued interest outstanding) at a conversion price equal to $<span id="xdx_907_eus-gaap--SharePrice_c20251010__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HolderMember_pd" title="Share price">3.00</span> per share (“Conversion Offer”). The Holders of a total of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20251010__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HolderMember_pp0p" title="Principal amount">475,000</span> principal amount of </span>Notes (plus $39,000 of accrued interest as of October 10, 2025) agreed to accept the Conversion Offer and accordingly received an aggregate total of 171,347 shares of common stock of the Company. In connection with the conversion of the Notes, the Company recorded an inducement expense of $<span id="xdx_90B_ecustom--InducementExpense_c20251002__20251010__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HolderMember_pp0p" title="Inducement expense">136,000</span> representing the fair value of the additional shares that were issued in the conversion (t<span style="color: #001D35; background-color: white">he trading price of the Company’s common stock on the date of conversion was $1.59 per share) </span>over the amount of shares convertible pursuant to the original terms of the Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the Convertible Promissory Notes, the Company recorded a discount in the amount of $<span id="xdx_906_ecustom--Discount_c20251101__20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Discount">72,000</span>. The discount is being amortized over the term of Convertible Promissory Notes. For the eight months ended June 30, 2026 and the year ended October 31, 2025, $<span id="xdx_904_ecustom--DebtAmortizedDiscount_c20251101__20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Debt amortized discount">5,000</span>, $<span id="xdx_90F_ecustom--DebtAmortizedDiscount_c20241101__20251031__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Debt amortized discount">39,000</span> (including $15,000 of unamortized discounts associated with the converted Notes outstanding as of October 10, 2025), respectively, of the discounts recorded in connection with the issuance of the Note have been amortized, resulting to unamortized debt discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_c20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Debt discount">2,000</span> and $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_c20251031__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Debt discount">7,000</span> as of June 30, 2026 and October 31, 2025, respectively. As of June 30, 2026, the remaining outstanding Notes of $<span id="xdx_908_ecustom--RemainingOutstanding_c20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pd" title="Remaining outstanding">250,000</span> are convertible into a maximum of <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20251101__20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pd" title="Number of shares converted">41,667</span> shares (see Note 21).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, the Company has paid $<span id="xdx_908_eus-gaap--InterestPaid_pp0d_c20251101__20260630__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zNar5LWQuin8" title="Interest paid">0</span>, $<span id="xdx_906_eus-gaap--InterestPaid_pp0d_c20241101__20251031__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zPyZNOHAaTVd" title="Interest paid">20,000</span> and $<span id="xdx_90D_eus-gaap--InterestPaid_pp0d_c20231101__20241031__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zVj0GWPKen77" title="Interest paid">64,000</span> respectively, of interest on the Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities were offered and sold in a private offering exempt from the registration requirements of the Securities Act, pursuant to the exemptions from registration afforded by Rule 506(b) of Regulation D under the Securities Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDebtTableTextBlock_zCldXbwYQVA9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8B0_zWgRQXscpHd2">Schedule of notes payable</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49D_20260630_zlwyZYbOg9A6" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_490_20251031_zLJUNf91Xd1j" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebt_iI_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Convertible Promissory Notes</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">250,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0d_di_zsCooepJqkig" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Unamortized discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(2,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(7,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtCurrent_iI_pp0d_z8HSZq7Ok5f1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total Notes Payable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">248,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">243,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 250000 250000 2000 7000 248000 243000 2026-09-30 0.080 20 6.00 3.00 475000 136000 72000 5000 39000 2000 7000 250000 41667 0 20000 64000 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_ztRvatJPTOA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 – <span id="xdx_824_zZ1TqG3caFq3">INCOME TAXES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files a consolidated federal income tax return that includes all of its subsidiaries. For the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, the Company incurred operating losses, and therefore, there was not any current income tax expense amount recorded during those periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated provision for income taxes for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024 consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfProvisionForIncomeTaxTableTaxtBlockTextBlock_zl8IS7f5l8p1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="display: none"><span id="xdx_8B2_zYkyLNQ5y3w2">Schedule of provision for income tax</span></span></td> <td> </td> <td> </td> <td id="xdx_49B_20251101__20260630_ztHxJzFBtHPk" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49C_20241101__20251031_zZQJOfL8ipm1" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20231101__20241031_zIjgRHdkZg48" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="text-align: center"><b>Eight Months Ended<br/> June 30,</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Years Ended<br/> October 31,</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2025</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2024</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td></tr> <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlxszxfk7Lgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0d_maCITEBzz6t_zcGdMyfbU42j" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Federal</td> <td> </td> <td>$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td> <td> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0d_maCITEBzz6t_z8Ir28jSP5d9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">State</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0d_mtCITEBzz6t_maITEBzPO0_zVaqEiipK5wj" style="vertical-align: bottom; background-color: White"> <td style="color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Current Income Tax Expense (Benefit)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxesAbstract_iB_zF2YgNZLhkHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0d_maDITEBzwuA_zpgfQ85SDdjh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Federal</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">(206,000</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(312,000</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(207,000</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0d_maDITEBzwuA_z8vVbwl6EX6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">State</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(37,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(37,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0d_mtDITEBzwuA_maITEBzPO0_zCIy76froWMl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred Income Tax Expense (Benefit)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(243,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(349,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(217,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0d_di_msITEBzPO0_zzIS5TOaVDK1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in Valuation Allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">243,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">349,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">217,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0d_mtITEBzPO0_zoHmJkmV4rnl" style="vertical-align: bottom; background-color: White"> <td style="color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Income tax provision </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zkhgGHOtUSi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective tax rates differ from the federal statutory rate of <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20251101__20260630_pd" title="Statutory income tax rate"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20241101__20251031_pd" title="Statutory income tax rate"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c20231101__20241031_pd" title="Statutory income tax rate">21%</span></span></span> for 2026, 2025 and 2024 applied to income before income taxes. A reconciliation of the U.S. federal statutory tax amount to the Company’s effective tax amount is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeicPCEW7OQi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BA_zIyrzlgGxRSg">Schedule of effective income tax rate</span></span></td> <td> </td> <td> </td> <td id="xdx_49B_20251101__20260630_z6S2mMd3phC3" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49C_20241101__20251031_zQsJGEKunvsb" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20231101__20241031_z9f8esDg3aCd" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td><b> </b></td> <td colspan="2" style="text-align: center"><b>Eight Months Ended<br/> June 30,</b></td> <td><b> </b></td> <td style="font-weight: bold"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Years Ended<br/> October 31,</b></td> <td style="font-weight: bold"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2025</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2024</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maTITEBz4ky_zMRqOmhUnBFd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Tax at federal statutory rate</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">(1,115,000</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(1,113,000</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(989,000</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maTITEBz4ky_zI3Bz5rppB65" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">State taxes, net of federal benefit</td> <td> </td> <td> </td> <td style="text-align: right">(265,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(265,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(61,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maTITEBz4ky_zTq8xRoF03u" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Permanent differences</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--StockbasedCompensation_maTITEBz4ky_zuIaQOv07mV6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">1,341,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,198,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,002,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maTITEBz4ky_zN3FDYdp8vvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(204,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(169,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(169,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--TotalIncomeTaxExpenseBenefit_iT_pp0d_mtTITEBz4ky_maITEBz6vT_zy7YnoE8wLge" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total income tax expense (benefit)</td> <td> </td> <td> </td> <td style="text-align: right">(243,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(349,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(217,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz6vT_zWOFaRO2gUzb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Change in valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">243,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">349,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">217,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0d_mtITEBz6vT_zuJDgOTczVl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> Income tax provision</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zvpcgJcgX2S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had a federal net operating loss carryover of $21,459,000 as of June 30, 2026, of which 98% is available to offset future taxable income indefinitely. The Company had state net operating loss carryovers of $10,405,000 of which $7,982,000, carryover indefinitely and the balance expires in varying amounts through 2041.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNRqaTpGP39j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="display: none"><span id="xdx_8BA_z2xRGDrLHKz7">Schedule of deferred tax assets and liabilities</span></span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20260630_zmcml1AFOI3g" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251031_zJjW2vcQFEAe" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/> 2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/> 2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zHJuFhk9g8K8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred Tax Assets:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pp0d_maDTAGzuRV_z0G8rwO0vFK3" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Stock based compensation</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">9,044,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">6,491,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_i01I_pp0d_maDTAGzuRV_zSVvkTKuU1Fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net operating loss carryforward-Federal</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,506,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,485,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_i01I_pp0d_maDTAGzuRV_zvHmqjTJVOI8" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net operating loss carryforward-State</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">582,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,065,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_i01I_pp0d_maDTAGzuRV_zCOYURofOzk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzuRV_zxfG1j99S6o7" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total deferred tax assets:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">14,132,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">12,041,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zw07UwhokXLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred Tax Liabilities:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01I_pp0d_maDTLzW6O_zsTnxNrg0jg3" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Property and equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">165,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">144,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01TI_pp0d_mtDTLzW6O_zau8J3vBOjec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">165,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">144,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0d_di_zwvIaHPSwikd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Valuation Allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(13,967,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(11,897,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0d_zjLQ4XnLMCi4" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_ziSznV5mbJM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB ASC 740 requires a valuation allowance against deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. At June 30, 2026 and October 31, 2025, the net deferred tax asset was offset by a full valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to Code Sec. 382 of the Internal Revenue Code (“the Code”), the utilization of net operating loss carryforwards may be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. The Company may be subject to such limitation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">I</span><span style="text-decoration: underline">R</span><span style="text-decoration: underline">S Penalties</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of October 31, 2023, the Company had accrued $<span id="xdx_90E_eus-gaap--IncomeTaxExaminationPenaltiesExpense_c20221101__20231031_pp0p" title="Penalties">86,000</span> of accrued tax penalties and interest on the balance sheet in connection with penalties and interest assessed by the Internal Revenue Service (“IRS”) for delinquent income tax returns for the periods since inception through the tax year ended October 31, 2016 that were not filed until December 2017 (“Delinquent Filed Returns”). The Company filed a “Request for Collection Due Process Equivalent Hearing” (“Request”) in September 2021 seeking an abatement of the penalties and interest. A hearing was held on June 28, 2022 and during February 2024, the IRS notified the Company that the Company’s appeal for full abatement of penalties and interest ($92,000 as of February 2024) associated with the Delinquent Filed Returns was granted. The Company recorded the abatement as other income for the year ended October 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfProvisionForIncomeTaxTableTaxtBlockTextBlock_zl8IS7f5l8p1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="display: none"><span id="xdx_8B2_zYkyLNQ5y3w2">Schedule of provision for income tax</span></span></td> <td> </td> <td> </td> <td id="xdx_49B_20251101__20260630_ztHxJzFBtHPk" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49C_20241101__20251031_zZQJOfL8ipm1" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20231101__20241031_zIjgRHdkZg48" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="text-align: center"><b>Eight Months Ended<br/> June 30,</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Years Ended<br/> October 31,</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2025</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2024</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td></tr> <tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zlxszxfk7Lgg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0d_maCITEBzz6t_zcGdMyfbU42j" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Federal</td> <td> </td> <td>$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td> <td> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1091">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0d_maCITEBzz6t_z8Ir28jSP5d9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">State</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0d_mtCITEBzz6t_maITEBzPO0_zVaqEiipK5wj" style="vertical-align: bottom; background-color: White"> <td style="color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Current Income Tax Expense (Benefit)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">-</span></td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxesAbstract_iB_zF2YgNZLhkHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pp0d_maDITEBzwuA_zpgfQ85SDdjh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Federal</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">(206,000</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(312,000</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(207,000</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pp0d_maDITEBzwuA_z8vVbwl6EX6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">State</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(37,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(37,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0d_mtDITEBzwuA_maITEBzPO0_zCIy76froWMl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred Income Tax Expense (Benefit)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(243,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(349,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(217,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_i01N_pp0d_di_msITEBzPO0_zzIS5TOaVDK1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Change in Valuation Allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">243,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">349,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">217,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0d_mtITEBzPO0_zoHmJkmV4rnl" style="vertical-align: bottom; background-color: White"> <td style="color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Income tax provision </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -206000 -312000 -207000 -37000 -37000 -10000 -243000 -349000 -217000 -243000 -349000 -217000 0.21 0.21 0.21 <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zeicPCEW7OQi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="display: none"><span id="xdx_8BA_zIyrzlgGxRSg">Schedule of effective income tax rate</span></span></td> <td> </td> <td> </td> <td id="xdx_49B_20251101__20260630_z6S2mMd3phC3" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49C_20241101__20251031_zQsJGEKunvsb" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20231101__20241031_z9f8esDg3aCd" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td><b> </b></td> <td colspan="2" style="text-align: center"><b>Eight Months Ended<br/> June 30,</b></td> <td><b> </b></td> <td style="font-weight: bold"><b> </b></td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Years Ended<br/> October 31,</b></td> <td style="font-weight: bold"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b> </b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2025</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2024</b></td> <td style="padding-bottom: 1pt; font-weight: bold"><b> </b></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maTITEBz4ky_zMRqOmhUnBFd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Tax at federal statutory rate</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">(1,115,000</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(1,113,000</td> <td style="width: 1%; text-align: left">)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">(989,000</td> <td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maTITEBz4ky_zI3Bz5rppB65" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">State taxes, net of federal benefit</td> <td> </td> <td> </td> <td style="text-align: right">(265,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(265,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(61,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maTITEBz4ky_zTq8xRoF03u" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Permanent differences</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--StockbasedCompensation_maTITEBz4ky_zuIaQOv07mV6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">1,341,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,198,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,002,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maTITEBz4ky_zN3FDYdp8vvc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(204,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(169,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(169,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--TotalIncomeTaxExpenseBenefit_iT_pp0d_mtTITEBz4ky_maITEBz6vT_zy7YnoE8wLge" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total income tax expense (benefit)</td> <td> </td> <td> </td> <td style="text-align: right">(243,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(349,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(217,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBz6vT_zWOFaRO2gUzb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Change in valuation allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">243,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">349,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">217,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0d_mtITEBz6vT_zuJDgOTczVl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; color: White; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> Income tax provision</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -1115000 -1113000 -989000 -265000 -265000 -61000 1341000 1198000 1002000 -204000 -169000 -169000 -243000 -349000 -217000 243000 349000 217000 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zNRqaTpGP39j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span style="display: none"><span id="xdx_8BA_z2xRGDrLHKz7">Schedule of deferred tax assets and liabilities</span></span></td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20260630_zmcml1AFOI3g" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251031_zJjW2vcQFEAe" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,<br/> 2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">October 31,<br/> 2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zHJuFhk9g8K8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred Tax Assets:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_pp0d_maDTAGzuRV_z0G8rwO0vFK3" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Stock based compensation</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">9,044,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">6,491,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_i01I_pp0d_maDTAGzuRV_zSVvkTKuU1Fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net operating loss carryforward-Federal</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,506,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,485,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_i01I_pp0d_maDTAGzuRV_zvHmqjTJVOI8" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net operating loss carryforward-State</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">582,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,065,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_i01I_pp0d_maDTAGzuRV_zCOYURofOzk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1179">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0d_mtDTAGzuRV_zxfG1j99S6o7" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total deferred tax assets:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">14,132,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">12,041,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zw07UwhokXLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred Tax Liabilities:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01I_pp0d_maDTLzW6O_zsTnxNrg0jg3" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Property and equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">165,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">144,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilities_i01TI_pp0d_mtDTLzW6O_zau8J3vBOjec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total deferred tax liabilities:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">165,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">144,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0d_di_zwvIaHPSwikd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Valuation Allowance</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(13,967,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(11,897,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0d_zjLQ4XnLMCi4" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1197">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 9044000 6491000 4506000 4485000 582000 1065000 14132000 12041000 165000 144000 165000 144000 13967000 11897000 86000 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLD8bR6eVOIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 – <span id="xdx_821_zKc1dX3FfVRb">CAPITAL STOCK</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Preferred Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20251031_pd" title="Preferred stock, shares authorized">10,000,000</span> shares of $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20251031_pd" title="Preferred stock, par value">0.001</span> par value preferred stock in one or more designated series, each of which shall be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. The Company’s board of directors is authorized, without stockholders’ approval, within any limitations prescribed by law and the Company’s Articles of Incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Series C Preferred Shares</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 17, 2022, the Company filed a Certificate of Designation for a newly created Series C Non-Convertible Preferred Stock consisting of <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20220817__us-gaap--StatementClassOfStockAxis__custom--SeriesCNonConvertiblePreferredStockMember_zk0iMVa2TcRj" title="Preferred stock, shares authorized">100</span> shares, $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220817__us-gaap--StatementClassOfStockAxis__custom--SeriesCNonConvertiblePreferredStockMember_zolMm9WuGig7" title="Preferred stock, par value">0.001</span> par value of authorized but unissued preferred stock of the Company (“Series C Preferred Shares”). The Company initially issued each of Skycrest and Greyt, 50 shares of the Series C Preferred Shares in connection with a “change in control” transaction” consummated in August 2022. On December 17, 2024, the Company filed an Amendment (the “Amendment”) to the Certificate of Designation of our Series C Preferred Shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During December 2024, Skycrest requested that it be allowed to transfer the 50 shares of Series C Preferred Shares of the Company it holds to Ian T. Bothwell, the Company’s Chief Executive Officer and Chief Financial Officer (“Transfer”). In December 2024, the Board of Directors of the Company approved the Transfer and the Transfer was completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Series C Preferred Shares vote together with shares of our common stock as a single class on all matters presented to a vote of stockholders and represent 51% of the voting control of the Company, except as required by law. The Series C Preferred Shares are not convertible into common stock, do not have any dividend rights and do have a nominal liquidation preference. The Series C Preferred Shares also have certain protective provisions, such as requiring the vote of a majority of Series C Preferred Shares to change or amend their rights, powers, privileges, limitations and restrictions, including the assignment of interests and redemption provisions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Common Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 7, 2023, the Company filed a certificate of amendment to its Articles of Incorporation to effect a reverse split of our issued and outstanding common stock on a one-for-two-hundred basis. The reverse stock split was effective with FINRA on November 28, 2023 (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. All share and per share amounts have been retroactively adjusted to reflect the split as if it occurred at the earliest period presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Sale Of Common Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2024, the Company completed a $500,000 private financing (“Financing”) with a single accredited investor (“Investor”). In the Financing, the Company sold and issued to the Investor <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240701__20240708__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z6pVODLZhQYe" title="Issuances of common stock, shares">250,000</span> shares of common stock (“Shares”) and warrants to purchase an additional <span id="xdx_906_ecustom--NumberOfWarrantsToPurchase_c20240701__20240708__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z8CP62RSHUkf" title="Warrant to purchase">83,333</span> Shares (the “Warrants”) (see Note 13). In connection with the Financing, the Company agreed to provide the Investor certain piggy-back registration rights under the Securities Act of 1933, as amended (“Securities Act”) with respect to the Shares purchased and the Shares underlying the Warrants purchased. The proceeds are being used for working capital purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2025, <span id="xdx_904_ecustom--SubscriptionAgreementDescription_c20251101__20260630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_ztotHxrhusEd" title="Subscription agreement description">ZEO entered into a subscription agreement (“Subscription Agreement”) with a single accredited investor (the “Investor”) pursuant to which the Investor agreed to purchase 250,000 shares of our common stock (the “Shares”) in a private transaction for an aggregate purchase price of $1,000,000 (the “Purchase Price”). The Shares were to be issued and sold and the Purchase Price paid in ten (10) equal monthly installments commencing on August 1, 2025 and ending on May 1, 2026. As of October 31, 2025, 75,000 shares have been sold for an aggregate of $300,000 in accordance with the Subscription Agreement. On November 1, 2025, an additional 25,000 shares were sold for $100,000 in accordance with the Subscription Agreement. On February 10, 2026, the Subscription Agreement was amended whereby the total number of Shares to be purchased under the Subscription Agreement was reduced to 100,000 Shares and no further shares are issuable. As of June 30, 2026, a total of 100,000 shares have been sold for an aggregate amount of $400,000 pursuant to the Subscription Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above securities were offered and sold to the investors in accordance with the exemption from registration afforded by Section 4(a)(2) of and/or Rule 506(b) of Regulation D under the Securities Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Private Offering – Common Stock and Warrants</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From November 2025 to June 2026, the Company sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251101__20260630__srt--TitleOfIndividualAxis__custom--FifteenInvestorsMember_zr5NO4rTfcnh" title="Number of units sold">8.2</span> Units to fifteen investors for an aggregate purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20251101__20260630__srt--TitleOfIndividualAxis__custom--EightInvestorsMember_pp0p" title="Aggregate purchase price">2,050,000</span> in a private transaction. <span id="xdx_904_ecustom--SharesDescription_c20251101__20260630__srt--TitleOfIndividualAxis__custom--FifteenInvestorsMember_zF1NoDofViN3" title="Shares description">Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis.</span> In connection with the sale of the Units, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251101__20260630__srt--TitleOfIndividualAxis__custom--FifteenInvestorsMember_zDk1fATbaig9" title="Shares issued">512,500</span> shares of common stock and <span id="xdx_903_ecustom--NumberOfWarrantsPurchased_c20251101__20260630__srt--TitleOfIndividualAxis__custom--FifteenInvestorsMember_zauDSndVaJu" title="Number of warrants purchased">512,500</span> warrants to purchase shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above securities were offered and sold to the investors in accordance with the exemption from registration afforded by Section 4(a)(2) of and/or Rule 506(b) of Regulation D under the Securities Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"><b>Issuance of Equity Instruments for Services </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">2021 Plan</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2021, the Company adopted the 2021 Equity Incentive Plan (“2021 Plan”). The 2021 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares (an “Award”) to any person who is an employee or director of, or consultant to the Company. The maximum aggregate number of shares that may be issued pursuant to all Awards was <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20210901__20210930__us-gaap--PlanNameAxis__custom--N22021PlanMember_pd" title="Maximum aggregate number of shares">1,250,000</span> shares. On June 6, 2023, the Company’s board of directors and stockholders holding a majority of the Company’s voting power, approved an increase in the number of shares of the Company’s common stock reserved for issuance under the Company’s 2021 Plan from 1,250,000 shares to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20230601__20230606__us-gaap--PlanNameAxis__custom--N22021PlanMember_pd" title="Maximum aggregate number of shares">2,500,000</span> shares. On June 10, 2026, the Company’s board of directors and stockholders holding a majority of the Company’s voting power, approved an increase in the number of shares of the Company’s common stock reserved for issuance under the Company’s 2021 Plan from 2,500,000 shares to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c20260601__20260610__us-gaap--PlanNameAxis__custom--N22021PlanMember_pd" title="Maximum aggregate number of shares">7,500,000</span> shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan is administered by (a) the board of the directors of the Company; or (b) a committee designated by the board, which Committee shall be constituted in such a manner as to satisfy the applicable laws and to permit such grants and related transactions under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b-3. Once appointed, such committee shall continue to serve in its designated capacity until otherwise directed by the board. The board of directors may at any time amend, suspend, or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company’s shareholders to the extent such approval is required by applicable laws.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2026, a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--PlanNameAxis__custom--N22021PlanMember_zRZIkHMrjzM7" title="Number of shares, outstanding">5,962,395</span> Awards (net of <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260630__us-gaap--PlanNameAxis__custom--N22021PlanMember_zDcc9FD2osEa" title="Future issuance">1,379,524</span> Awards redeposited for future issuance) that have been awarded under the 2021 Plan remain issued and outstanding. As of October 31, 2025, a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251031__us-gaap--PlanNameAxis__custom--N22021PlanMember_zWapN1LC2CT" title="Number of shares, outstanding">1,595,482</span> Awards (net of <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20251031__us-gaap--PlanNameAxis__custom--N22021PlanMember_z95MySDs1wAd" title="Future issuance">1,243,647</span> Awards redeposited for future issuance) that have been awarded under the 2021 Plan remain issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock Awards</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fiscal Year October 31, 2024 Issuances</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective January 31, 2024, the Company and a legal firm performing services to the Company agreed to exchange $<span id="xdx_902_eus-gaap--LegalFees_c20240101__20240131_pp0p" title="Legal fees payable">20,000</span> of legal fees payable due to the legal firm for <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesOther_c20240101__20240131_pd" title="Stock issued in exchange of legal fees payable, shares">20,000</span> shares of newly issued common stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueOther_c20240101__20240131_pp0p" title="Stock issued in exchange of legal fees payable">20,000</span>, representing a 20% discount to the closing price of the common stock of the Company on the date the arrangement was agreed to by both the Company and the legal firm. The shares were issued to the legal firm in April 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective April 1, 2024, the Company entered into sales distribution agreement with a sales and marketing company (“Salesco”). Salesco was entitled to receive commissions on sales of the Company’s products to customers introduced by Salesco in the form of cash and common stock of the Company based on sales milestones. In connection with the agreement, the Company agreed to pay Salesco a monthly advance of $<span id="xdx_90C_ecustom--AdvancesPayable_c20240401__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_pp0p" title="Monthly advance">15,000</span> for the first 6 months, provided however, that the last 2 monthly retainers were subject to Salesco achieving a certain minimum amount in sales during the applicable month. The monthly retainers were to be repaid from commissions earned by Salesco on sales of the Company’s products that are generated through Salesco. In addition, Salesco was granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20240330__20240401__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_pd" title="Shares granted">30,000</span> shares of the Company’s common stock which vests over <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240330__20240401__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_ztl8OJgbp4Kb" title="Vesting period"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20241101__20251031__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_zk9E0jeFnyXj" title="Vesting period">2</span></span> years, quarterly, except the quarterly vesting period will “cliff vest” upon the Company receiving $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20241101__20251031__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_pd" title="Shares granted">300,000</span> in cumulative sales from customers introduced by Salesco. The agreement may be terminated by the Company upon the six-month anniversary of the agreement. The <span id="xdx_904_ecustom--CumulativeSalesFromCustomers_c20241101__20251031__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_pp0p" title="Cumulative sales from customers">30,000</span> grant of shares was valued at $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20240330__20240401__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_pp0p" title="Stock-based compensation expense">60,000</span> based on the closing price of the common stock of the Company on the effective date of the agreement of $2.00. The Company provided notice of termination of the agreement with Salesco during the eight months ended June 30, 2026. The Company recorded $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20241101__20251031__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_pp0p" title="Stock-based compensation expense">8,000</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_pp0d_c20231101__20241031__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_ze3wvdDs7wUc" title="Stock-based compensation expense">18,000</span> of stock-based compensation expense during the years ended October 31, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During April 2024 through August 2024, in consideration for agreeing to serve on the Company’s medical advisory board, the Board approved the issuance to a total of twenty individuals an aggregate of 155,000 shares of unregistered common stock valued at ranges between $<span id="xdx_904_eus-gaap--SharePrice_iI_c20240831__srt--CounterpartyNameAxis__custom--TwentyIndividualsMember__srt--RangeAxis__srt--MinimumMember_zFpD8jz34D1c" title="Share Price">1.04</span> per share and $<span id="xdx_904_eus-gaap--SharePrice_iI_c20240831__srt--CounterpartyNameAxis__custom--TwentyIndividualsMember__srt--RangeAxis__srt--MaximumMember_zK7MTC0Bhqk7" title="Share Price">2.75 </span>per share, the closing price of the common stock of the Company on the respective grant dates. The shares vest annually over the three-year period from the date of grant. The Company will amortize $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0d_c20240402__20240831__srt--CounterpartyNameAxis__custom--TwentyIndividualsMember_zgPEUNZUFaX3" title="Value of shares issued">271,000</span> of stock-based compensation expense over a three-year vesting period. The Company recorded $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20251101__20260630__srt--CounterpartyNameAxis__custom--TwentyIndividualsMember_pp0p" title="Stock-based compensation expense">34,000</span>, $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pp0d_c20241101__20251031__srt--CounterpartyNameAxis__custom--TwentyIndividualsMember_z9RI7CAEvfb4" title="Stock-based compensation expense">82,000</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0d_c20231101__20241031__srt--CounterpartyNameAxis__custom--TwentyIndividualsMember_zHiN90AZnQtl" title="Stock-based compensation expense">57,000</span> of stock-based compensation expense during the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2024, pursuant to the Company’s 2021 Incentive Stock Plan (“Incentive Plan”), the <span id="xdx_903_ecustom--IncentivePlanDescription_c20240330__20240401__us-gaap--PlanNameAxis__custom--SalesDistributionAgreementMember__srt--CounterpartyNameAxis__custom--SalescoMember_zZIz5C18WZUj" title="Description incentive plan">Company’s Board of Directors (“Board”) awarded 125,000 and 62,500 shares of the Company’s common stock to Jerry Glauser and Leathem Stearn or their nominees, respectively (“Stock Grants”), both members of the Board, valued at $2.00 per share, the closing price of the common stock of the Company on the grant date. The Stock Grants vest in full as of the date of the grant. The Company recorded a total of $375,000 of stock-based compensation expense during the year ended October 31, 2024, in connection with the Stock Grants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fiscal Year October 31, 2025 Issuances</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2025, in connection with an agreement with an independent sales representative (“Representative”), the Company agreed to grant the Representative <span id="xdx_904_ecustom--GrantOfUnvestedRestrictedCommonStock_c20250202__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_pd" title="Grant of unvested restricted common stock">40,000</span> shares of the Company’s common stock which were to vest quarterly over a 2-year period beginning with the first month subsequent to the monthly period that the Representative generated a cumulative amount of sales for the Company in excess of $500,000 (“Sales Milestone”). In addition, the Representative will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Representative in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated by the Company at any time upon 30 days written notice for failure of Representative to meet sales targets, to be solely determined by the Company. The fair value of the shares as of the date of grant was $<span id="xdx_90C_ecustom--FairValueOfNonvestedSharesGranted_c20241101__20251031__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_pp0p" title="Fair value of the shares as of the date of grant"><span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20241101__20251031__us-gaap--AwardTypeAxis__custom--RestrictedStockAwardsMember_pp0p" title="Stock-based compensation expense">104,000</span></span>. The Company terminated the agreement during May 2026 without the Representative achieving the minimum Sales Milestone. As a result, the shares were forfeited and the Company did not record any expense in connection with the grant of shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2025, the Company entered into an agreement with a non-affiliated consultant (the “Consultant”) to advise the Company on strategic communication investor relation programs (“Consulting Agreement”). <span id="xdx_900_ecustom--GrantOfUnvestedRestrictedCommonStockDescription_pp0d_c20250501__20250508__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z3CSqnSvUaN5" title="Grant of unvested restricted common stock description">In connection with the Consultant Agreement, the Company granted the Consultant 100,000 shares of common stock (“Shares”) and warrants to purchase an additional 500,000 shares of common stock (the “Warrants”). 50,000 of the Shares with a fair value of $143,000 vested upon execution of the Consulting Agreement and the remaining 50% with a fair value of $143,000 will vest on the six-month anniversary of the Consulting Agreement. During the periods ended June 30, 2026 and the year ended October 31, 2025, the Company amortized $143,000 and $143,000, respectively, of expenses related to the fair value of the shares. The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable on the terms provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. </span>The grant date fair value of the warrants granted was $<span id="xdx_90A_ecustom--FairValueOfNonvestedSharesGranted_c20250501__20250508__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_pp0p" title="Fair value of the shares as of the date of grant">1,428,000</span>. The Company will amortize $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20250501__20250508__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation expense">1,428,000</span> of stock-based compensation when management estimates the vesting the conditions are probable of being achieved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 23, 2025, <span id="xdx_904_ecustom--GrantOfUnvestedRestrictedCommonStockDescription_pp0d_c20250501__20250523__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--SecondConsultantMember_zdxX73ZQ6DN5">in connection with an agreement with a second consultant (“Second Consultant”), the Company agreed to grant the Second Consultant 40,000 shares of the Company’s common stock which shall vest quarterly over a 2-year period commencing on the date that sales obtained by the Company from customers introduced by Second Consultant exceed $400,000 (“Milestone”) and provided that the Milestone is achieved by December 31, 2025. Upon termination of the agreement for any reason, any unvested stock shall be forfeited. In addition, the Second Consultant will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Second Consultant in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated at any time by either party upon 30 days written notice. </span>The fair value of the shares as of the date of grant was $<span id="xdx_909_ecustom--FairValueOfNonvestedSharesGranted_c20250501__20250523__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--SecondConsultantMember_pp0p">82,000</span>. The Company will amortize $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20250501__20250523__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--SecondConsultantMember_pp0p">82,000</span> of stock-based compensation prorata over the vesting period once the Second Consultant has achieved minimum Sales Milestone. During May 2026, the Company and the Second Consultant amended the agreement whereby the Milestone was terminated without the Second Consultant achieving the Milestone and the shares were forfeited and the Company did not record any expense in connection with the grant of shares. As an inducement to enter into the amendment, the Company agreed to issue the Second Consultant 25,000 shares of common stock of the Company with a fair value of $___, if customer sales attributed to the Second Consultant exceeds $200,000 for 2 consecutive months during the months from May 2026 through December 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 25, 2025, in connection with the Acquisition (see Note 18), the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250601__20250625__us-gaap--BusinessAcquisitionAxis__custom--BioLuminaLLCMember_pd" title="Number of restricted shares acquired">30,000</span> restricted shares of the Company’s common stock valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20250601__20250625__us-gaap--BusinessAcquisitionAxis__custom--BioLuminaLLCMember_pp0p" title="Value of restricted shares acquired">58,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Eight Month June 30, 2026 Issuances</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2025, the Company entered into a consulting agreement with a third party to provide certain market engagement and investor relations consulting services to the Company. Pursuant to the Consulting Agreement, the Company issued the consultant <span id="xdx_90D_ecustom--NumberOfSharesAwarded_c20251130__20251201__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pd">10,000</span> restricted shares of common stock of the Company, 5,000 shares which vested and were issued on the agreement date and 5,000 Shares which vested on the 90^th day after the agreement date. The 10,000 grant of shares were valued at $<span id="xdx_90F_eus-gaap--SharePrice_c20251201__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pd">2.05</span> per share, the closing price of the common stock of the Company on the effective date of the grant. The Company recorded a total of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20251101__20260630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--CounterpartyNameAxis__custom--ConsultantMember_zflYgkiDtIrk" title="Stock-based compensation">21,000</span> of stock-based compensation expense based on the grant date fair value of these shares during the eight months ended June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 23, 2025, in consideration for his performance, the Company awarded an employee of the Company, a bonus in the form of a restricted stock grant under the Company’s 2021 Plan of <span id="xdx_90A_ecustom--NumberOfSharesAwarded_c20251202__20251223__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Number of shares awarded">25,000</span> shares of the Company’s common stock, to vest as to 12,500 shares on the date of the grant and the remaining 12,500 shares on the first anniversary of the award date. The 25,000 grant of shares was valued at $<span id="xdx_907_eus-gaap--SharePrice_c20251223__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pd" title="Share Price">2.66</span> per share, the closing price of the common stock of the Company on the effective date of the grant. The Company will amortize $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20251202__20251223__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Stock-based compensation">66,000</span> of stock-based compensation in accordance with the vesting periods. The Company recorded a total of $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--EmployeeMember_pp0p" title="Stock-based compensation">50,000</span> of stock-based compensation expense based on the grant date fair value of these shares during the eight months ended June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 14, 2026, pursuant to the Company’s 2021 Plan, the Company’s Compensation Committee (“Comp Board”) awarded <span id="xdx_906_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--CounterpartyNameAxis__custom--IanBothwellMember_pd" title="Number of shares awarded">175,000</span> shares of the Company’s common stock to Ian Bothwell, the Company’s Chief Executive Officer and <span id="xdx_900_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--TitleOfIndividualAxis__custom--ChiefMedicalOfficerMember__srt--CounterpartyNameAxis__custom--DrGeorgeShapiroMember_pd" title="Number of shares awarded">175,000</span> shares of the Company’s common stock to Dr. George Shapiro, the Company’s Chief Medical Officer. The Comp Board also approved the grant of <span id="xdx_902_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--GreytVenturesLLCMember_pd" title="Number of shares awarded">175,000</span> shares of common stock of the Company to Greyt Ventures LLC, a principal shareholder of the Company in consideration of consulting services rendered to the Company. The <span id="xdx_908_ecustom--NumberOfSharesAwarded_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Number of shares awarded">525,000</span> grant of shares was valued at $<span id="xdx_90F_eus-gaap--SharePrice_c20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember_pd" title="Share Price">2.66</span> per share, the closing price of the common stock of the Company on the effective date of the grant. The Company will amortize $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20260101__20260114__us-gaap--PlanNameAxis__custom--N2021PlanMember_pp0p" title="Stock-based compensation">1,395,000</span> of stock-based compensation expense over the one-year vesting term. The Company recorded $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021PlanMember_pp0p" title="Stock-based compensation">799,000</span> of stock-based compensation expense during the eight months ended June 30, 2026. The shares have not yet vested but have been issued as of June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective January 23, 2026, Dr. Kisiday was appointed the Company’s Chief Technology Officer and the Company entered into an employment agreement (“Employment Agreement”) with Dr. Kisiday. In connection with Dr. Kisiday’s Employment Agreement, Dr. Kisiday was granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260123__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_zDiAQx0NDMtg" title="Non-vested shares granted">50,000</span> shares of common stock under the 2021 Plan. The stock grant vests as to 20,000 shares on the first anniversary of the of the Employment Agreement and 30,000 shares on the second anniversary of the Employment Agreement. The 50,000 grant of shares was valued at $<span id="xdx_905_eus-gaap--SharePrice_iI_c20260123__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_zNBLh7PFcH88" title="Share Price">2.74</span> per share, the closing price of the common stock of the Company on the effective date of the Employment Agreement. The Company will amortize $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0d_c20260101__20260123__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_zDfDWedEFH0a" title="Stock-based compensation">137,000</span> of stock-based compensation expense over the two-year vesting term. Effective March 23, 2026, Dr. Kisiday’s employment was terminated and the <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20260101__20260123__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--PlanNameAxis__custom--N2021PlanMember__srt--CounterpartyNameAxis__custom--DrKisidayMember_zhX6e6PXzxR9" title="Forfeited in period">50,000</span> stock grant was forfeited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period February 2026 to June 2026, in consideration for agreeing to join the Company’s medical advisory board or as a consultant, the Company issued to twelve individuals an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20251101__20260630__srt--CounterpartyNameAxis__custom--ConsultantMember_pd" title="Shares issued">182,500</span> shares of unregistered common stock valued between $<span id="xdx_907_eus-gaap--SharePrice_c20260630__srt--RangeAxis__srt--MinimumMember__srt--CounterpartyNameAxis__custom--ConsultantMember_pd" title="Share Price">1.66</span> and $<span id="xdx_905_eus-gaap--SharePrice_c20260630__srt--CounterpartyNameAxis__custom--ConsultantMember__srt--RangeAxis__srt--MaximumMember_pd" title="Share Price">2.45</span> per share, the closing price of the common stock of the Company on the respective grant dates. 10,000 of the shares vested immediately and the remaining 172,500 shares vest over periods up to a maximum of 3 years. The Company will record $367,000 of stock-based compensation expense based on the grant date fair value of these shares over the respective vesting terms. The Company recorded a total of $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20251101__20260630__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation">72,000</span> of stock-based compensation expense based on the grant date fair value of these shares during the eight months ended June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the eight months ended June 30, 2026, <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20251101__20260630__srt--CounterpartyNameAxis__custom--ConsultantMember_zzBFRx3qVqL4" title="Option vested">20,833</span> and <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20241101__20250630__srt--CounterpartyNameAxis__custom--ConsultantMember_zVuWZCDzFQM6" title="Option vested"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20231101__20240630__srt--CounterpartyNameAxis__custom--ConsultantMember_z53JlBwMZrQ3" title="Option vested">50,000</span></span> shares that were granted in 2024 and 2025, respectively, vested, of which $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20251101__20260430__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation">34,000</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20241101__20250430__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation"><span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20231101__20240430__srt--CounterpartyNameAxis__custom--ConsultantMember_pp0p" title="Stock-based compensation">143,000</span></span>, respectively, of stock based compensation expense was recognized during the eight months ended June 30, 2026. The shares have not yet been issued as of June 30, 2026. In addition, 125,000 shares granted prior to October 31, 2025 were forfeited due to termination and/or failure to satisfy service or performance conditions of the respective agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of unvested restricted stock activity for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zfqxo2mp8zrf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span id="xdx_8BB_zQW9gOQ5khsa">Schedule of non vested share activity</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Non-vested<br/> Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Grant Date Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Non-vested Shares at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20231101__20241031_zWyEclSP8X06" title="Number of nonvested shares outstanding at beginning">100,000</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_906_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20231101__20241031_zBBlh7c2aIy4" title="Fair value of nonvested shares outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231101__20241031_zoGMa8hOsoOf" title="Weighted- average grant date value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-vested Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231101__20241031_pd" title="Non-vested shares granted">185,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_ecustom--FairValueOfNonvestedSharesGranted_c20231101__20241031_pp0p" title="Fair value of non-vested shares granted">331,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231101__20241031_pd" title="Weighted- average grant date value, non-vested shares granted">1.79</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20231101__20241031_zwSKHmFula6e" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_ecustom--FairValueOfVestedShares_iN_pp0d_di_c20231101__20241031_zw2mhWPp6xD5" title="Fair value of vested shares">(74,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20231101__20241031_pd" title="Weighted- average grant date value, vested"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20241031_zv4oIVfkLnTg" title="Expired/forfeited">(100,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20231101__20241031_zvpgHKL9PNpd" title="Fair value of expired/forfeited shares"><span style="-sec-ix-hidden: xdx2ixbrl1380">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20241031_pd" title="Weighted- average grant date value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-vested Shares at October 31, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20241101__20251031_zAm14w4CBFUa" title="Number of nonvested shares outstanding at beginning">185,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20241101__20251031_zRoe8y8LYgu5" title="Fair value of nonvested shares outstanding at beginning">257,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20241101__20251031_zJzDfQFU3X96" title="Weighted- average grant date value, outstanding at beginning">1.79</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-vested Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241101__20251031_pd" title="Non-vested shares granted">180,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_ecustom--FairValueOfNonvestedSharesGranted_c20241101__20251031_pp0p" title="Fair value of non-vested shares granted">473,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20241101__20251031_pd" title="Weighted- average grant date value, non-vested shares granted">2.54</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20241101__20251031_z40tIq2PjmZh" title="Vested">(105,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_ecustom--FairValueOfVestedShares_iN_pp0d_di_c20241101__20251031_zs3J4IqZcP35" title="Fair value of vested shares">(233,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20241101__20251031_pd" title="Weighted- average grant date value, vested"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20241101__20251031_z4JUeG67axNe" title="Expired/forfeited">(31,667</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20241101__20251031_zkK4OR96gkQ4" title="Fair value of expired/forfeited shares">(46,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031_pd" title="Weighted- average grant date value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-vested Shares at October 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20251101__20260630_zVvCzIwEeRYb" title="Number of nonvested shares outstanding at beginning">228,333</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20251101__20260630_zXXKtVMgr9F2" title="Fair value of nonvested shares outstanding at beginning">451,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20251101__20260630_zRCPbFc68ux3" title="Weighted- average grant date value, outstanding at beginning">2.05</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260630_zszMSStOCCrd" title="Non-vested shares granted">792,500</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_ecustom--FairValueOfNonvestedSharesGranted_pp0d_c20251101__20260630_zojr46Ye4Skl" title="Fair value of non-vested shares granted">1,986,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20251101__20260630_zYpZP2QVtUyg" title="Weighted- average grant date value, non-vested shares granted">2.51</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20251101__20260630_zpbjWMvgWNtg" title="Vested">(103,333</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_ecustom--FairValueOfVestedShares_iN_pp0d_di_c20251101__20260630_zFsmHvZbbVfj" title="Fair value of vested shares">(1,118,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20251101__20260630_zMerLNwBKEK4" title="Weighted- average grant date value, vested"><span style="-sec-ix-hidden: xdx2ixbrl1424">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260630_z4ZVXpwP29Oh" title="Expired/forfeited">(175,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20251101__20260630_zP1iYiUoUxfj" title="Fair value of expired/forfeited shares">(357,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260630_zTqtHbLcpp53" title="Weighted- average grant date value, expired/forfeited">2.05</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-vested Shares at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20251101__20260630_z0q42Cxvkvh6" title="Number of nonvested shares, outstanding at end">742,500</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--FairValueOfNonvestedShares_iE_pp0d_c20251101__20260630_zLOmFSBXm978" title="Fair value of nonvested shares, outstanding at end">962,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20251101__20260630_zXbBhoNpV0w" title="Weighted- average grant date value, outstanding at end">2.47</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded a total of $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__custom--UnvestedStockGrantsMember_ztaT8g3wFCN8" title="Stock-based compensation expense">1,119,000</span>, $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20241101__20251031__us-gaap--AwardTypeAxis__custom--UnvestedStockGrantsMember_pp0p" title="Stock-based compensation expense">233,000</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20231101__20241031__us-gaap--AwardTypeAxis__custom--UnvestedStockGrantsMember_pp0p" title="Stock-based compensation expense">74,000</span> of stock-based compensation expense based on the grant date fair value of these shares during the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2026, the Company has issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20260630__us-gaap--AwardTypeAxis__custom--UnvestedSharesMember_zHtfRMYm4pLj" title="Shares issued">525,000</span> shares that have not yet vested. There was approximately $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241101__20251031__us-gaap--AwardTypeAxis__custom--UnvestedSharesMember_z39LKD4Xq8M1">962,000 </span>of unamortized compensation associated with unvested stock grants outstanding as of June 30, 2026 that will be amortized over their respective remaining service periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 10000000 0.001 100 0.001 250000 83333 ZEO entered into a subscription agreement (“Subscription Agreement”) with a single accredited investor (the “Investor”) pursuant to which the Investor agreed to purchase 250,000 shares of our common stock (the “Shares”) in a private transaction for an aggregate purchase price of $1,000,000 (the “Purchase Price”). The Shares were to be issued and sold and the Purchase Price paid in ten (10) equal monthly installments commencing on August 1, 2025 and ending on May 1, 2026. As of October 31, 2025, 75,000 shares have been sold for an aggregate of $300,000 in accordance with the Subscription Agreement. On November 1, 2025, an additional 25,000 shares were sold for $100,000 in accordance with the Subscription Agreement. On February 10, 2026, the Subscription Agreement was amended whereby the total number of Shares to be purchased under the Subscription Agreement was reduced to 100,000 Shares and no further shares are issuable. As of June 30, 2026, a total of 100,000 shares have been sold for an aggregate amount of $400,000 pursuant to the Subscription Agreement. 8.2 2050000 Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. 512500 512500 1250000 2500000 7500000 5962395 1379524 1595482 1243647 20000 20000 20000 15000 30000 P2Y P2Y 300000 30000 60000 8000 18000 1.04 2.75 271000 34000 82000 57000 Company’s Board of Directors (“Board”) awarded 125,000 and 62,500 shares of the Company’s common stock to Jerry Glauser and Leathem Stearn or their nominees, respectively (“Stock Grants”), both members of the Board, valued at $2.00 per share, the closing price of the common stock of the Company on the grant date. The Stock Grants vest in full as of the date of the grant. The Company recorded a total of $375,000 of stock-based compensation expense during the year ended October 31, 2024, in connection with the Stock Grants. 40000 104000 104000 In connection with the Consultant Agreement, the Company granted the Consultant 100,000 shares of common stock (“Shares”) and warrants to purchase an additional 500,000 shares of common stock (the “Warrants”). 50,000 of the Shares with a fair value of $143,000 vested upon execution of the Consulting Agreement and the remaining 50% with a fair value of $143,000 will vest on the six-month anniversary of the Consulting Agreement. During the periods ended June 30, 2026 and the year ended October 31, 2025, the Company amortized $143,000 and $143,000, respectively, of expenses related to the fair value of the shares. The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable on the terms provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. 1428000 1428000 in connection with an agreement with a second consultant (“Second Consultant”), the Company agreed to grant the Second Consultant 40,000 shares of the Company’s common stock which shall vest quarterly over a 2-year period commencing on the date that sales obtained by the Company from customers introduced by Second Consultant exceed $400,000 (“Milestone”) and provided that the Milestone is achieved by December 31, 2025. Upon termination of the agreement for any reason, any unvested stock shall be forfeited. In addition, the Second Consultant will be entitled to receive commissions on sales of the Company’s products to customers introduced by the Second Consultant in the form of cash and common stock of the Company based on sales milestones. The agreement may be terminated at any time by either party upon 30 days written notice. 82000 82000 30000 58000 10000 2.05 21000 25000 2.66 66000 50000 175000 175000 175000 525000 2.66 1395000 799000 50000 2.74 137000 50000 182500 1.66 2.45 72000 20833 50000 50000 34000 143000 143000 <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_zfqxo2mp8zrf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><span id="xdx_8BB_zQW9gOQ5khsa">Schedule of non vested share activity</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Non-vested<br/> Shares</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Grant Date Value</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Non-vested Shares at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20231101__20241031_zWyEclSP8X06" title="Number of nonvested shares outstanding at beginning">100,000</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_906_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20231101__20241031_zBBlh7c2aIy4" title="Fair value of nonvested shares outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1362">-</span></span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231101__20241031_zoGMa8hOsoOf" title="Weighted- average grant date value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1364">-</span></span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-vested Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231101__20241031_pd" title="Non-vested shares granted">185,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_ecustom--FairValueOfNonvestedSharesGranted_c20231101__20241031_pp0p" title="Fair value of non-vested shares granted">331,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231101__20241031_pd" title="Weighted- average grant date value, non-vested shares granted">1.79</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20231101__20241031_zwSKHmFula6e" title="Vested"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90D_ecustom--FairValueOfVestedShares_iN_pp0d_di_c20231101__20241031_zw2mhWPp6xD5" title="Fair value of vested shares">(74,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20231101__20241031_pd" title="Weighted- average grant date value, vested"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20241031_zv4oIVfkLnTg" title="Expired/forfeited">(100,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20231101__20241031_zvpgHKL9PNpd" title="Fair value of expired/forfeited shares"><span style="-sec-ix-hidden: xdx2ixbrl1380">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20241031_pd" title="Weighted- average grant date value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-vested Shares at October 31, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20241101__20251031_zAm14w4CBFUa" title="Number of nonvested shares outstanding at beginning">185,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20241101__20251031_zRoe8y8LYgu5" title="Fair value of nonvested shares outstanding at beginning">257,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20241101__20251031_zJzDfQFU3X96" title="Weighted- average grant date value, outstanding at beginning">1.79</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-vested Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241101__20251031_pd" title="Non-vested shares granted">180,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_ecustom--FairValueOfNonvestedSharesGranted_c20241101__20251031_pp0p" title="Fair value of non-vested shares granted">473,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20241101__20251031_pd" title="Weighted- average grant date value, non-vested shares granted">2.54</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20241101__20251031_z40tIq2PjmZh" title="Vested">(105,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_ecustom--FairValueOfVestedShares_iN_pp0d_di_c20241101__20251031_zs3J4IqZcP35" title="Fair value of vested shares">(233,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20241101__20251031_pd" title="Weighted- average grant date value, vested"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20241101__20251031_z4JUeG67axNe" title="Expired/forfeited">(31,667</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20241101__20251031_zkK4OR96gkQ4" title="Fair value of expired/forfeited shares">(46,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031_pd" title="Weighted- average grant date value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-vested Shares at October 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20251101__20260630_zVvCzIwEeRYb" title="Number of nonvested shares outstanding at beginning">228,333</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_ecustom--FairValueOfNonvestedShares_iS_pp0d_c20251101__20260630_zXXKtVMgr9F2" title="Fair value of nonvested shares outstanding at beginning">451,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20251101__20260630_zRCPbFc68ux3" title="Weighted- average grant date value, outstanding at beginning">2.05</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Shares Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260630_zszMSStOCCrd" title="Non-vested shares granted">792,500</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_903_ecustom--FairValueOfNonvestedSharesGranted_pp0d_c20251101__20260630_zojr46Ye4Skl" title="Fair value of non-vested shares granted">1,986,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20251101__20260630_zYpZP2QVtUyg" title="Weighted- average grant date value, non-vested shares granted">2.51</span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Vested</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20251101__20260630_zpbjWMvgWNtg" title="Vested">(103,333</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_ecustom--FairValueOfVestedShares_iN_pp0d_di_c20251101__20260630_zFsmHvZbbVfj" title="Fair value of vested shares">(1,118,000</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20251101__20260630_zMerLNwBKEK4" title="Weighted- average grant date value, vested"><span style="-sec-ix-hidden: xdx2ixbrl1424">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260630_z4ZVXpwP29Oh" title="Expired/forfeited">(175,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--FairValueOfExpiredforfeitedShares_iN_pp0d_di_c20251101__20260630_zP1iYiUoUxfj" title="Fair value of expired/forfeited shares">(357,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260630_zTqtHbLcpp53" title="Weighted- average grant date value, expired/forfeited">2.05</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-vested Shares at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20251101__20260630_z0q42Cxvkvh6" title="Number of nonvested shares, outstanding at end">742,500</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--FairValueOfNonvestedShares_iE_pp0d_c20251101__20260630_zLOmFSBXm978" title="Fair value of nonvested shares, outstanding at end">962,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20251101__20260630_zXbBhoNpV0w" title="Weighted- average grant date value, outstanding at end">2.47</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 100000 185000 331000 1.79 74000 100000 185000 257000 1.79 180000 473000 2.54 105000 233000 31667 46000 228333 451000 2.05 792500 1986000 2.51 103333 1118000 175000 357000 2.05 742500 962000 2.47 1119000 233000 74000 525000 962000 <p id="xdx_806_ecustom--StockOptionsWarrantsTextBlock_zOAHEakffH6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 – <span id="xdx_823_zX5EowrZ9go9">STOCK OPTIONS AND WARRANTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued option securities under its Incentive Plan and warrants entitling the holder to purchase shares of its common stock at specified prices and for specified exercise periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Options:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company’s option activity for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSVkt1f7S3K" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8B3_zZ0nhIuwn681">Schedule of stock options and warrants</span></span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<br/>Shares</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted-average<br/>Exercise Price</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<br/>Contractual<br/>Term (years)</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate<br/>Intrinsic Value</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPU5SjmLGtt2" title="Number of shares, outstanding beginning balance">895,750</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvi3tVn88yC3" title="Weighted-average exercise price, outstanding beginning balance">2.97</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221101__20231031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXegRKb28iC4" title="Remaining contractual term (years), outstanding beginning balance">5.67</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuGQgVa9UAB1" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1457">-</span></span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, granted">622,538</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, granted">2.52</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_ecustom--RemainingContractualTermYearsGranted_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQZSZQfyBN0j" title="Remaining contractual term (years), granted">9.42</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_ecustom--AggregateIntrinsicValueGranted_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1465">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1469">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5c6thwUvsib" title="Number of shares, expired/forfeited">(555,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, expired/forfeited">2.53</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHajkYIfQFD2" title="Remaining contractual term (years), expired/forfeited">3.74</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_ecustom--AggregateIntrinsicValueExpiredforfeited_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyrX3BoRvm5e" title="Number of shares, outstanding beginning balance">963,288</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhT6Gt3ZOGG9" title="Weighted-average exercise price, outstanding beginning balance">2.94</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzK9CDPUJod" title="Remaining contractual term (years), outstanding beginning balance">8.07</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztk0IoTkPmGe" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1487">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, granted">241,341</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, granted">2.90</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--RemainingContractualTermYearsGranted_pp0d_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSTTcDBxro28" title="Remaining contractual term (years), granted">5.00</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_ecustom--AggregateIntrinsicValueGranted_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1495">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90C_ecustom--AggregateIntrinsicValueGranted_pp0d_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdpKLcRBiqX2" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1497">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1499">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1501">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7CYX3o3ryQa" title="Number of shares, expired/forfeited">(32,147</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, expired/forfeited">3.40</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z0gzPrHnbQFl" title="Remaining contractual term (years), expired/forfeited">4.12</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--AggregateIntrinsicValueExpiredforfeited_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1509">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh0pqMmX7yMg" title="Number of shares, outstanding beginning balance">1,172,482</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8LlgXOv3c61" title="Weighted-average exercise price, outstanding beginning balance">2.91</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjWUqNCNC7ud" title="Remaining contractual term (years), outstanding beginning balance">6.61</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zk317Z5XhkGi" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1517">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7s2TDSNAqn6" title="Number of shares, granted">3,915,290</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRlxVatehMB6" title="Weighted-average exercise price, granted">1.68</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_ecustom--RemainingContractualTermYearsGranted_pp0d_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqtpZBU8NZSl" title="Remaining contractual term (years), granted">9.79</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_ecustom--AggregateIntrinsicValueGranted_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCRVySmalLC3" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1525">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_ecustom--AggregateIntrinsicValueGranted_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zE0yXvbis7f5" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjUeagCz0Rv8" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztBhbUrJ5jG6" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1531">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXqhh12G8sj2" title="Number of shares, expired/forfeited">(85,877</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zciwFHc72nwg" title="Weighted-average exercise price, expired/forfeited">2.74</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1JNeAfwjiJ4" title="Remaining contractual term (years), expired/forfeited">2.97</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--AggregateIntrinsicValueExpiredforfeited_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsOONy5baZy1" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1539">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQL77UB0o0Ih" title="Number of shares outstanding ending balance">5,001,895</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH5oVziY9QNd" title="Weighted-average exercise price outstanding ending balance">1.95</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhGyL3smqM92" title="Remaining contractual term (years), outstanding beginning balance">9.07</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zviYuVNYKzyb" title="Aggregate intrinsic value outstanding ending balance">430,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Exercisable at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, exercisable">3,108,726</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercisable">2.10</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGUwGC8oBCP1" title="Remaining contractual term (years) outstanding, exercisable">8.56</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0d_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKT6PXOwNKE7" title="Aggregate intrinsic value, exercisable">224,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zu1rKZ6M94nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Year ended October 31, 2024 Options</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2024, under its Incentive Plan, the Board approved the granting of options to certain employees, officers and directors to purchase 622,538 shares of its common stock. <span id="xdx_907_ecustom--VestingPeriod_c20231101__20241031__srt--TitleOfIndividualAxis__srt--DirectorMember_zFUz00ZbIDVa" title="Vesting period">The options vest over various periods ranging from 6 months to 3 years, expire five to ten years from the date of grant and had an aggregate fair value of $<span id="xdx_904_ecustom--OptionGrantDateFairValue_c20241031__srt--TitleOfIndividualAxis__srt--DirectorMember_pp0p" title="Option grant date fair value">1,438,000</span> at the date of grant. </span>The Company valued the options using a Black-Scholes option pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAssumptionsUsedForTheOptionsGrantedTableTextBlock_zpPRB4tp0ECa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="display: none"><span id="xdx_8BF_zk3EDgQhXFM1">Schedule of assumptions used for the options granted</span></span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 85%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise prices</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Exercise prices">2.00</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_pd" title="Exercise prices">4.50</span></p></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expected dividends</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_pd" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Expected volatility">156%</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zZwiOLYQWbL4" title="Expected volatility">159</span></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Risk free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Risk free interest rate">4.20%</span> - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zIhGmMMk08X2" title="Risk free interest rate">4.34</span></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expected term of options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zgAO0FxxeHi7" title="Expected life of options">6.0</span> years</td> <td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zjxz7dXwjOPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended October 31, 2024, all options issued to Dr. Leider, the former Chief Executive Officer, that were not vested amounting to 190,000 at the time of the expiration of his employment agreement on May 31, 2024, were forfeited. In addition, all options issued to Dr. Leider and Dr. Howard Golub, the former Chief Science Officer, and an employee, that were vested amounting to <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20241101__20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrLeiderMember_pd" title="Option vested">95,000</span>, <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20241101__20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrHowardGolubMember_pd" title="Option vested">250,000</span>, and <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20241101__20251031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeeMember_pd" title="Option vested">20,000</span>, respectively, at the time of the expiration of their employment agreements, were not exercised by August 31, 2024 as required under the Incentive Plan, and as a result expired.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Year Ended October 31, 2025 Options</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2025, under its Incentive Plan, the Board approved the granting of options to certain employees to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241101__20251031__srt--TitleOfIndividualAxis__srt--DirectorMember_zoREwWyE45ch">11,341</span> shares of its common stock. The <span id="xdx_908_ecustom--VestingPeriod_c20241101__20251031__srt--TitleOfIndividualAxis__srt--DirectorMember_zivDZmtnmCc1">options vest annually over 3 years, expire five years from the date of grant</span> and had an aggregate fair value of $<span id="xdx_906_ecustom--OptionGrantDateFairValue_iI_pp0d_c20251031__srt--TitleOfIndividualAxis__srt--DirectorMember_zmjXGqu1Hp5i">39,000</span> at the date of grant.</p> <p id="xdx_8A1_zQu5xIeNGC4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended October 31, 2025, the Board approved the granting of options to purchase an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241101__20251031__srt--TitleOfIndividualAxis__custom--Dr.EvertsMember_zuDdqL5HnzYd">65,000</span> shares of its common stock to Dr. Everts, Chief Science and Technology Officer of the Company and Mr. Ron Borsheim, Chief Sales Officer of the Company in accordance with their employment agreements. The options are exercisable until the fifth anniversary date of the date of issuance and had an aggregate fair value of $<span id="xdx_909_ecustom--OptionGrantDateFairValue_iI_pp0d_c20251031__srt--TitleOfIndividualAxis__custom--Dr.EvertsMember_zISvGA6uh0mb">177,000</span>. The <span id="xdx_90C_ecustom--VestingPeriod_c20241101__20251031__srt--TitleOfIndividualAxis__custom--Dr.EvertsMember_zkUZrp1VGVp3">options vest over a five-year period.</span></p> <p id="xdx_8AA_zRQV9beDrTyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2025, under its Incentive Plan, the Board approved the granting of options to certain employees, officers and directors to purchase <span id="xdx_90B_ecustom--GrantOfUnvestedRestrictedCommonStock_c20250508__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_pd" title="Grant of unvested restricted common stock">165,000</span> shares of its common stock. 153,000 of the options vest immediately and 12,000 of the options vest over a 4-month period, expire five years from the date of grant and had an aggregate fair value of $<span id="xdx_90F_ecustom--FairValueOfNonvestedSharesGranted_c20250501__20250508__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_pp0p" title="Fair value of the shares as of the date of grant">472,000</span> at the date of grant. The Company valued the options using a Black-Scholes option pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfOptionPricingModelTableTextBlock_zs2PFR6ZBH6j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span id="xdx_8B6_zyIcS6vzUf71" style="display: none">Schedule of option pricing model</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 85%; font-size: 10pt; text-align: left">Exercise prices</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zQjQFUcC6lv5" title="Exercise prices">2.50</span> - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_z0LudEGjQ6G3" title="Exercise prices">4.50</span></span></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Expected dividends</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zP25T0FJ0aIh" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1602">-</span></span></td> <td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_z7zTSTpaacxk" title="Expected volatility">148%</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zqTxbXMAQKNd" title="Expected volatility">179</span></span></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Risk free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zym1gq7gq7yf" title="Risk free interest rate">3.91%</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zr8S9zDne7dd" title="Risk free interest rate">4.36</span></span></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Expected term of options</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zfhDw2MUG0Y7" title="Expected life of options">5.0</span> years</span></td> <td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zhMZm1btZnKa" style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_8A5_zurGmPcXkAKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eight Months Ended June 30, 2026 Options</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the eight months ended June 30, 2026, under its Incentive Plan, the Board approved the granting of options to certain employees to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260630__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd">7,790</span> shares of its common stock. The options vest annually over 3 years, expire five years from the date of grant and had an aggregate fair value of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20251101__20260630__srt--TitleOfIndividualAxis__custom--EmployeesMember_pp0p">20,000</span> at the date of grant.</p> <p id="xdx_8A3_znSjI8MiO3ek" style="text-align: justify; margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2026, the Board granted fully vested stock options to purchase an aggregate of 2,032,500 shares of common stock under the 2021 Plan at an exercise price of $1.67 per share. Options for 625,000 shares, granted to Ian Bothwell, the Company’s Chief Executive Officer and 625,000 shares of the Company’s common stock to Dr. George Shapiro, the Company’s Chief Medical Officer and 625,000 to Greyt Ventures LLC, a principal shareholder of the Company, have a 10-year term and are exercisable on a cashless basis; options for 80,000 shares, granted to a non-executive director, and options for 77,500 shares granted to certain employees, and a consultant, have a 5-year term and are not exercisable on a cashless basis. The awards were fully vested on the grant date, and the aggregate grant-date fair value of $3,395,000 was recognized as stock-based compensation expense on the grant date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company valued the options using a Black-Scholes option pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfGrantingOptionPricingModelTableTextBlock_zRFsiFEDiXs2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 3)"> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BB_zazTOUgFXOR1" style="display: none">Schedule of granting option pricing model</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 82%; text-align: left"><span style="font-size: 10pt">Exercise prices</span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zFBWHCrv3cCg" title="Exercise prices">1.67</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zZV4yIOkZPD8" title="Exercise prices">4.50</span></span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> </tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected dividends</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--Dr.EvertsMember_zWOU6W972ika" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1622">-</span></span></span></td> <td style="vertical-align: bottom; text-align: justify"> </td> </tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected volatility</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zo2RtoitzOE9" title="Expected volatility">138%</span> - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zqRcb7ytOQKa" title="Expected volatility">233</span></span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">%</span></td> </tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Risk free interest rate</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zBN4rEeA6RU1" title="Risk free interest rate">3.79%</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zsyHx1n9LYNb" title="Risk free interest rate">4.55</span></span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">%</span></td> </tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected term of options</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember__srt--RangeAxis__srt--MinimumMember_zQGcFWZ2rpia" title="Expected life of options">2.5</span> years - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember__srt--RangeAxis__srt--MaximumMember_zCUiWNZmnmu2" title="Expected life of options">10.0</span> years</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> </tr> </table> <p id="xdx_8AC_ziydcEoU11nh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options totaling <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20241101__20251031__srt--TitleOfIndividualAxis__custom--EmployeesMember_pd" title="Number of shares issued">85,877</span> that were previously issued to employees that are no longer employed by the Company as of June 30, 2026, were forfeited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, the Company amortized $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__custom--OptionsVestingMember_zKDh6qskipN5" title="Stock compensation costs">3,596,000</span>, $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pp0d_c20241101__20251031__us-gaap--AwardTypeAxis__custom--OptionsVestingMember_zIW53CTd5VE7" title="Stock compensation costs">1,523,000</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__custom--OptionsVestingMember_zB0MJX8nCgW7" title="Stock compensation costs">953,000</span>, respectively, of stock compensation costs associated with options vesting during the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There was approximately $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260630__us-gaap--AwardTypeAxis__custom--OptionsOutstandingMember_zub346ZI2Laa">51,000</span> of unamortized compensation associated with options outstanding as of June 30, 2026 that will be amortized over their respective remaining service periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company’s warrant activity for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantActivityTableTextBlock_zJjvZdnA0QA8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8BC_ztc1xlf9fuOh">Schedule of warrant activity</span></span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<br/>Shares</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted-average<br/>Exercise Price</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<br/>Contractual<br/>Term (years)</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate<br/>Intrinsic Value</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znw5KGZdQl9k" title="Number of shares, outstanding beginning balance">1,675,906</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zABooZgTp7H6" title="Weighted-average exercise price, outstanding beginning balance">4.54</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221101__20231031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFt2aSdRaZwf" title="Remaining contractual term (years), outstanding">8.47</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWus4a47Y5k" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">883,333</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, granted">2.32</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_ecustom--RemainingContractualTermYearsGranted_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zf40F7Yf51Ei" title="Remaining contractual term (years), granted">9.21</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_ecustom--AggregateIntrinsicValueGranted_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmtC5oJl60Ih" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1664">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1666">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z184xEzVkXSk" title="Number of shares, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1672">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--AggregateIntrinsicValueExpiredforfeited_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6okUJZYuhW4" title="Number of shares, outstanding beginning balance">2,559,239</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj9cMUgyJPEa" title="Weighted-average exercise price, outstanding beginning balance">3.77</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlcnipAQV38c">7.97</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8a5MAoJffml" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1681">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">555,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVc7pCZu0iqa" title="Weighted-average exercise price, granted">6.23</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_ecustom--RemainingContractualTermYearsGranted_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6tDtz8XjfMg" title="Remaining contractual term (years), granted">3.20</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_906_ecustom--AggregateIntrinsicValueGranted_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1689">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr6iIMnuWJSj" title="Number of shares, exercised">(21,277</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zgyrWRy16v7b" title="Weighted-average exercise price, exercised">2.35</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_ecustom--RemainingContractualTermYearsGrantedExercised_iP3us-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkhgatLuZTde" title="Remaining contractual term (years), granted, exercised">1.76</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1697">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFDLRrpA5sJ1" title="Number of shares, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1699">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1701">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--AggregateIntrinsicValueExpiredforfeited_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvkUDei5jXvc" title="Number of shares outstanding beginning balance">3,092,962</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zalJ8aVBNP87" title="Weighted-average exercise price outstanding Beginning balance">4.22</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVHSfJrAzwll">6.24</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3VYJwhW0n0l" title="Aggregate intrinsic value outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1710">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">512,500</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, granted">4.00</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_ecustom--RemainingContractualTermYearsGranted_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKAh085BV4D5" title="Remaining contractual term (years), granted">4.90</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_ecustom--AggregateIntrinsicValueGranted_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdSZJb1DuZGl" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1718">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEybjgUDKsX6" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1720">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9FwHwG2TtXe" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1724">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuDZlWo2h1Ha" title="Number of shares, expired/forfeited">(400,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq4t39QaGqF4" title="Weighted-average exercise price, expired/forfeited">7.00</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--RemainingContractualTermYearsExpiredforfeited_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqwj6ciZdusa" title="Remaining contractual term (years), expired/forfeited">1.85</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--AggregateIntrinsicValueExpiredforfeited_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfyQshOm8Xea" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmtPvNCSPD83" title="Number of shares outstanding ending balance">3,205,462</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqq02hamyVqc" title="Weighted-average exercise price outstanding ending balance">3.84</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjJ5x7Wmp2r9">5.86</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq8wDDQuS7z9" title="Aggregate intrinsic value outstanding ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1739">-</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Exercisable at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercisable">3,105,462</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercisable">3.80</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyPrgCIbfAte" title="Remaining contractual term (years), exercisable">5.99</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zVUhCvy0dhq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fiscal Year Ended October 31, 2024 Warrants</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 8, 2024, in connection with the Financing (see Note 12), the Company issued the Investor a cashless warrant to purchase an aggregate of <span id="xdx_90C_ecustom--NumberOfWarrantsToPurchase_c20240701__20240708__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Warrant to purchase">83,333</span> shares of common stock. The warrant is exercisable for $<span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_c20240701__20240708__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Exercise price">2.00 </span>per share (the closing price of the Company’s common stock on the date of grant was $1.66), until the tenth anniversary date of the date of issuance. The exercise price and number of shares issuable upon exercise of the warrant are subject to adjustment to give effect to stock splits, stock dividends and other recapitalization events and the sale of shares at a purchase price less than the exercise price then in effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 11, 2024, the Company granted warrants to purchase <span id="xdx_906_ecustom--NumberOfWarrantsToPurchase_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Warrant to purchase">350,000</span> shares of common stock to each of two consultants and then principal shareholders of the Company (“Consultants”). The Warrants vest in equal monthly installments over an eighteen (18) month period from the date of grant. Once vested, the Warrants are exercisable for a period of ten (<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsMuzXFJNvw5" title="Term">10</span>) years from the date of grant at an exercise price of $<span id="xdx_90B_eus-gaap--WarrantExercisePriceIncrease_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Exercise price">2.35</span> per share (subject to adjustment for stock splits, stock dividends and similar recapitalization events). The Consultants, who are the controlling stockholders of the Company, were also accorded piggy-back registration rights under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the shares of common stock issuable upon exercise of the warrants. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Risk free interest rate">4.20%</span>, (2) term of <span id="xdx_908_ecustom--WarrantsExercisablePeriod_dtY_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zt3Bp4K7b2S6" title="Warrants exercisable period">10</span> years, (3) expected stock volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Expected stock volatility">159%</span>, and (4) expected dividend rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Expected dividend rate">0%</span>. The grant date fair value of the warrants granted to each of the Consultants was $823,000 (total $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20240701__20240711__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Fair value of warrants granted">1,645,000</span>). The Company will amortize $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0d_c20240701__20240711__srt--CounterpartyNameAxis__custom--TwoConsultantsMember_zBMZIgq6CeLd" title="Stock-based compensation expense">1,645,000</span> of stock-based compensation expense over the vesting period of 18 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2024, the Company entered into an agreement with a third party to provide consulting services for a one-year period. As consideration for agreeing to provide consulting services to the Company, the Company agreed to issue the consultant vested warrants to purchase <span id="xdx_902_ecustom--NumberOfWarrantsToPurchase_c20240801__20240831__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Warrant to purchase">100,000</span> shares of unregistered common stock. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240801__20240831__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Risk free interest rate">3.96%</span>, (2) term of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240801__20240831__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znDQ5DFoxUdk" title="Term">3</span> years, (3) expected stock volatility of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240801__20240831__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Expected stock volatility">147%</span>, and (4) expected dividend rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20240801__20240831__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Expected dividend rate">0%</span>. The grant date fair value of the warrants granted was $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20240801__20240831__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Fair value of warrants granted">185,000</span>. The Company will amortize $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pp0d_c20240801__20240831__srt--CounterpartyNameAxis__custom--ThirdPartyMember_z481InkGHl2d" title="Stock-based compensation expense">185,000</span> of stock-based compensation expense over the term of the consulting agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fiscal Year Ended October 31, 2025 Warrants</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90F_ecustom--GrantOfUnvestedRestrictedCommonStockDescription_c20250501__20250508__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zGHYK2YZJK19" title="Grant of unvested restricted common stock description">In connection with the Consulting Agreement discussed in Note 12, during May 2025, the Company granted the Consultant warrants to purchase 500,000 shares of its common stock (the “Warrants”). The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. </span>The grant date fair value of the warrants granted was $1,428,000. The Company will begin to amortize the $1,428,000 when management estimates the vesting conditions are probable of being achieved. During June 2026, the Consulting Agreement was amended whereby four (4) tranches of the Warrants to purchase an aggregate of <span id="xdx_909_ecustom--NumberOfWarrantsToPurchase_c20251101__20260630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--N4tranchesMember_pd" title="Warrant to purchase">400,000</span> shares of its common stock were terminated and forfeited (total of $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20260630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--N4tranchesMember_pp0p" title="Unamortized compensation costs">1,141,000</span> of unamortized stock compensation costs).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2025, the Company awarded warrants to purchase <span id="xdx_903_ecustom--PurchasedOfWarrants_c20250501__20250508_pd" title="Purchased of warrants">55,000</span> shares of our common stock to Greyt Ventures, LLC, a principal shareholder of the Company in consideration of consulting services rendered to the Company. The warrants are fully vested as of the award date and are exercisable for a period of five (<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250501__20250508_zr4iJ69YVcI2" title="Exercisable for a period">5</span>) years from the award date at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20250508_pd" title="Exercise price">2.86</span> per share. The Company valued the warrants using a Black-Scholes option pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfBlockScholesOptionPricingModelTableTextBlock_zWoe4GA0XpSl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 5)"> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span id="xdx_8B8_z6WHxbHqz8Zb" style="display: none">Schedule of Black-Scholes option pricing model</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 85%; text-align: justify">Exercise prices</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_pd" title="Exercise prices">2.86</span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Expected dividends</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_pd" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></span></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Expected volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_zpsvWp8Zz17k" title="Expected volatility">148</span></td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Risk free interest rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_zmbXGSd2jM15" title="Risk free interest rate">4.00</span></td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Expected term of options</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_zt77Y8GPc4k" title="Expected life of options">5.0</span> years</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> <p id="xdx_8A6_zr5RyYqgz9g6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 25, 2025, the <span id="xdx_904_ecustom--WarrantsDescription_c20250601__20250625__us-gaap--BusinessAcquisitionAxis__custom--BioLuminaLLCMember_zEJlDqPFLEpa" title="Warrants description">Company received notice from a holder of warrants to exercise 21,277 warrants to purchase 21,277 shares of common stock of the Company for a total exercise price of $50,000 ($2.35 per share). The proceeds were received, and the shares were issued on July 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eight Months Ended June 30, 2026 Warrants</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in Note 12, from November 2025 to June 2026, the Company sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251101__20260630_pd" title="Number of units sold">8.2</span> Units to fifteen investors for an aggregate purchase price of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20251101__20260630_pp0p" title="Aggregate purchase price">2,050,000</span> in a private transaction. <span id="xdx_90F_ecustom--SharesDescription_c20251101__20260630_z2ZZylJgLXbk" title="Shares description">Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. In connection with the sale of the Units, the Company issued 512,500 shares of common stock and 512,500 warrants to purchase shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, the Company amortized $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjomLCR1gFac" title="Stock compensation costs">215,000</span>, $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Stock compensation costs">2,937,000</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Stock compensation costs">2,450,000</span>, respectively, of stock compensation costs associated with warrants issued during the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Included in the table above is approximately $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSyBJt7ppAH2" title="Stock-based compensation expense">231,000</span> of unamortized compensation associated with 100,000 warrants outstanding as of June 30, 2026. The Warrants are exercisable at $<span id="xdx_909_eus-gaap--WarrantExercisePriceIncrease_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Exercise price">5.00</span> per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of one hundred and eighty (180) days from the date they become exercisable. The fair value of the warrants was determined to be $231,000. The Company will begin to amortize the $231,000 fair value when management estimates the vesting conditions are probable of being achieved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0d_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyZYeshRbhti" title="Unamortized compensation costs">231,000</span> of unamortized compensation associated with warrants outstanding as of June 30, 2026 that will be amortized over their respective remaining service periods. There was approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Unamortized compensation costs">1,270,000</span> of unamortized compensation associated with warrants outstanding as of October 31, 2025 that will be amortized over their respective remaining service periods. There was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Unamortized compensation costs">3,005,000</span> of unamortized compensation associated with warrants outstanding as of October 31, 2024 that will be amortized over their respective remaining service periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock compensation expense is classified under general and administrative expenses in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSVkt1f7S3K" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8B3_zZ0nhIuwn681">Schedule of stock options and warrants</span></span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<br/>Shares</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted-average<br/>Exercise Price</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<br/>Contractual<br/>Term (years)</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate<br/>Intrinsic Value</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPU5SjmLGtt2" title="Number of shares, outstanding beginning balance">895,750</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvi3tVn88yC3" title="Weighted-average exercise price, outstanding beginning balance">2.97</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221101__20231031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXegRKb28iC4" title="Remaining contractual term (years), outstanding beginning balance">5.67</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuGQgVa9UAB1" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1457">-</span></span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, granted">622,538</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, granted">2.52</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_ecustom--RemainingContractualTermYearsGranted_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQZSZQfyBN0j" title="Remaining contractual term (years), granted">9.42</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_ecustom--AggregateIntrinsicValueGranted_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1465">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1467">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1469">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1471">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5c6thwUvsib" title="Number of shares, expired/forfeited">(555,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, expired/forfeited">2.53</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHajkYIfQFD2" title="Remaining contractual term (years), expired/forfeited">3.74</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_ecustom--AggregateIntrinsicValueExpiredforfeited_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1479">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zyrX3BoRvm5e" title="Number of shares, outstanding beginning balance">963,288</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhT6Gt3ZOGG9" title="Weighted-average exercise price, outstanding beginning balance">2.94</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzK9CDPUJod" title="Remaining contractual term (years), outstanding beginning balance">8.07</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztk0IoTkPmGe" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1487">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, granted">241,341</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, granted">2.90</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_ecustom--RemainingContractualTermYearsGranted_pp0d_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSTTcDBxro28" title="Remaining contractual term (years), granted">5.00</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_ecustom--AggregateIntrinsicValueGranted_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1495">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90C_ecustom--AggregateIntrinsicValueGranted_pp0d_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zdpKLcRBiqX2" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1497">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1499">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1501">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7CYX3o3ryQa" title="Number of shares, expired/forfeited">(32,147</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, expired/forfeited">3.40</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z0gzPrHnbQFl" title="Remaining contractual term (years), expired/forfeited">4.12</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--AggregateIntrinsicValueExpiredforfeited_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1509">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zh0pqMmX7yMg" title="Number of shares, outstanding beginning balance">1,172,482</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8LlgXOv3c61" title="Weighted-average exercise price, outstanding beginning balance">2.91</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjWUqNCNC7ud" title="Remaining contractual term (years), outstanding beginning balance">6.61</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zk317Z5XhkGi" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1517">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7s2TDSNAqn6" title="Number of shares, granted">3,915,290</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRlxVatehMB6" title="Weighted-average exercise price, granted">1.68</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_ecustom--RemainingContractualTermYearsGranted_pp0d_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqtpZBU8NZSl" title="Remaining contractual term (years), granted">9.79</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_ecustom--AggregateIntrinsicValueGranted_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCRVySmalLC3" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1525">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_ecustom--AggregateIntrinsicValueGranted_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zE0yXvbis7f5" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjUeagCz0Rv8" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztBhbUrJ5jG6" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1531">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXqhh12G8sj2" title="Number of shares, expired/forfeited">(85,877</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zciwFHc72nwg" title="Weighted-average exercise price, expired/forfeited">2.74</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--RemainingContractualTermYearsExpiredforfeited_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1JNeAfwjiJ4" title="Remaining contractual term (years), expired/forfeited">2.97</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_ecustom--AggregateIntrinsicValueExpiredforfeited_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsOONy5baZy1" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1539">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQL77UB0o0Ih" title="Number of shares outstanding ending balance">5,001,895</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH5oVziY9QNd" title="Weighted-average exercise price outstanding ending balance">1.95</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhGyL3smqM92" title="Remaining contractual term (years), outstanding beginning balance">9.07</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zviYuVNYKzyb" title="Aggregate intrinsic value outstanding ending balance">430,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Exercisable at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Number of shares, exercisable">3,108,726</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pd" title="Weighted-average exercise price, exercisable">2.10</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGUwGC8oBCP1" title="Remaining contractual term (years) outstanding, exercisable">8.56</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0d_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKT6PXOwNKE7" title="Aggregate intrinsic value, exercisable">224,000</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 895750 2.97 P5Y8M1D 622538 2.52 P9Y5M1D 555000 2.53 P3Y8M26D 963288 2.94 P8Y25D 241341 2.90 P5Y 32147 3.40 P4Y1M13D 1172482 2.91 P6Y7M9D 3915290 1.68 P9Y9M14D 85877 2.74 P2Y11M19D 5001895 1.95 P9Y25D 430000 3108726 2.10 P8Y6M21D 224000 The options vest over various periods ranging from 6 months to 3 years, expire five to ten years from the date of grant and had an aggregate fair value of $1,438,000 at the date of grant. 1438000 <table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfAssumptionsUsedForTheOptionsGrantedTableTextBlock_zpPRB4tp0ECa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="display: none"><span id="xdx_8BF_zk3EDgQhXFM1">Schedule of assumptions used for the options granted</span></span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 85%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exercise prices</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Exercise prices">2.00</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_pd" title="Exercise prices">4.50</span></p></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expected dividends</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_pd" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Expected volatility">156%</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zZwiOLYQWbL4" title="Expected volatility">159</span></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Risk free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_pd" title="Risk free interest rate">4.20%</span> - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zIhGmMMk08X2" title="Risk free interest rate">4.34</span></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Expected term of options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zgAO0FxxeHi7" title="Expected life of options">6.0</span> years</td> <td style="text-align: left"> </td></tr> </table> 2.00 4.50 1.56 1.59 0.0420 0.0434 P6Y 95000 250000 20000 11341 options vest annually over 3 years, expire five years from the date of grant 39000 65000 177000 options vest over a five-year period. 165000 472000 <table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfOptionPricingModelTableTextBlock_zs2PFR6ZBH6j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span id="xdx_8B6_zyIcS6vzUf71" style="display: none">Schedule of option pricing model</span></td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 85%; font-size: 10pt; text-align: left">Exercise prices</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zQjQFUcC6lv5" title="Exercise prices">2.50</span> - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_z0LudEGjQ6G3" title="Exercise prices">4.50</span></span></td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Expected dividends</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zP25T0FJ0aIh" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1602">-</span></span></td> <td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_z7zTSTpaacxk" title="Expected volatility">148%</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zqTxbXMAQKNd" title="Expected volatility">179</span></span></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Risk free interest rate</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MinimumMember_zym1gq7gq7yf" title="Risk free interest rate">3.91%</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember__srt--RangeAxis__srt--MaximumMember_zr8S9zDne7dd" title="Risk free interest rate">4.36</span></span></td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left">Expected term of options</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zfhDw2MUG0Y7" title="Expected life of options">5.0</span> years</span></td> <td style="font-size: 10pt; text-align: left"> </td></tr> </table> 2.50 4.50 1.48 1.79 0.0391 0.0436 P5Y 7790 20000 <table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfGrantingOptionPricingModelTableTextBlock_zRFsiFEDiXs2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 3)"> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BB_zazTOUgFXOR1" style="display: none">Schedule of granting option pricing model</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 82%; text-align: left"><span style="font-size: 10pt">Exercise prices</span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><span style="font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zFBWHCrv3cCg" title="Exercise prices">1.67</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zZV4yIOkZPD8" title="Exercise prices">4.50</span></span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> </tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected dividends</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--Dr.EvertsMember_zWOU6W972ika" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1622">-</span></span></span></td> <td style="vertical-align: bottom; text-align: justify"> </td> </tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected volatility</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zo2RtoitzOE9" title="Expected volatility">138%</span> - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zqRcb7ytOQKa" title="Expected volatility">233</span></span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">%</span></td> </tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Risk free interest rate</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zBN4rEeA6RU1" title="Risk free interest rate">3.79%</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zsyHx1n9LYNb" title="Risk free interest rate">4.55</span></span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">%</span></td> </tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected term of options</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember__srt--RangeAxis__srt--MinimumMember_zQGcFWZ2rpia" title="Expected life of options">2.5</span> years - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--IanBothwellMember__srt--RangeAxis__srt--MaximumMember_zCUiWNZmnmu2" title="Expected life of options">10.0</span> years</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> </tr> </table> 1.67 4.50 1.38 2.33 0.0379 0.0455 P2Y6M P10Y 85877 3596000 1523000 953000 51000 <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfWarrantActivityTableTextBlock_zJjvZdnA0QA8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8BC_ztc1xlf9fuOh">Schedule of warrant activity</span></span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of<br/>Shares</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted-average<br/>Exercise Price</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Remaining<br/>Contractual<br/>Term (years)</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate<br/>Intrinsic Value</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">Outstanding at October 31, 2023</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_znw5KGZdQl9k" title="Number of shares, outstanding beginning balance">1,675,906</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zABooZgTp7H6" title="Weighted-average exercise price, outstanding beginning balance">4.54</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 9%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221101__20231031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFt2aSdRaZwf" title="Remaining contractual term (years), outstanding">8.47</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjWus4a47Y5k" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">883,333</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, granted">2.32</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_ecustom--RemainingContractualTermYearsGranted_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zf40F7Yf51Ei" title="Remaining contractual term (years), granted">9.21</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_ecustom--AggregateIntrinsicValueGranted_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmtC5oJl60Ih" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1664">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1666">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1668">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z184xEzVkXSk" title="Number of shares, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1670">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1672">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--AggregateIntrinsicValueExpiredforfeited_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1674">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6okUJZYuhW4" title="Number of shares, outstanding beginning balance">2,559,239</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zj9cMUgyJPEa" title="Weighted-average exercise price, outstanding beginning balance">3.77</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231101__20241031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlcnipAQV38c">7.97</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8a5MAoJffml" title="Aggregate intrinsic value, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1681">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">555,000</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVc7pCZu0iqa" title="Weighted-average exercise price, granted">6.23</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_901_ecustom--RemainingContractualTermYearsGranted_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z6tDtz8XjfMg" title="Remaining contractual term (years), granted">3.20</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_906_ecustom--AggregateIntrinsicValueGranted_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1689">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr6iIMnuWJSj" title="Number of shares, exercised">(21,277</span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zgyrWRy16v7b" title="Weighted-average exercise price, exercised">2.35</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_902_ecustom--RemainingContractualTermYearsGrantedExercised_iP3us-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zkhgatLuZTde" title="Remaining contractual term (years), granted, exercised">1.76</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1697">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; padding-bottom: 1pt; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFDLRrpA5sJ1" title="Number of shares, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1699">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1701">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--AggregateIntrinsicValueExpiredforfeited_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at October 31, 2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvkUDei5jXvc" title="Number of shares outstanding beginning balance">3,092,962</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zalJ8aVBNP87" title="Weighted-average exercise price outstanding Beginning balance">4.22</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20241101__20251031__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zVHSfJrAzwll">6.24</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3VYJwhW0n0l" title="Aggregate intrinsic value outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1710">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, granted">512,500</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, granted">4.00</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_ecustom--RemainingContractualTermYearsGranted_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKAh085BV4D5" title="Remaining contractual term (years), granted">4.90</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_ecustom--AggregateIntrinsicValueGranted_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zdSZJb1DuZGl" title="Aggregate intrinsic value, granted"><span style="-sec-ix-hidden: xdx2ixbrl1718">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEybjgUDKsX6" title="Number of shares, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1720">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1722">-</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9FwHwG2TtXe" title="Aggregate intrinsic value, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1724">-</span></span></td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Expired/Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zuDZlWo2h1Ha" title="Number of shares, expired/forfeited">(400,000</span></td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq4t39QaGqF4" title="Weighted-average exercise price, expired/forfeited">7.00</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--RemainingContractualTermYearsExpiredforfeited_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqwj6ciZdusa" title="Remaining contractual term (years), expired/forfeited">1.85</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_ecustom--AggregateIntrinsicValueExpiredforfeited_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfyQshOm8Xea" title="Aggregate intrinsic value, expired/forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Outstanding at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmtPvNCSPD83" title="Number of shares outstanding ending balance">3,205,462</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zqq02hamyVqc" title="Weighted-average exercise price outstanding ending balance">3.84</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjJ5x7Wmp2r9">5.86</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0d_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zq8wDDQuS7z9" title="Aggregate intrinsic value outstanding ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1739">-</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Exercisable at June 30, 2026</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Number of shares, exercisable">3,105,462</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pd" title="Weighted-average exercise price, exercisable">3.80</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyPrgCIbfAte" title="Remaining contractual term (years), exercisable">5.99</span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20260630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p" title="Aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1675906 4.54 P8Y5M19D 883333 2.32 P9Y2M15D 2559239 3.77 P7Y11M19D 555000 6.23 P3Y2M12D 21277 2.35 P1Y9M3D 3092962 4.22 P6Y2M26D 512500 4.00 P4Y10M24D 400000 7.00 P1Y10M6D 3205462 3.84 P5Y10M9D 3105462 3.80 P5Y11M26D 83333 2.00 350000 P10Y 2.35 0.0420 P10Y 1.59 0 1645000 1645000 100000 0.0396 P3Y 1.47 0 185000 185000 In connection with the Consulting Agreement discussed in Note 12, during May 2025, the Company granted the Consultant warrants to purchase 500,000 shares of its common stock (the “Warrants”). The Warrants vest in five equal tranches of 100,000 shares, at various exercise prices ranging between $3.50 - $10.00 per share, and are exercisable based upon meeting certain conditions provided in the Consulting Agreement. Once vested, the Warrants are exercisable for a period of ninety (90) days from the date they become exercisable. The Company valued the warrants on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions: (1) risk free interest rate 4.00%, (2) term of 3 years, (3) expected stock volatility of 143%, and (4) expected dividend rate of 0%. 400000 1141000 55000 P5Y 2.86 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfBlockScholesOptionPricingModelTableTextBlock_zWoe4GA0XpSl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details 5)"> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span id="xdx_8B8_z6WHxbHqz8Zb" style="display: none">Schedule of Black-Scholes option pricing model</span></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 85%; text-align: justify">Exercise prices</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_pd" title="Exercise prices">2.86</span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Expected dividends</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_pd" title="Expected dividends"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></span></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Expected volatility</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_zpsvWp8Zz17k" title="Expected volatility">148</span></td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: white"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Risk free interest rate</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_zmbXGSd2jM15" title="Risk free interest rate">4.00</span></td> <td style="vertical-align: bottom; text-align: justify">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">Expected term of options</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250501__20250508__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_zt77Y8GPc4k" title="Expected life of options">5.0</span> years</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table> 2.86 1.48 0.0400 P5Y Company received notice from a holder of warrants to exercise 21,277 warrants to purchase 21,277 shares of common stock of the Company for a total exercise price of $50,000 ($2.35 per share). The proceeds were received, and the shares were issued on July 30, 2025. 8.2 2050000 Each Unit consists of (i) 62,500 shares of common stock and (ii) warrants to purchase 62,500 shares of common stock of the Company at an exercise price of $4.00 until November 30, 2030. The warrants may be exercised on a cashless basis. In connection with the sale of the Units, the Company issued 512,500 shares of common stock and 512,500 warrants to purchase shares of common stock. 215000 2937000 2450000 231000 5.00 231000 1270000 3005000 <p id="xdx_800_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_ze2lH6j28kDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14 – <span id="xdx_821_zsRckGYstmCa">SHARE-BASED COMPENSATION LIABILITY TO RELATED PARTIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 10, 2026, the Board granted stock options to purchase an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260602__20260610__srt--TitleOfIndividualAxis__custom--IanBothwellMember_zUgJbJcIUXp3" title="Options granted">1,875,000</span> shares of common stock under the 2021 Plan to Ian Bothwell, the Company’s Chief Executive Officer (<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260602__20260610__srt--TitleOfIndividualAxis__custom--Dr.GeorgeShapiroMember_znYExEl04s3f" title="Options granted">625,000</span> shares), Dr. George Shapiro, the Company’s Chief Medical Officer (<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260602__20260610__srt--TitleOfIndividualAxis__custom--GreytVenturesLLCMember_z5TWO6MleyV8" title="Options granted">625,000</span> shares) and Greyt Ventures LLC, a principal shareholder of the Company (625,000 shares) (the “Incentive Options”). The Incentive Options have an exercise price of $<span id="xdx_90B_eus-gaap--StockOptionExercisePriceIncrease_c20260601__20260610__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember_pd" title="Options exercise price">1.67</span> per share, are exercisable on a cashless basis through June 10, 2036, and vest in full upon the first to occur of (a) the Company achieving a market capitalization of at least $125 million for 30 consecutive trading days (a market condition), (b) the completion of a specified licensing transaction (a performance condition), or (c) the Company being selected as a 2026 X-Prize finalist (a performance condition). The X-Prize condition subsequently expired without achievement. The Incentive Options contain an antidilution provision that applies upon issuances of common stock or common-equivalent securities equal to 10% or more of the Company’s then-outstanding common stock (a “qualifying issuance”), under which the exercise price may be reduced to the issuance price, if lower, and/or the number of shares issuable upon exercise may be increased pursuant to a contractual formula.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because the antidilution provision indexes the Incentive Options to a factor in addition to the Company’s share price that is not a market, performance, or service condition, the Incentive Options are classified as liabilities and are remeasured at fair value at the end of each reporting period until settlement. Fair value is estimated using a Monte Carlo simulation model that incorporates the market condition and the expected effect of the antidilution provision. The grant-date fair value was $2.0603 per option ($<span id="xdx_906_eus-gaap--ShareBasedCompensation_pp0d_c20251101__20260630__srt--TitleOfIndividualAxis__custom--MonteCarloSimulationMember_zbApY9lWWYIf" title="Stock compensation costs">3,863,100</span> in the aggregate), and the fair value at June 30, 2026 was $2.0279 per option ($3,802,000 in the aggregate). The market-condition derived service period established at the grant date was approximately 0.92 years and remained the basis for compensation-cost recognition as of June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the transition period ended June 30, 2026, the Company recognized $<span id="xdx_90E_ecustom--ShareBasedCompensationLiability_iI_c20260630_zVZiJ9ht4Md9" title="Compensation expense related">227,000</span> of stock-based compensation expense related to the Incentive Options, with a corresponding share-based compensation liability. Based on the fair value at June 30, 2026, approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0d_c20260630_zXAAPUeeSQ9e" title="Unamortized compensation costs">3,575,000</span> of compensation cost remained unrecognized. The amount of compensation cost ultimately recognized is subject to change based on subsequent fair-value remeasurements and the applicable requisite service period. No qualifying issuance triggering the antidilution provision occurred through June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The grant-date fair value of the Incentive Options was determined using a Monte Carlo simulation model with the following assumptions: (i) dividend yield of 0%; (ii) expected volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MaximumMember_pd" title="Expected stock volatility">232.97%</span>; (iii) risk-free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MaximumMember_pd" title="Risk free interest rate">4.55%</span>; (iv) contractual term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MaximumMember_zEOew10lzTL1" title="Term">10</span> years; and (v) management’s expectations regarding the circumstances, size, pricing, and structure of a potential qualifying issuance. The fair value of the Incentive Options at June 30, 2026 was determined using a Monte Carlo simulation model with the following assumptions: (i) dividend yield of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MinimumMember_pd" title="Expected dividend rate">0%</span>; (ii) expected volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MinimumMember_pd" title="Expected stock volatility">231.97%</span>; (iii) risk-free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MinimumMember_pd" title="Risk free interest rate">4.44%</span>; (iv) remaining contractual term of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251101__20260630__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__srt--CounterpartyNameAxis__custom--MonteCarloMember__srt--RangeAxis__srt--MinimumMember_z0jT2DkncAwh" title="Term">9.95</span> years; and (v) management’s expectations regarding the circumstances, size, pricing, and structure of a potential qualifying issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides a roll-forward of the share-based compensation liability measured at fair value on a recurring basis using unobservable level 3 inputs for the period ended June 30, 2026 as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ShareBasedCompensationLiabilityMeasuredAtFairValueTableTextBlock_zOMevMBLrkig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SHARE BASED COMPENSATION LIABILITY TO RELATED PARTIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B6_z9Sxruiu9Wdj" style="display: none">Schedule of roll-forward of the share based compensation</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation liability</span></td> <td style="width: 1%; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 9%; font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of beginning of period – October 31, 2025</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCompensationLiabilityValue_iS_c20251101__20260630__srt--CounterpartyNameAxis__custom--MonteCarloMember_zEVhEwsTDFO2" title="Compensation liability, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1869">-</span></span></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation expense</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20251101__20260630__srt--CounterpartyNameAxis__custom--MonteCarloMember_z0Moa7xjS00k" title="Stock based compensation expense">227,000</span></span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of end of period – June 30, 2026</span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCompensationLiabilityValue_iE_c20251101__20260630__srt--CounterpartyNameAxis__custom--MonteCarloMember_zeOnVLg6Phi1" title="Compensation liability, ending balance">227,000</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 1875000 625000 625000 1.67 3863100 227000 3575000 2.3297 0.0455 P10Y 0 2.3197 0.0444 P9Y11M12D <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ShareBasedCompensationLiabilityMeasuredAtFairValueTableTextBlock_zOMevMBLrkig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SHARE BASED COMPENSATION LIABILITY TO RELATED PARTIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span id="xdx_8B6_z9Sxruiu9Wdj" style="display: none">Schedule of roll-forward of the share based compensation</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation liability</span></td> <td style="width: 1%; font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 9%; font-size: 12pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 1%; font-size: 12pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of beginning of period – October 31, 2025</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCompensationLiabilityValue_iS_c20251101__20260630__srt--CounterpartyNameAxis__custom--MonteCarloMember_zEVhEwsTDFO2" title="Compensation liability, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1869">-</span></span></span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation expense</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20251101__20260630__srt--CounterpartyNameAxis__custom--MonteCarloMember_z0Moa7xjS00k" title="Stock based compensation expense">227,000</span></span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance as of end of period – June 30, 2026</span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCompensationLiabilityValue_iE_c20251101__20260630__srt--CounterpartyNameAxis__custom--MonteCarloMember_zeOnVLg6Phi1" title="Compensation liability, ending balance">227,000</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 227000 227000 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zr1FKe1W2woa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 15 – <span id="xdx_82E_zTvX43sRl1t6">COMMITMENTS AND CONTINGENCIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dr. John D. Kisiday, Ph.D.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective January 23, 2026, Dr. Kisiday was appointed the Company’s Chief Science Officer. Dr. Kisiday’s employment agreement (“Employment Agreement”) provides for a base salary of $<span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20260101__20260123__srt--CounterpartyNameAxis__custom--DrKisidayMember__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_pp0p" title="Base salary for first year">175,000</span> and a stock grant of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20260101__20260123__srt--CounterpartyNameAxis__custom--DrKisidayMember__us-gaap--PlanNameAxis__custom--N2021IncentiveStockPlanMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_pd" title="Non-vested shares granted">50,000</span> shares of common stock under our 2021 Incentive Plan. The stock grant vests as to 20,000 shares on the first anniversary of the of the Employment Agreement and 30,000 shares on the second anniversary of the Employment Agreement, contingent upon Dr. Kisiday’s continued employment with the Company. In addition, if Dr. Kisiday brought a commercially viable new product and/or business opportunity to the Company outside the existing scope of the Company’s current line of business, Dr. Kisiday will be entitled to receive additional compensation therefor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Kisiday’s employment with the Company was “At Will” meaning that his employment with the Company and his Employment Agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the Employment Agreement). Notwithstanding the foregoing, if at any time after the first ninety (90) days of the term, the Company terminates Dr. Kisiday’s employment without Cause or Dr. Kisiday terminates his employment with the Company for “Good Reason” (as defined in the Employment Agreement), Dr. Kisiday will be entitled to receive severance in an amount equal to one quarter (1/4) month’s salary for each successive three (3) months of employment completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Kisiday’s employment agreement contains customary confidentiality, non-competition and non-solicitation covenants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2026, as provided for under the Employment Agreement, the Company provided Dr. Kisiday with notice that his employment was being terminated effective March 23, 2026. As a result of Dr. Kisiday’s termination, the stock grant was forfeited in full effective March 23, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Purchase Commitments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During July 2025, the Company entered into an exclusive supply agreement (“Supply Agreement”) with a third-party contract manufacturer (“CDMO”) in connection with the manufacturing and processing of certain biological products (“CDMO Products”) that the Company intends to sell to third party medical providers. Under the terms of the Supply Agreement, the Company prepaid $500,000. Under the terms of the Supply Agreement, the deposits will be applied against the actual CDMO Products that are released to the Company. The Company has agreed to make a minimum of 8 purchase orders within specified periods based on satisfactory release of prior productions of the CDMO Products (“Minimum Purchase Orders”). In connection with each purchase order, the Company is required to have minimum deposits paid to the CDMO equal to 50% of the value of the purchase order. The Supply Agreement may be extended by the Company based on submitting a minimum amount of additional purchase orders after the Minimum Purchase Orders have been released. As of June 30, 2026 and October 31, 2025, outstanding advances were $<span id="xdx_903_eus-gaap--CustomerAdvancesCurrent_iI_pp0d_c20260630__us-gaap--TypeOfArrangementAxis__custom--SupplyAgreementMember_zjwWoN7eJb6l" title="Outstanding advances">42,000</span> and $<span id="xdx_90C_eus-gaap--CustomerAdvancesCurrent_c20251031__us-gaap--TypeOfArrangementAxis__custom--SupplyAgreementMember_pp0p" title="Outstanding advances">267,000</span>, respectively that is included in prepaid expenses in the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Skincare Agreement</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2022, the Company entered into a joint development agreement and supply agreement with a third-party supplier (“Supplier”) that develops and manufactures various devices and related equipment and consumables used in the skincare industry (“Skincare Agreement”) that are marketed and sold directly and/or through its affiliates or third parties, in the United States of America and in most major international markets. During September 2023, the Company and the Supplier agreed to enter into an Amendment and Restatement of the Skincare Agreement (“Amended Skincare Agreement”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 12, 2024, in connection with the mutual agreement to terminate the Amended Skincare Agreement, the Company and the Supplier entered into a settlement agreement and general release (“Settlement”). As of the date of the Settlement, both the Company and Exotropin had yet to deliver the Ingredient or the Moisturizer to the Supplier. In connection with the Settlement, the parties released each other from all outstanding duties and/or obligations owed by one party to the other party as set forth in the Settlement, including but not limited to the Company’s obligation to supply any Combined Product to the Supplier and the Supplier’s obligation to make or place any additional orders to the Company for the Combined Product. In connection with the Settlement, the Company retained the $403,000 payment that the Supplier made to the Company in connection with the Initial Purchase Order, and the Company was not obligated to deliver any of the Combined Product to the Supplier, including the portion of the Combined Product to be provided in connection with the Initial Purchase Order. Concurrent with the execution of the Settlement, the Company and Exotropin entered into a settlement and general release (“Release”) whereby the parties released each other from all outstanding duties and/or obligations owed by one party to the other party as set forth in the Release including but not limited to Exotropin’s obligation to supply any Moisturizer to the Company pursuant to the Amended Skincare Agreement and the Company’s obligation to make or place any additional orders to Exotropin for the Moisturizer. In connection with the Release, Exotropin retained the Moisturizer Prepayment that was paid by the Company of $235,000 in November 2023, and Exotropin was not obligated to deliver any of the Moisturizer to the Company, including portion of the Moisturizer to be provided in connection with the Moisturizer Prepayment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the above settlements, the Company has recorded $<span id="xdx_908_ecustom--GainNetOfObligationsInConnectionWithTerminationOfSupplyAgreement_pp0d_c20231101__20241031_zwVQ3Ez7vHCb" title="Gain, net of obligations in connection with termination of supply agreement (see Note 14)">168,000 </span>of other income during the year ended October 31, 2024 in connection with the net settlement amount associated with the Amended Skincare Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Deferred Revenue</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts received by the Company for products that have yet to be delivered to the customers as of June 30, 2026 and October 31, 2025 are reflected in the Company’s balance sheet as deferred revenues and were comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfDeferredRevenueTableTextBlock_z5OGgNMhZlIl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="display: none"><span id="xdx_8BB_zJiP6nc7Dto1">Schedule of deferred revenue</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49E_20260630_zVN1qOPc5hmj" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49C_20251031_zcUvVNcZxazi" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr id="xdx_40A_ecustom--Advances_iI_pp0d_maDRzg7d_z7FP1CDPqDw2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Advances On Future Purchases Of Inventory</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">361,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--SalesToCustomersNotYetDelivered_iI_pp0d_maDRzg7d_zL2zIcYAi2Nj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Sales To Customers Not Yet Delivered</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">457,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">453,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredRevenue_iTI_pp0d_mtDRzg7d_z6lW7Core6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total Deferred Revenue</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">818,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">598,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"><b>Legal Matters</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Albert Mitrani and Dr. Maria Ines Mitrani</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 7, 2023, the Company filed a four-count complaint with the Seventeenth Judicial Circuit in and for Broward County, Florida against Albert Mitrani and Dr. Maria Ines Mitrani, co-founders of the Company. Albert Mitrani was a former director and executive officer of the Company (most recently serving as Chief Executive Officer from September 2019 to July 2022 and as Executive Vice President of Sales from July 2022 until his termination in May 2023) and Dr. Mitrani is a former director and former executive officer of the Company (serving as Chief Science Officer from November 2016 until her termination in April 2023). The complaint alleges (i) breach of contract; (ii) breach of fiduciary duty; and (iii) tortious interference with business relationships; and seeks injunctive relief, in connection with, <i>inter alia</i>, non-solicitation and non-competition violations, misappropriation of Company materials and proprietary information resulting in unjust enrichment, causing detriment to business relationships and goodwill towards customers and physicians, self-dealing and misconduct afoul to the Company’s business interests as members of the Company’s board of directors, executive officers and minority equity interest holders—all causing irreparable harm to the Company. The complaint seeks injunctive relief, in addition to both compensatory and punitive damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective November 13, 2023, the Company entered into a settlement agreement with Albert Mitrani and Dr. Maria Ines Mitrani, pursuant to which it resolved various claims against the Mitranis, including those set forth in the previously reported Florida state action the Company had filed against the Mitranis. As part of the settlement, Albert Mitrani and Dr. Maria Ines Mitrani returned to the Company an aggregate of <span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodShares_c20241101__20241113_pd" title="Shares repurchased, shares">1,164,742</span> shares of the Company’s common stock held by them respectively and the parties exchanged mutual releases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Consultants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 5, 2024, the Company entered into a settlement agreement with a prior consultant of the Company, pursuant to which it resolved various claims that had been brought by the Company against a prior consultant. As part of the settlement, the consultants agreed to return to the Company <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_c20250801__20250805__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantsMember_pd" title="Shares repurchased, shares">237,602</span> shares of ZEO common stock held by the consultants in exchange for a payment of $<span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20250801__20250805__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantsMember_pp0p" title="Shares repurchased, value">80,000</span> and the parties exchanged mutual releases. The shares were returned to the Company in October 2024 and were redeposited back into the Company’s treasury of authorized and unissued shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Dr. Leider</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s employment agreement with Dr. Harry Leider, its former Chief Executive Officer (“Leider Employment Agreement”) had an initial term that ended May 31, 2024. The Leider Employment Agreement was not renewed and accordingly, the Leider Employment Agreement expired and the employment of Dr. Leider by the Company ended on May 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 12, 2024, the Company and Dr. Leider entered into a settlement agreement and general release whereby the Company agreed to pay Dr. Leider $40,000 in exchange for each party executing mutual releases in connection with the non-renewal of Dr. Leider’s employment agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Dr. Golub</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s employment agreement with Dr. Howard Golub, its former Chief Science Officer (“Golub Employment Agreement”) had an initial term that ended May 31, 2024. The Golub Employment Agreement was not renewed and accordingly, the Golub Employment Agreement expired and the employment of Dr. Golub by the Company ended on May 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2024, Dr. Golub (“Plaintiff”), filed a complaint in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida against the Company, alleging a breach of contract as a result of the Company’s failure to pay Plaintiff severance in the amount of $<span id="xdx_90B_eus-gaap--LitigationSettlementExpense_c20251101__20251114__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HowardGolubMember_pp0p" title="Settlement expenses">150,000 </span>in connection with the non-renewal of the Golub Employment Agreement. During June 2026, the parties entered into an agreement settling the matter and the action was dismissed with prejudice.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Exotropin</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2023, the Company entered into the Sales Agreement with Exotropin. On August 15, 2025, the Company terminated the Sales Agreement for cause. Exotropin filed a complaint (Case No. CACE-25-013178, in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida) against the Company for declaratory judgment on August 29, 2025, concerning the parties’ June 19, 2024, Amended and Restated Sales Representative Agreement, seeking declarations related to termination and the survival/enforceability of certain restrictive and other clauses. On November 6, 2025, the Company moved to dismiss Exotropin’s complaint. The Company filed counterclaims on November 17, 2025. On January 7, 2026, Exotropin filed a First Amended Complaint. On April 6, 2026, the parties filed a Joint Notice of Settlement with the Court. On April 13, 2026, the parties filed a Joint Stipulation of Dismissal With Prejudice, dismissing the action and all claims, counterclaims, and defenses asserted therein with prejudice, with each party bearing its own attorneys’ fees, costs, and expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>BioXtek</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 4, 2025, the Company entered into a Binding Memorandum of Understanding (“Binding MOU”) with BioXtek, LLC, a Florida limited liability company (“BioXtek”) setting forth the terms of a joint development, manufacturing, marketing and funding arrangement to be entered into by the Company and BioXtek in various phases (“Joint Venture”). In June 2025, BioXtek sought to terminate a Binding MOU between BioXtek and the Company and related Joint Venture with the Company for alleged breaches by the Company with respect to both the Binding MOU and the Joint Venture. The Company contested BioXtek’s allegations. On December 17, 2025, the Company commenced an action against BioXtek (Case No. CACE-25-019364, in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida) and filed an amended complaint on January 5, 2026, asserting claims for breach of contract and implied covenant, fraudulent inducement, violation of the Florida Deceptive and Unfair Trade Practices Act, equitable accounting, and declaratory judgment. The Company seeks damages for expectancy/consequential losses, equitable relief, and fees. Mediation was conducted on June 11, 2026, but did not resolve the dispute. The parties are engaged in written discovery. On August 5, 2026, the case was transferred to the Complex Business Litigation Division (Division 07) before Judge David A. Haimes. On August 14, 2026, BioXtek served its initial disclosures. On August 20, 2026, the Court entered a Uniform Trial Order setting the case for trial during the period of January 3, 2028, through March 24, 2028, with a calendar call on December 15, 2027.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioXtek filed its Answer and Affirmative Defenses to Amended Complaint and Counterclaims on September 21, 2026. BioXtek’s affirmative defenses allege, inter alia, prior material breach, fraudulent concealment, failure of conditions precedent, unenforceability of agreements to agree, valid contractual termination, waiver and estoppel, speculative damages, independent tort doctrine, and lack of FDUTPA standing. BioXtek’s counterclaims allege breach of contract, unjust enrichment, declaratory judgment, fraudulent inducement, negligent misrepresentation, and account stated. The Company intends to respond to BioXtek’s affirmative defenses and counterclaims and vigorously defend against the counterclaims.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Neurovive Holding Co., LLC</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 26, 2026, Neurovive Holding Co., LLC (“Neurovive”), Paragon Medical Group, LLC (“Paragon”), and Dr. David Buechner (“Dr. Buechner,” and together with Neurovive and Paragon, “Plaintiffs”), filed a complaint in the Circuit Court of Benton County, Arkansas Civil Division against the Company asserting claims for breach of contract, breach of fiduciary duty, misappropriation of trade secrets, fraud, promissory estoppel, unjust enrichment and conversion (“Complaint”). Plaintiffs are seeking preliminary and permanent injunctive relief and compensatory damages. The litigation stems from a previous arrangement whereby Plaintiffs and the Company had sought to jointly pursue a proposed clinical trial (“Venture”) based on Plaintiffs agreeing to provide the necessary funding for the Venture (“Funding Obligations”). After a prolonged unsuccessful effort to secure the Funding Obligations, the Plaintiffs unilaterally elected to terminate further efforts to pursue the Venture.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The case was removed to the United States District Court for the Western District of Arkansas, Fayetteville Division, Case No. 5:26-cv-05055. On June 30, 2026, the Court granted the Company’s Motion to Transfer Venue pursuant to 28 U.S.C. § 1404(a), and the case was transferred to the United States District Court for the Southern District of Florida, Fort Lauderdale Division, where it was docketed as Case No. 0:26-cv-62090-AHS. In August 2026, the Company filed a Motion for Judgment on the Pleadings pursuant to Federal Rule of Civil Procedure 12(c), seeking dismissal of all counts of the Complaint with prejudice. Plaintiffs filed a response in opposition and the Company will file a reply. Discovery is proceeding. Both sides have exchanged initial disclosures and document productions, and the Company has served written discovery on Plaintiffs. We are unable to express an opinion as to the possible outcome of this matter. The Company disputes all allegations and intends to vigorously pursue all available legal remedies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the foregoing, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 175000 50000 42000 267000 168000 <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfDeferredRevenueTableTextBlock_z5OGgNMhZlIl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="display: none"><span id="xdx_8BB_zJiP6nc7Dto1">Schedule of deferred revenue</span></span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49E_20260630_zVN1qOPc5hmj" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td id="xdx_49C_20251031_zcUvVNcZxazi" style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">June 30,<br/>2026</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">October 31,<br/>2025</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr id="xdx_40A_ecustom--Advances_iI_pp0d_maDRzg7d_z7FP1CDPqDw2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Advances On Future Purchases Of Inventory</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">361,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">145,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--SalesToCustomersNotYetDelivered_iI_pp0d_maDRzg7d_zL2zIcYAi2Nj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Sales To Customers Not Yet Delivered</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">457,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">453,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredRevenue_iTI_pp0d_mtDRzg7d_z6lW7Core6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total Deferred Revenue</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">818,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">598,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 361000 145000 457000 453000 818000 598000 1164742 237602 80000 150000 <p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zLBr1V3HT28d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 16 – <span id="xdx_823_zLLOZFCqrBlh">RELATED PARTY TRANSACTIONS</span></b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Sales to Related Parties</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, the Company sold a total of approximately $<span id="xdx_904_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_pp0d_c20251101__20260630__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_zQOGKbKyYrE1" title="Proceed from sale of products">0</span>, $<span id="xdx_90B_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20241101__20251031__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_pp0p" title="Proceed from sale of products">88,000</span> and $<span id="xdx_90D_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_c20231101__20241031__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember_pp0p" title="Proceed from sale of products">199,000</span>, respectively, of product to a management services organization (“MSO”) that provides administrative services and contracts for medical supplies for several medical practices, of which Dr. George Shapiro, the Company’s Chief Medical Officer and a member of the board of directors has an indirect economic interest in the parent company that owns the MSO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the eight months ended June 30, 2026, the Company sold a total of approximately $<span id="xdx_901_eus-gaap--ProceedsFromSaleOfOtherProductiveAssets_pp0d_c20251101__20260630__dei--LegalEntityAxis__custom--ManagementServicesOrganizationMember__srt--CounterpartyNameAxis__custom--DrGeorgeShapiroMember_zuiPKtj9Ise" title="Proceed from sale of products">70,000</span> of product to a medical practice of which Dr. George Shapiro, the Company’s Chief Medical Officer and a member of the board of directors has an economic interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Sale Of Exotropin Interests</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2026 (“Execution Date”) the Company, Greyt and Skycrest Holdings, LLC, a former principal shareholder of the Company (“Skycrest” and, together with the Company and Greyt, each a “Seller” and collectively “Sellers”) entered into a purchase and sales agreement (“Agreement”) to sell their Membership Units in Exotropin and terminate the Sales Representative Agreement (“Sales Agreement”) between the Company and Exotropin. During the eight months ended June 30, 2026, the Company recorded a gain of $<span id="xdx_903_ecustom--GainFromSaleOfExotropinInterests_pp0d_c20251101__20260630_z3yZ9x2MjNEk" title="Gain from sale of Exotropin interests">390,000</span> from the sale of its Exotropin interests comprised of the proceeds of $<span id="xdx_905_ecustom--ProceedsFromSaleOfInterestsInExotropin_pp0d_c20251101__20260630_z27nfaoHulAi" title="Proceeds from sale of interests in Exotropin">376,000</span> received from the sale of its interests in Exotropin and the reduction of previously recorded liabilities of $<span id="xdx_909_ecustom--ReductionOfPreviouslyRecordedLiabilities_pp0d_c20251101__20260630_zaWX5qEg24X3" title="Reduction of previously recorded liabilities">14,000</span>. For the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024, $<span id="xdx_909_eus-gaap--PaymentsForCommissions_pp0d_c20251101__20260630__us-gaap--TypeOfArrangementAxis__custom--SalesRepresentativeAgreementMember_zmpuw2RG6bDa" title="Commissions">0</span>, $<span id="xdx_90B_eus-gaap--PaymentsForCommissions_pp0d_c20241101__20251031__us-gaap--TypeOfArrangementAxis__custom--SalesRepresentativeAgreementMember_zBsSrxqFsRLc" title="Commissions">45,000</span> and $<span id="xdx_903_eus-gaap--PaymentsForCommissions_pp0d_c20231101__20241031__us-gaap--TypeOfArrangementAxis__custom--SalesRepresentativeAgreementMember_zHr3Ed9mdRMc" title="Commissions">81,000</span> of commissions, respectively, were paid to the Company in connection with the Sales Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Investment in Serephon</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 12, 2026, Ian Bothwell, Dr. George Shapiro, Greyt and the Company formed Serephon LLC (“Serephon”), a Delaware limited liability company. Serephon intends to act as a management services organization providing non-clinical administrative, operational, advisory, technology, marketing, management, equipment, procurement, and other lawful support services to physician-owned medical practices and other lawful healthcare-adjacent businesses, while not engaging in the practice of medicine.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Serephon business, the Company will agree to supply biologic products to Serephon and/or Serephon’s participating clinics, in exchange for an initial fifty percent (50%) Class A limited liability company membership interest (48 units) in Serephon, with the remaining Class A limited liability company membership interests owned equally by Greyt (16 units), Dr. Shapiro (16 Units) and Mr. Bothwell (16 Units).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 8 for discussion on Investment in Variable Interest Entity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Debt Extinguishment</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended October 31, 2024, the Company wrote-off the full balance of the advances payable to an affiliate of a former executive of $<span id="xdx_90C_ecustom--AdvancesPayable_c20241031_pp0p" title="Advances payable">221,000</span>. The Company recorded the write-off as other income during the year ended October 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Stock Compensation</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the above related party transactions, during the period ended June 30, 2026 and the years ended October 31, 2025 and 2024,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_90E_ecustom--CompensationExpenseRelated_c20251101__20260630__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zfRWPJtgz023" title="Compensation expense related">799,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, $<span id="xdx_907_ecustom--CompensationExpenseRelated_c20241101__20251031__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zYWekuua45l6">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_902_ecustom--CompensationExpenseRelated_c20231101__20241031__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zFE35jqwvCbl">375,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, of compensation expense related to fair value of shares issued to officers and directors and related parties. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20251101__20260630__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_z7fzNhLLITjg" title="Stock compensation costs">3,456,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20241101__20251031__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zWsj5duXGWA1">1,289,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20231101__20241031__srt--TitleOfIndividualAxis__custom--EmployeesOfficersAndDirectorsMember_zWy0P820aaPl">776,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, of compensation expense related to fair value of options granted to officers and directors and related parties.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.25in"></td> <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_90C_ecustom--CompensationExpenseRelated_c20251101__20260630_zLJsxyMPJl51">227,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, $<span id="xdx_907_ecustom--CompensationExpenseRelated_c20241101__20251031_zVxl4Y2D3Wu9">0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_ecustom--CompensationExpenseRelated_c20231101__20241031_zhVRGASk3Hy2">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively, of expense related to share-based compensation accounted for as a liability in connection with options granted to officers and directors and related parties.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify"><span style="font-size: 10pt">The Company recognized $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20251101__20260630__srt--TitleOfIndividualAxis__custom--RelatedPartiesMember_zQxeeoGVwidf" title="Stock compensation costs">215,000</span>, $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20241101__20251031__srt--TitleOfIndividualAxis__custom--RelatedPartiesMember_zoomGYoq8J51">2,802,000</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20231101__20241031__srt--TitleOfIndividualAxis__custom--RelatedPartiesMember_z4hMbFbKUTyl">2,294,000</span>, respectively, of compensation expense related to fair value of warrants granted to related parties.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 14 for discussion of Share-Based Compensation Liability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0 88000 199000 70000 390000 376000 14000 0 45000 81000 221000 799000 0 375000 3456000 1289000 776000 227000 0 0 215000 2802000 2294000 <p id="xdx_806_eus-gaap--OtherIncomeAndOtherExpenseDisclosureTextBlock_zQBwraOvWYvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 17 – <span id="xdx_826_zPOaiF63MfD8">OTHER INCOME</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zbGT5wALVmAa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INCOME (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8B7_z5q9TOHCgQga">Schedule of other Income</span></span></td> <td> </td> <td> </td> <td id="xdx_49B_20251101__20260630_zYz6jzyxnFy7" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_499_20241101__20251031_zSVzXMutDUE9" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_498_20231101__20241031_zICswwAXD8a9" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Eight Months Ended <br/> June 30,</b></td> <td> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Years Ended<br/> October 31,</td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2025</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr id="xdx_404_ecustom--OtherIncomeExpenseAbstract_iB_z3wHWTkGWoc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Other income</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--GainOnWriteoffOfAdvancesPayableToFormerOfficerAndSettlementOnOutstandingPayables_i01_pp0d_maNIEzLAR_zEJBbb8kY76e" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 64%; text-align: left">Gain on write-off of advances payable to former officer and settlement on outstanding payables (see Note 16)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%"><span style="-sec-ix-hidden: xdx2ixbrl1958">-</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1959">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">221,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--GainNetOfObligationsInConnectionWithTerminationOfSupplyAgreement_i01_pp0d_maNIEzLAR_z81tuSbQ8fb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Gain, net of obligations in connection with termination of supply agreement (see Note 15)</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1962">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1963">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">168,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--GainOnSaleOfExotropinInterests_i01N_pp0d_di_msNIEzLAR_zyObJ6gvYyI" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Gain on sale of Exotropin interests</td> <td> </td> <td> </td> <td style="text-align: right">390,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1967">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ResolutionAndSettlementOfLongOutstandingPayables_i01_pp0d_maNIEzLAR_z8hmVfn4LYL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Resolution and settlement of long outstanding payables</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">19,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">176,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--CommissionsOnSalesOfExotropinProducts_i01_pp0d_maNIEzLAR_z2AAM6O6uzid" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Commissions on sales of Exotropin products</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">61,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">87,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ProceedsFromInsuranceClaim_i01_pp0d_maNIEzLAR_z4VTNYGG1nM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from insurance claim</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">89,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherIncome_i01_pp0d_maNIEzLAR_zRHWFAxVB8X1" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">27,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">21,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">10,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_i01T_pp0d_mtNIEzLAR_zE4SI2h6MnPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">417,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">101,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">751,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_zbGT5wALVmAa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INCOME (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="display: none"><span id="xdx_8B7_z5q9TOHCgQga">Schedule of other Income</span></span></td> <td> </td> <td> </td> <td id="xdx_49B_20251101__20260630_zYz6jzyxnFy7" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_499_20241101__20251031_zSVzXMutDUE9" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_498_20231101__20241031_zICswwAXD8a9" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"> </td> <td> </td> <td colspan="2" style="vertical-align: bottom; text-align: center"><b>Eight Months Ended <br/> June 30,</b></td> <td> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Years Ended<br/> October 31,</td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; vertical-align: bottom; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2025</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"> </td></tr> <tr id="xdx_404_ecustom--OtherIncomeExpenseAbstract_iB_z3wHWTkGWoc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Other income</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--GainOnWriteoffOfAdvancesPayableToFormerOfficerAndSettlementOnOutstandingPayables_i01_pp0d_maNIEzLAR_zEJBbb8kY76e" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 64%; text-align: left">Gain on write-off of advances payable to former officer and settlement on outstanding payables (see Note 16)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%"><span style="-sec-ix-hidden: xdx2ixbrl1958">-</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1959">-</span></td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">221,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--GainNetOfObligationsInConnectionWithTerminationOfSupplyAgreement_i01_pp0d_maNIEzLAR_z81tuSbQ8fb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Gain, net of obligations in connection with termination of supply agreement (see Note 15)</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1962">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1963">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">168,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--GainOnSaleOfExotropinInterests_i01N_pp0d_di_msNIEzLAR_zyObJ6gvYyI" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Gain on sale of Exotropin interests</td> <td> </td> <td> </td> <td style="text-align: right">390,000</td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1967">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--ResolutionAndSettlementOfLongOutstandingPayables_i01_pp0d_maNIEzLAR_z8hmVfn4LYL2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Resolution and settlement of long outstanding payables</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1970">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">19,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">176,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--CommissionsOnSalesOfExotropinProducts_i01_pp0d_maNIEzLAR_z2AAM6O6uzid" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Commissions on sales of Exotropin products</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">61,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">87,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--ProceedsFromInsuranceClaim_i01_pp0d_maNIEzLAR_z4VTNYGG1nM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from insurance claim</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">89,000</td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherIncome_i01_pp0d_maNIEzLAR_zRHWFAxVB8X1" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">27,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">21,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">10,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_i01T_pp0d_mtNIEzLAR_zE4SI2h6MnPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">417,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">101,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">751,000</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 221000 168000 -390000 19000 176000 61000 87000 89000 27000 21000 10000 417000 101000 751000 <p id="xdx_80D_eus-gaap--AssetAcquisitionTextBlock_znOmK48JNOSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 18 – <span id="xdx_820_zP9BxKOta1fh">ACQUISITION OF BIOLUMINA ASSETS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 25, 2025 (“Closing Date”), the Company entered into a stock purchase agreement with BioLumina, LLC (“BIO”), a Delaware limited liability company, and all of its members (each a “Member” and collectively “Members”), whereby the Company acquired all of the outstanding membership interests of BIO (“Acquisition”) held by the Members for a total purchase price of $<span id="xdx_907_ecustom--PurchasePrice_c20250601__20250626_pp0p" title="Purchase price">200,000</span> (“Purchase Price”). The assets of BIO at the time of the Acquisition consisted primarily of finished goods inventory valued at $200,000 (“Inventory”), certain intellectual property consisting of various trademark applications and certain software platforms used to process product sales orders. At the time of the Acquisition, BIO’s historical cumulative sales were less than $50,000. The Company treated the purchase of BIO as an acquisition of assets. The Company did not assign any value to the intellectual property. Inventory was valued at the lower of replacement cost or the portion of the Purchase Price allocated towards inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Price paid was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td> <td style="width: 0.25in; text-align: left">(a)</td> <td style="text-align: justify">A $25,000 cash payment (the “Cash Purchase Price”), paid on the Closing Date to the Members <i>pro rata</i>; and</td> </tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: justify; font-size: 10pt">(b)</td> <td style="text-align: justify; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20250601__20250625__us-gaap--BusinessAcquisitionAxis__custom--BioLuminaLLCMember_zIPzNthW8go1" title="Number of restricted shares acquired">30,000</span> restricted shares of the Company’s common stock valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20250601__20250625__us-gaap--BusinessAcquisitionAxis__custom--BioLuminaLLCMember__us-gaap--StatementClassOfStockAxis__custom--ZeoSharesMember_pp0p" title="Value of restricted shares acquired">75,000</span> (the “Zeo Shares”) issued on the Closing Date, to the Members, <i>pro rata</i>; with respect to which the Members will be accorded (1) piggyback registration rights under the Securities Act of 1933, as amended and (2) a right to put their Zeo Shares back to the Company on the first anniversary of Closing (the “True Up Date”) at a price of $2.50 per share ($75,000 in the aggregate); and</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: justify; font-size: 10pt">(c)</td> <td style="text-align: justify; font-size: 10pt">A royalty (“Royalty”), payable to the Members, <i>pro rata</i>, equal to 10% of the gross cash proceeds (excluding shipping, handling, returns and credits) received by the Company from the sale of BIO’s Inventory acquired at closing (the “Product”) during the first year following the Closing Date, up to a maximum of $100,000 (the “Royalty”) which Royalty will be payable to the Members, <i>pro rata</i>, within 5 business days of the True-Up Date. In the event the Royalty amount as of the True-Up Date is less than $100,000 (a “Shortfall”), then the Company agrees to pay the Members, <i>pro rata</i>, a cash payment in the amount of the Shortfall within 90 days after the True-Up Date. In addition, the Members shall have the option, to apply their <i>pro rata</i> share of the Royalty (inclusive of any Shortfall), to the purchase of additional restricted shares of the Company’s common stock at a purchase price equal to 75% of the average closing trading price of the common stock for the 5 trading days immediately prior to the True-Up Date, provided however that in no event shall the purchase price be lower than $2.50 per Share.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2026, none of the Members elected to put back their Zeo Shares to the Company. During the eight months ended June 30, 2026, two of the members agreed to accept full payment of the Royalty and Shortfall payment owing totaling in the aggregate $50,000 through the transfer of inventory. As of September 30, 2026, all amounts owed to Members in connection with Royalty and Shortfall were paid in full.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Acquisition, the Company recorded an obligation of $16,500 representing the difference in the fair value of the ZEO Shares on the Closing Date ($58,500) and the amount that the Company has agreed to provide in the event of a Shortfall. At October 31, 2025 and June 30, 2026, the Company recorded an additional cumulative obligation of $<span id="xdx_90B_ecustom--AdditionalObligation_c20251031_pp0p" title="Additional obligation">2,000 </span>and $5,000 to reflect the loss in the fair value of the ZEO Shares from the Closing Date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 200000 30000 75000 2000 <p id="xdx_808_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zTrLu5ZOlJqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 19 – <span id="xdx_823_z9Wk2xTL2j5a">SEGMENT INFORMATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under ASC 280, Segment Reporting, operating segments are defined as components of an enterprise where discrete financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and in assessing performance. The Company operates and manages its business as one reportable and operating segment. The measure of segment assets is reported on the balance sheet as total assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s Chief Executive Officer, who is also the CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM for the eight months ended June 30, 2026 and the years ended October 31, 2025 and 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZgUc0QARW63" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <span id="xdx_8B4_zyh0qOE6Xp7a">Schedule of significant segment expenses</span></td> <td> </td> <td> </td> <td id="xdx_49F_20251101__20260630_zsih1ho7Uh69" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20241101__20251031_zFXhgmroT168" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_498_20231101__20241031_zxOD4MtK7hsl" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"><b>Eight Months Ended<br/> June 30,</b></td> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended<br/> October 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_maNILzBY5_z6AQwHjX5QDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">5,868,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">5,199,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,620,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CostOfRevenue_iN_di_msNILzBY5_zbQu34lvKwg6" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cost of revenues</td> <td> </td> <td> </td> <td style="text-align: right">(1,128,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(931,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(844,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--SalariesAndWages_iN_di_msNILzBY5_zv7EJTWQaaka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Salaries &amp; consulting fees</td> <td> </td> <td> </td> <td style="text-align: right">(2,087,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(2,956,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,034,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--ProfessionalFees_iN_di_msNILzBY5_zjv4gr2HHkJ7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Professional fees</td> <td> </td> <td> </td> <td style="text-align: right">(857,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(575,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(497,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_iN_di_msNILzBY5_zTdpMOuN9cok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">(5,157,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,693,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,853,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--LaborAndRelatedExpense_iN_di_msNILzBY5_zDHQRusj1ouh" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lab expenses</td> <td> </td> <td> </td> <td style="text-align: right">(393,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(387,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(208,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_msNILzBY5_znTX1Ou6LFme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research &amp; development</td> <td> </td> <td> </td> <td style="text-align: right">(65,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(100,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(164,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--PaymentsForCommission_maNILzBY5_z2RFZXKbQrw7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commissions</td> <td> </td> <td> </td> <td style="text-align: right">(678,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(521,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(734,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--MarketingExpense_iN_di_msNILzBY5_ziI5oghvh9D1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Marketing</td> <td> </td> <td> </td> <td style="text-align: right">(560,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(139,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(249,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OfficersCompensation_iN_di_msNILzBY5_ztn0kdh8Thr9" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Office expenses &amp; other</td> <td> </td> <td> </td> <td style="text-align: right">(368,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(283,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(356,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpense_maNILzBY5_zMZ3aRXvaibi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expenses), net</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">387,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(135,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">614,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProfitLoss_iT_pp0d_mtNILzBY5_z2uGoKx892Zb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(5,038,000</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(5,521,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(4,705,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zZgUc0QARW63" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> <span id="xdx_8B4_zyh0qOE6Xp7a">Schedule of significant segment expenses</span></td> <td> </td> <td> </td> <td id="xdx_49F_20251101__20260630_zsih1ho7Uh69" style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_495_20241101__20251031_zFXhgmroT168" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_498_20231101__20241031_zxOD4MtK7hsl" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"><b>Eight Months Ended<br/> June 30,</b></td> <td> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended<br/> October 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2026</b></td> <td style="padding-bottom: 1pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--Revenues_maNILzBY5_z6AQwHjX5QDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Revenue</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">5,868,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">5,199,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">4,620,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CostOfRevenue_iN_di_msNILzBY5_zbQu34lvKwg6" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cost of revenues</td> <td> </td> <td> </td> <td style="text-align: right">(1,128,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(931,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(844,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--SalariesAndWages_iN_di_msNILzBY5_zv7EJTWQaaka" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Salaries &amp; consulting fees</td> <td> </td> <td> </td> <td style="text-align: right">(2,087,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(2,956,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,034,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--ProfessionalFees_iN_di_msNILzBY5_zjv4gr2HHkJ7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Professional fees</td> <td> </td> <td> </td> <td style="text-align: right">(857,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(575,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(497,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--EmployeeBenefitsAndShareBasedCompensationNoncash_iN_di_msNILzBY5_zTdpMOuN9cok" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td> <td> </td> <td> </td> <td style="text-align: right">(5,157,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,693,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,853,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--LaborAndRelatedExpense_iN_di_msNILzBY5_zDHQRusj1ouh" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lab expenses</td> <td> </td> <td> </td> <td style="text-align: right">(393,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(387,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(208,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_iN_di_msNILzBY5_znTX1Ou6LFme" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research &amp; development</td> <td> </td> <td> </td> <td style="text-align: right">(65,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(100,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(164,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_408_ecustom--PaymentsForCommission_maNILzBY5_z2RFZXKbQrw7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commissions</td> <td> </td> <td> </td> <td style="text-align: right">(678,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(521,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(734,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--MarketingExpense_iN_di_msNILzBY5_ziI5oghvh9D1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Marketing</td> <td> </td> <td> </td> <td style="text-align: right">(560,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(139,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(249,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OfficersCompensation_iN_di_msNILzBY5_ztn0kdh8Thr9" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Office expenses &amp; other</td> <td> </td> <td> </td> <td style="text-align: right">(368,000</td> <td>)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(283,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(356,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpense_maNILzBY5_zMZ3aRXvaibi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expenses), net</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">387,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(135,000</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">614,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProfitLoss_iT_pp0d_mtNILzBY5_z2uGoKx892Zb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(5,038,000</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(5,521,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(4,705,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 5868000 5199000 4620000 1128000 931000 844000 2087000 2956000 3034000 857000 575000 497000 5157000 4693000 3853000 393000 387000 208000 65000 100000 164000 -678000 -521000 -734000 560000 139000 249000 368000 283000 356000 387000 -135000 614000 -5038000 -5521000 -4705000 <p id="xdx_804_ecustom--UnauditedComparativeFinancialInformationTextBlock_z8CFy1OnQlYa" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE 20 – <span id="xdx_82B_zEKyn3sQXba1">UNAUDITED COMPARATIVE FINANCIAL INFORMATION</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited financial information for the eight months ended June 30, 2025 is presented for comparative purposes to the eight-month transition period ended June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Amounts rounded to the nearest thousand except share amounts)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--UnaudtedConsolidatedStatementsOperationsTableTextBlock_zyWVCfmRvibi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - UNAUDITED COMPARATIVE FINANCIAL INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B6_zxUpdsVR5pp4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> Schedule of Unaudited consolidated Statements Of Operation</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251101__20260630_zkrEr2DTc9Xa" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_491_20241101__20250630_zBIJL2FswKje" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">8 Months Ended<br/> June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-style: normal"> </span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-style: normal"> </span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-style: normal">(Unaudited)</span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td></tr> <tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenues (includes sales to related parties of approximately $70,000 and $52,000, respectively)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">5,868,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">3,098,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cost of revenues</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">1,128,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">566,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross profit</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,740,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,532,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_zvhuoSeExGLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">General and administrative expenses</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">10,165,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">6,793,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperations_zJ4U9b91UiT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss from operations</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,425,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,261,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherIncomeAndExpensesAbstract_i" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--GainOnSaleOfExotropinInterests_iN_di_zYIQC9GdC9Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on sale of Exotropin interests</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">390,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2077">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_iN_pp0d_di_z0vEtFHJIbhl" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(27,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(58,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ChangeInObligationToRepurchaseShares_iN_pp0d_di_zTsWilxbp8Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in obligation to repurchase shares</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncome_zcyIgNautRy6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other income</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">27,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">62,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ProfitLoss_zNr6tnZab1vh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,038,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,262,000</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_z3o3NtYqkS7c" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net income attributable to the non-controlling interests</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">36,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2092">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_z7jGwCmp1ixc" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss attributable to Zeo ScientifiX, Inc</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(5,074,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(4,262,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss per common share - basic and diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_906_eus-gaap--EarningsPerShareBasic_c20251101__20260630_pd" title="Net loss per common share - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20251101__20260630_pd" title="Net loss per common share - diluted">(0.68</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_904_eus-gaap--EarningsPerShareBasic_c20241101__20250630_pd" title="Net loss per common share - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20241101__20250630_pd" title="Net loss per common share - diluted">(0.67</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - basic and diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260630_pd" title="Weighted average number of common shares outstanding - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260630_pd" title="Weighted average number of common shares outstanding - diluted">7,493,536</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250630_pd" title="Weighted average number of common shares outstanding - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250630_pd" title="Weighted average number of common shares outstanding - diluted">6,356,800</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zhg9N8HxsVk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--UnaudtedConsolidatedStatementsOperationsTableTextBlock_zyWVCfmRvibi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - UNAUDITED COMPARATIVE FINANCIAL INFORMATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_8B6_zxUpdsVR5pp4" style="display: none; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> Schedule of Unaudited consolidated Statements Of Operation</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_49B_20251101__20260630_zkrEr2DTc9Xa" style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_491_20241101__20250630_zBIJL2FswKje" style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">8 Months Ended<br/> June 30,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-style: normal"> </span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-style: normal"> </span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-style: normal">(Unaudited)</span></td> <td style="font-weight: bold"><span style="font-style: normal"> </span></td></tr> <tr id="xdx_401_eus-gaap--Revenues_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Revenues (includes sales to related parties of approximately $70,000 and $52,000, respectively)</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">5,868,000</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">3,098,000</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Cost of revenues</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">1,128,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">566,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_i_pp0p" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross profit</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,740,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,532,000</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_zvhuoSeExGLd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">General and administrative expenses</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">10,165,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">6,793,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperations_zJ4U9b91UiT8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss from operations</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,425,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,261,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OtherIncomeAndExpensesAbstract_i" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income (expense)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--GainOnSaleOfExotropinInterests_iN_di_zYIQC9GdC9Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain on sale of Exotropin interests</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">390,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2077">-</span></td> <td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_iN_pp0d_di_z0vEtFHJIbhl" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest expense</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(27,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(58,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--ChangeInObligationToRepurchaseShares_iN_pp0d_di_zTsWilxbp8Cl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in obligation to repurchase shares</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(3,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,000</td> <td style="text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncome_zcyIgNautRy6" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other income</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">27,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">62,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ProfitLoss_zNr6tnZab1vh" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(5,038,000</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(4,262,000</td> <td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_z3o3NtYqkS7c" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net income attributable to the non-controlling interests</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">36,000</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2092">-</span></td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_z7jGwCmp1ixc" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss attributable to Zeo ScientifiX, Inc</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(5,074,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">(4,262,000</td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss per common share - basic and diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_906_eus-gaap--EarningsPerShareBasic_c20251101__20260630_pd" title="Net loss per common share - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_907_eus-gaap--EarningsPerShareDiluted_c20251101__20260630_pd" title="Net loss per common share - diluted">(0.68</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_904_eus-gaap--EarningsPerShareBasic_c20241101__20250630_pd" title="Net loss per common share - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_909_eus-gaap--EarningsPerShareDiluted_c20241101__20250630_pd" title="Net loss per common share - diluted">(0.67</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - basic and diluted</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260630_pd" title="Weighted average number of common shares outstanding - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260630_pd" title="Weighted average number of common shares outstanding - diluted">7,493,536</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250630_pd" title="Weighted average number of common shares outstanding - basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFVOQVVESVRFRCBDT01QQVJBVElWRSBGSU5BTkNJQUwgSU5GT1JNQVRJT04gKERldGFpbHMpAA__" id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250630_pd" title="Weighted average number of common shares outstanding - diluted">6,356,800</span></span></td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5868000 3098000 1128000 566000 4740000 2532000 10165000 6793000 -5425000 -4261000 -390000 27000 58000 3000 5000 27000 62000 -5038000 -4262000 36000 -5074000 -4262000 -0.68 -0.68 -0.67 -0.67 7493536 7493536 6356800 6356800 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_z2NILG0ArTak" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 21 – <span id="xdx_82E_zDesakoii193">SUBSEQUENT EVENTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Convertible Promissory Note</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">During September 2026, the Company paid the remaining outstanding Notes of $<span id="xdx_901_ecustom--RemainingOutstanding_c20260930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pd" title="Remaining outstanding">250,000</span> plus accrued interest totaling $<span id="xdx_908_eus-gaap--InterestPaid_c20260901__20260930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_pp0p" title="Accrued interest">268,900</span>.</span></p> 250000 268900 false false false false <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year-End</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="17" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Option Awards</b></span></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td><span style="font-size: 8pt"> </span></td> <td colspan="14" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Stock Awards</b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Name<br/> (a)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> Exercisable<br/> (b)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options<br/> Unexercisable<br/> (c)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Equity<br/> Incentive<br/> Plan Awards:<br/> Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Unearned<br/> Options<br/> (d)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Option<br/> Exercise<br/> Price<br/> (e)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Option<br/> Expiration<br/> Date<br/> (f)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Stock Awards<br/> Number of<br/> Shares or<br/> Units of Stock<br/> That Have<br/> Not Vested<br/> (g)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Market Value<br/> of Shares or<br/> Units of Stock<br/> That Have<br/> Not Vested<br/> (h)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Equity Incentive<br/> Plan Awards:<br/> Number of<br/> Unearned Shares,<br/> Units or<br/> Other Rights<br/> That Have<br/> Not Vested<br/> (i)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Equity Incentive<br/> Plan Awards:<br/> Market or<br/> Payout Value<br/> of Unearned<br/> Shares, Units<br/> of Other Rights<br/> That Have<br/> Not Vested<br/> (j)</b></span></td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; width: 28%"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_903_eecd--AwardsCloseToMnpiDiscIndName_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember_zFYhdliCpiGd" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ian T. Bothwell</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_907_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember_zbNvVpVL1Aji" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">37,500</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="width: 5%; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_903_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember_zkxmCk7efzKl" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5.60</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">02/26/30</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_900_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember1Member_zaPevyVkZSc6" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">150,000</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_905_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember1Member_ziJ3oZT2L197" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4.00</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">07/13/32</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90D_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember2Member_zIJAewhPBwI4" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">125,000</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90D_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember2Member_zkbxTOAyc2I" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.35</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">07/10/34</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90B_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember3Member_zf2y15VGm7o4" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">55,000</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_900_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember3Member_zFoeSGROKcs1" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.86</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">05/07/30</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_905_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember4Member_ztahHQcHOGs1">625,000</span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right">-</td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_905_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember4Member_z384G6e3tf0a">1.67</span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-size: 8pt">06/10/36</span></td> <td><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90C_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember5Member_zeWzBSZx67fa"><span style="-sec-ix-hidden: xdx2ixbrl2134">-</span></span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">625,000</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_904_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--IanTBothwellMember5Member_zhxVjalZrlQk">1.67</span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-size: 8pt">06/10/36</span></td> <td><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardsCloseToMnpiDiscIndName_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiroMember_zjLEhG4abOqg" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Dr. George Shapiro</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_904_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiroMember_zfWJAkDImqVc" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,750</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_901_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiroMember_zms1KrhL9Ypc" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">4.00</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">07/13/32</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90D_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro1Member_zg9A5fSQkSGh" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">125,000</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_901_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro1Member_zMA94LQnmZ8f" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.35</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">07/10/34</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_909_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro2Member_zedMQGN7a1t5" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">55,000</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90C_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro2Member_zgJN3IDu1ek8" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2.86</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">05/07/30</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90A_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro3Member_zBJEe7AeD2M2">625,000</span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right">-</td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90F_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro3Member_z2qpsZiaYE65">1.67</span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-size: 8pt">06/10/36</span></td> <td><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--AwardUndrlygSecuritiesAmt_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro4Member_zTJ8yADFY9M9"><span style="-sec-ix-hidden: xdx2ixbrl2145">-</span></span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">625,000</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--AwardExrcPrice_iI_c20260630__ecd--IndividualAxis__custom--DrGeorgeShapiro4Member_zOLl94AZMhWc">1.67</span></span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: center"><span style="font-size: 8pt">06/10/36</span></td> <td><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td> <td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td> <td style="text-align: right"><span style="font-size: 8pt">-</span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> </table> Ian T. Bothwell 37500 5.60 150000 4.00 125000 2.35 55000 2.86 625000 1.67 1.67 Dr. George Shapiro 15750 4.00 125000 2.35 55000 2.86 625000 1.67 1.67